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“You have to learn the rules of the game. And then you 
have to play better than anyone else.” 
 
“Devi imparare le regole del gioco. E poi devi giocare 
meglio di chiunque altro. “ 
Albert Einstein 
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ABSTRACT 
Medical Molecular farming is a term used to refer to the production of valuable 
biopharmaceuticals in plants. An important branch of medical molecular 
farming is represented by edible vaccines: engineered plants expressing major 
immunogenic proteins of pathogens that can be administered as subunit 
vaccines by oral route. Edible vaccines are particularly attractive due to low 
cost, heat stability, avoidance of injections and ability to induce specific 
antibodies in the mucosa, where enteric pathogens gain access to the body.The 
chances of acquiring mucosal immunity against infectious agents that enter the 
body across mucosal surface are also increases with the oral delivery of 
vaccines. 
This study is focused on seed-based vaccines against swine verocytotoxic 
Escherichia coli (VTEC). The third generation (R3) of two lines of Nicotiana 
tabacum expressing, respectively, the F18 adhesive fimbriae (n: 80) and the B 
subunit of the VT2e toxin (n: 80) of E. coli, were harvest in contention 
conditions (level 1). Four hundred and seventy grams of F18 positive seeds 
(F18s) and four hundred and fifty grams of VT2e-B positive seeds (VT2eBs) 
were collected. Even if no differences were observed in the germination index 
(F18s: 73.3%; VT2e-Bs: 76.6%; WT: 78.5%), F18s and VT2eBs germinated 
four days later than the wild type. This aspect was probably related to late 
metabolic employment of inclusion bodies that we observed in the vaccinal 
seeds by morphological analyses. Polymerase chain reaction, carried out on 
DNA from vaccinal plants, confirmed the stable integration of the bacterial-
origin genes into plant genome. The amount of F18 and VT2e-B was estimated 
respectively about 6.6-7.4 g and 34-37 g per 10 g seeds respectively by 
competitive indirect ELISA. The protective effect was evaluated, through an 
in-vivo trial, carried out at the Experimental Animal Research and Application 
Centre of the University of Milan, on 36 weaned piglets (controls, CG, n:18; 
treatment, TG, n:18) fed 20 g vaccinal seeds (10 g of each line) mixed with 40 
g of milk powder on days 0, 1, 2, 5 and 14. Controls received wild type tobacco 
seeds in the same way. 12 piglets per group were challenged at day 20 with 1010 
CFU of O138 E. coli. Throughout the experimental period (0-29 days), 
zootechnical performances and health status were monitored and biological 
 
 
 
samples were collected individually. After the immunization period (day 20th), 
the titer of total intestinal IgAs resulted higher in the treated piglets, which 
showed also a significant increase of the fecal anti-F18 and anti-VT2e-B 
Immunoglobulin-A, if compared with controls. The adopted oral delivery 
strategy appeared effective in reducing clinical signs after VTEC infection and 
was able to stimulate local immunity in gastrointestinal tract.  
Finally, the knowledge in mucosal immunity was deepened in collaboration 
with the Department of Infectious Diseases, University of Denver, Colorado.  
In particular a method for characterizing the effects of different mucosal 
bacterial pathogens such as Moraxella catarrhalis, (Mcat), Heamophilus 
influenzae type b (Hib), Haemophilus influenzae non typeable (NTHi), 
Staphilococcus aureus Cowan I (SAC) on the isotype of antibody production 
from human B cells, was set up.  
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RIASSUNTO 
“Medical Molecular farming” o “Agricoltura molecolare” è un termine usato 
per indicare la produzione su larga scala di molecole ad interesse medico o 
farmaceutico in pianta. In tale ambito un’importate attenzione è rivolta ai 
vaccini edibili: piante ingegnerizzate per l’espressione di proteine immunogene 
in grado di indurre, dopo somministrazione orale, una risposta immunitaria 
locale protettiva nei confronti del patogeno contro il quale sono state progettate. 
I vaccini edibili offrono numerosi vantaggi correlati alla facilità di 
somministrazione, ai bassi costi, alla faciltà di stoccaggio nonché alla 
possibilità di indurre una risposta immunitaria locale laddove il patogeno ha 
accesso nell’organismo. 
Questo studio si concentra sui semi vaccinali contro i ceppi Escherichia coli 
verocitotossico (VTEC) nei suinetti. La terza generazione (R3) di semi di due 
linee di Nicotiana tabacum che esprimono, rispettivamente la fimbria adesiva 
F18 (n: 80) e la subunità B della tossina VT2e (n: 80) derivanti da un ceppo di 
E. coli verocitotossico, sono state coltivate in serra con un livello di 
contenimento 1. Nello specifico, sono stati raccolti quattrocentosettanta grammi 
di semi F18 positivi (F18s) e quattrocentocinquanta grammi di semi VT2e-B 
positivi (VT2eBs). Anche se, non sono state osservate differenze nell'indice di 
germinazione (F18s: 73,3%; VT2e-B: 76,6%; WT: 78,5%), i semi F18s e 
VT2eBs hanno germinato quattro giorni più tardi rispetto ai semi di Nicotiana 
tabacum “wild type”. Questo aspetto è probabilmente correlato all’uso tardivo 
dei corpi di inclusione (proteine e lipidi) da parte delle varietà ingegnerizzate, 
come osservato nei tessuti vegetali attraverso analisi morfologiche con 
microscopia ottica ed elettronica. Le analisi di PCR, effettuate su DNA di piante 
vaccinali, hanno confermato l'integrazione stabile dei geni di origine batterica 
nel genoma vegetale. La quantità delle proteine F18 e VT2e-B è stata stimata 
essere rispettivamente circa 6,6-7,4 g e 34-37 g per 10 g di semi tramite saggi 
ELISA competitivo indiretto. L'effetto protettivo della somministrazione orale 
dei semi vaccinali nei confronti con ceppi VTEC è stato valutato, attraverso una 
sperimentazione in-vivo, effettuata presso il Centro Zootecnico Didattico 
Sperimentale dell'Università degli Studi di Milano. Nello specifico 36 suinetti 
 
 
 
svezzati a 21 giorni sono stati suddivisi casualmente in due gruppi sperimentali: 
controllo (CG, n:18) e trattamento (TG, n:18). Considerando l’inizio della 
sperimentazione il giorno 0, i soggetti del gruppo TG hanno ricevuto nei giorni 
0, 1, 2, 5 e 14 un trattamento corrispondente a 20 g di semi vaccinali macinati 
miscelati con 40 grammi di latte ricostituito in polvere. Il gruppo controllo ha 
invece ricevuto 20 g di semi di tabacco wild type. Al giorno 20, 12 suinetti 
rispettivamente del gruppo controllo e del gruppo trattamento sono stati infettati 
sperimentalemente con 1010 CFU del sierotipo O138 di E. coli. Durante tutto il 
periodo sperimentale (0-29 giorni), performances zootecniche e stato di salute 
sono stati monitorati e sono stati raccolti individualmente campioni biologici. 
Dopo il periodo di immunizzazione (giorno 20), il titolo di IgA intestinali totali 
è risultato essere superiore nei suinetti trattati, che inoltre mostravano un 
significativo aumento del titolo fecale di immunoglobuline A anti-F18 e anti-
VT2e-B rispetto ai controlli. La strategia adottata, tramite somministrazione 
orale è risultata efficace nel ridurre i segni clinici dopo l'infezione da VTEC ed 
è stata in grado di stimolare l'immunità locale nel tratto gastroenterico. Inoltre, 
la conoscenza delle tecniche immunologiche e un approfondimento 
sull’immunità mucosale locale sono state sviluppate in collaborazione con 
l’Università di Denver, Colorado. In particolare è stato messo a punto un 
metodo per caratterizzare gli effetti di diversi batteri patogeni mucosali, come 
Moraxella catarrhalis, (Mcat), Heamophilus influenzae di tipo b (Hib), 
Haemophilus influenzae non tipizzabile (NTHi), Staphilococcus aureus Cowan 
I (SAC) sulla produzione di anticorpi di cellule B umane 
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1-INTRODUCTION 
1.1-Molecular Farming  
The term Molecular farming generally refers to the production of 
pharmaceutically important and commercially valuable proteins in plants 
(Fischer and Emans, 2000). Historically, plants were used as an exceptionally 
valuable source for treatments and therapies. Thousands of plant species have 
been utilized for medicines and most of the world’s population employs them to 
treat acute and chronic health complications. After a change from wild collection 
to cultivation, improvements in plant biotechnologies, which occurred over a 
long period, aimed to directly improve and modify specialized elements of plants 
such as carbohydrates, proteins, oils, fats and vitamins. Nevertheless, the use of 
engineered plants as “bioreactors” is a quite new bioscience and is achieving 
momentum (Sharm and Sharma, 2009).  
Utilizing transgenic plants for the fabrication of high-value recombinant proteins 
for industrial and clinical purposes has become a promising substitute to usual 
bio-production systems, like bacteria, yeast, and cultured insects and animal 
cells. This innovative system has numerous advantages compared to 
conventional systems such as their safety, scale, cost-effectiveness, ease of 
distribution and storage (Table 1). 
Table 1: Comparison of different expression platforms for the production of pharmaceuticals 
(modified from Spök and Karner, 2008). 
 
 
Comparisons Transgenic 
Plant 
Plant Cell 
Culture 
Bacteria Yeast Mammalian 
Cell Culture 
Transgenic 
Animals 
Overall cost Very low Medium Low Medium High High 
Scale-up 
capacity 
Very high Medium High High Very low Low 
Production 
scale 
Worldwide Limited Limited Limited Limited Limited 
Protein yield High High Medium High Medium-High High 
Protein folding 
accuracy 
High High Low Medium High High 
Glycosylation 
Minor 
differences 
Minor 
differences 
None Incorrect Correct Correct 
Product quality High High Low Medium High High 
Contamination 
risks 
Low Low Endotoxins Low 
Virus, Prions, 
oncogenic 
DNA 
Virus, Prions, 
oncogenic 
DNA 
Safety High 
Non-
specific 
Low Unknown Medium High 
12 
 
Plants can be sources of pharmaceutical proteins, such as blood-component 
substitutes (Magnuson et al., 1998), mammalian antibodies (Fischer et al., 
1999a), and vaccine subunits (Walmsley and Arntzen, 2000). By using 
engineered plants, scientists succeeded in incorporating genes into host plants 
that were subsequently induced to generate pharmaceuticals (Torrent et al., 
2009b). Barta et al. (1986) have produced the first plant-based medical protein 
during their studies, generating a human growth hormone in tobacco (Nicotiana 
tabacum spp).  
Although the idea of creating human proteins and antibodies in plants was at first 
seen with skepticism, crops showed to offer a unique combination of advantages 
as well as remarkable features compared with those of the conventional 
production systems. During the last decades, plants generally have been 
extensively investigated as unconventional systems for the production of 
pharmaceuticals proteins. 
Easy and cheap to grow. Plants possess excellent biosynthetic capabilities 
including the ability to use the sun energy (photosynthesis) and/or very simple 
media to support significant biomass and protein accumulation. They have a 
large potential for low-cost production of high quality and bioactive recombinant 
proteins (Sharm and Sharma, 2009; Obembe et al., 2011; Paul and Ma, 2010). 
In the near future, the world’s population and the request for cheap end effective 
medical products will grow once again; plants will be the main help for humans 
and animals. Compared to conventional systems, plants are cheap and harmless. 
As showed in Daniell et al. (2001b), the cost of monoclonal antibodies produced 
with the hybridomas method is 1000$/gram and 100$/gram when using 
transgenic animals but when using transgenic plants, the productions cost 
decreases to 50$/gram.  
Safety. Safety, for humans and animals, is important to avoid outbursts of 
infections and diseases; plants decrease health risks from pathogens cross-
contaminations. Plants are not infected by possible human pathogens, such as 
bacteria, prions or viruses, which reduces production costs, and minimizes health 
dangers. 
13 
 
Features and limitations of traditional production systems. To supply the 
extensive demand of medical proteins, the pharmaceutical industry 
industrialized some production systems. Plants classically produce recombinant 
proteins with the correct folding activity and glycosylation (Schillberg et al., 
2005; Yian et al., 2015). For instance, targets for specific human recombinant 
antibodies are recognized in the clinic as in the therapeutics and denote a major 
new class of drugs. Therapeutic effectiveness depends on the development of 
complexes with target molecules and consequent activation of downstream 
biologic mechanisms, which result in the removal of the target. The activation 
of effector mechanisms depends on the characteristics of the structure of the 
antibodies molecule that derives from post-translational modifications, in 
particular, from glycosylation. The production of curative antibodies with a 
stable glycoform profile is a significant challenge for the biopharmaceutical 
industry. Indeed, bacteria do not perform glycosylation of heterologous proteins, 
yeasts as Pichia pastoris and Saccharomices cerevisiae lead to hyper-
glycosylation, no sialyltransferase activity. Instead, insect cells generate 
extensive glycosylation, no sialyltransferase activity and insect specific glycans, 
could be unsafe (e.g. bee venom-related to anaphylactic shock). Mammalian cell 
cultures are pricy and raise concerns about safety. Glycosylation outlines depend 
on cell lines and culturing circumstances. Plants and their glycol engineering 
confer naturally closer human glycan’s (Table 2). However, broad engineering 
could be limited due to serious side effects of altering glycosylation patterns of 
endogenous proteins. In addition, plants do not generate endotoxins (unlike 
bacteria) and they do not support replication of human viruses (on the contrary 
of mammalians cells). 
N-glycosylation in mammal cells versus plants  
Mammals  Plants  
 1,6 core fucosylation 
 proximal 1,4 galactosidation 
 terminal sialylation 
  complex glycans dominate 
 1,3 core fucosylation & 1,2 core 
xylose  
 proximal galactosidation not common,  
 only 1,3 type proximal 1,3 
fucosylation 
 no terminal sialylation 
Table 2: Foremost differences in term of N-glycosylation pathway between mammal and plant 
cells. Plants do not generate endotoxins (unlike bacteria) and they do not support replication of 
human viruses (on the contrary of mammalians cells). 
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The precise control of glycosylation permitted the production of plant-derived 
glycoproteins with humanlike or human-compatible glycans, as well as 
biobetters (the term biobetter indicates a recombinant protein drug that is in the 
same class as an existing biopharmaceutical but is not indistinguishable), in 
which the glycan profiles have been poked to improve efficacy or longevity, or 
to make downstream processing easier. 
The technology is now accessible for harvesting and processing plants and plant 
products on a large scale. The quantity of recombinant product that can be 
produced approaches industrial-scale levels. The purification requisite can be 
escaped when the plant tissue, which contains the recombinant protein, is used 
orally. Plants can be guided on target proteins in intracellular compartments in 
which they are more stable, or even to express them straightforwardly in certain 
compartments (chloroplasts, seeds).  
1.2-Selection of the host species  
For the effective production of recombinant product, selection of the host species 
is essential. Even in the beginning, the Arabidopsis thaliana and the Nicotiana 
tabacum models, which are easy to transform and manipulate, were the main 
system for the production of most of the plant-derived recombinant proteins. For 
this purpose, today a large number of plant species are being used such as 
tomato, banana, rice, maize, wheat, carrot, soybean, pea, potato, lettuce and alfa-
alfa (Kamenarova et al., 2005). A large variety of products can be created in 
plants, but each one has its own specific necessities for its production. The choice 
of the host species is associated with the type of protein in question i.e. the 
recombinant protein form, which will be produced at the end (Table 3). Together 
with the technical improvements, a huge number of plant species attracted the 
attention of the scientific community. Generally, domesticated species are 
chosen over wild species for molecular farming since they are adapted to a broad 
range of environmental conditions because of their commercialization. Yet, wild 
species could be more strategic as they will not be mistaken for food crops and 
would report the issue of food crop mix-up with transgenic products. 
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Plants Advantages  Disadvantages  
Tobacco Efficient transformation system. 
Abundant material for protein characterization. 
Toxic alkaloids. 
Potential for outcrossing in field. 
Arabidopsis  
thaliana  
Efficient transformation system. 
The genome sequence was completed in 2000. 
Extensive EST resources are available.  
Not suitable for cultivation on an 
agricultural scale. 
Potato  Efficient transformation system. 
Tuber is edible raw. 
Tuber specific promoters available.  
Clonally propagated. 
Relatively low tuber protein content.  
Unpalatable raw form cooking may cause 
denaturation and poor immunogenicity of 
vaccines.  
Tomato Relatively efficient transformation system.  
Fruit is edible raw.  
Fruit specific promoter is available.  
Industrial fruit processing well establishes. 
Industrial greenhouse culture well establish. 
Relatively low fruit protein content. 
Acidity fruit may be incompatible with 
some antigen or for delivery to infants. 
No in vitro system to test fruit 
expression.  
Alfa-alfa Relatively efficient transformation system.  
High protein content in leaves. 
Leaves edible uncooked.  
Ideal system for animal vaccines.  
Potential for outcrossing in field.  
Deep root system problematic for 
cleaning in field. 
Legumes 
and cereals  
Production technology well establish.  
High protein content in seeds.  
Stable protein in stored seeds.  
Well suited for animal’s vaccines.  
Industrial seed processing well establishes.  
Inefficient transformation system. 
Heating or cooking for human use may 
cause denaturation poor immunogenicity 
for vaccines.  
Potential for outcrossing in field for some 
species. 
Banana Cultivated widely in developing countries 
(vaccines are needed). 
Eaten raw by infants and adults.  
Clonally propagated. 
Once stablish, abundant end inexpensive fruit 
is available on 10-12 months cycle.  
Inefficient transformation system.  
Little data available on gene expression 
especially for fruit specific promoters.  
High cultivation space requirement, 
expensive in greenhouse. 
Table 3: Features for different plants host system (by Warzecha and Mason, 2003) 
 
The production of plant-derived pharmaceuticals has attracted huge interest for 
their industrial development. Some achievements of MMF are listed in table 4. 
Table 4: Plant-derived pharmaceuticals in clinical trials, modified from U.S. National Institutes 
of Health Clinical Trial (2016). 
 
Product Host Application Clinical Trial Status Sponsor 
Taliglucerase alfa; 
Recombinant 
glucocerebrosidase 
(prGCD) 
Carrot cell 
culture 
Gaucher 
disease 
NCT00376168 
Phase 3 
completed 
(2012); FDA 
approved 
(2012) 
Protalix, Karmiel, 
Israel 
ZMApp  Tobacco Ebola Virus NCT02363322 
Phase 1 and 2 
(2015) 
National Institute of 
Allergy and Infectious 
Diseases (NIAID), 
Bethesda, MD, USA 
Vaccine Pfs25 
VLP 
Tobacco Malaria NCT02013687 
Phase 1 
(2015) 
Center for Molecular 
Biotechnology, 
Plymouth, MI, USA 
Vaccine 
Recombinant 
protective antigen 
Tobacco Anthrax NCT02239172 
Phase 1 
(2014) 
Center for Molecular 
Biotechnology, 
Plymouth, MI, USA 
HAI-05 Tobacco 
H5N1 
Vaccine 
NCT01250795 
Phase 1 
(2011) 
Center for Molecular 
Biotechnology, 
Plymouth, MI, USA 
Recombinant 
human intrinsic 
factor 
Arabidopsis 
thaliana 
Vitamin B12 
deficiency 
NCT00279552 
Phase 2 
completed 
(2006) 
University in Aarhus, 
Aarhus, Denmark 
16 
 
In particular, some success stories are mentioned below. 
Mapp Biopharmaceutical Inc., a company positioned in San Diego, CA, USA 
produced a drug in tobacco leaves named ZMapp, which has been used to fight 
the 2014 Ebola virus outbreak in Africa (Arntzen et al., 2015). By October 2014, 
seven infected patients got an early treatment with ZMapp and recovered. 
However, another patient, receiving a late treatment with ZMapp in November 
2014, encountered the disease and died. Further Ebola patients were unable to 
receive the treatment due to an insufficient stock of ZMapp. This is unfortunate 
as it is the only drug up to date that has been effectively used to treat patients 
infected with the Ebola virus, even though it has not been officially accepted by 
the U.S. Food and Drug Administration (FDA). ZMapp underwent a clinical 
Phase I and two trials in 2015, sponsored by the National Institute of Allergy and 
Infectious Diseases (NIAID).  
Middle East respiratory syndrome coronavirus (MERS-CoV) is a developing 
illness. Due to the high mortality rate of MERS (above 35%), it caused a public 
panic in South Korea during May 2015. By 27 November 2015, MERS-CoV 
infected 1618 patients and caused 579 deaths globally. Over 26 countries 
reported MERS-CoV cases. Today, still no effective drug is available to treat the 
MERS-CoV virus. Plant Biotechnology Inc. (Hayward, CA, USA) produced an 
immune-adhesin (DPP4-Fc) in transgenic tobacco. Purified DPP4-Fc presents a 
strong binding to MERS-CoV and inhibits the virus from infecting lung cells. In 
June 2015, Plant Biotechnology Inc. received funding’s from NIAID to support 
further development and testing of this. 
1.3-Plants Transformation: an overview  
Plants transformation indicates the introduction and integration of endogenous 
DNA into the plants genome and the consequential expression of exogenous 
genes. Today, the two main expression targets are considered seeds and leaves. 
The two major leafy crops used for the production of recombinant proteins are 
tobacco and alfa-alfa, which both have a high leaf biomass yield because they 
can be cropped more times a year. The principal drawback of leaf transformation 
is that the harvested leaves generally have a restricted shelf life. The recombinant 
proteins endure in a humid situation and are therefore somewhat unstable, which 
17 
 
can decrease product yields, the benefit of seed transformation is that 
recombinant proteins can be directed to accumulate specifically in the dried 
seeds. Therefore, although seed biomass yields are lower than the leaf biomass 
yields of tobacco and alfa-alfa this is balanced by the increased stability of the 
proteins. Seeds are natural storage organs, with the best biochemical 
environment for the accumulation of large amounts of proteins. The 
accumulation of proteins in the seed rather than vegetative organs also precludes 
any toxic effects on the host plant. Finally, the extraction of proteins from seeds 
is enabled because the target protein is condensed in a small volume; most cereal 
seeds lack the phenolic compounds that are often found in leaves and which 
interfere with processing, and the seed proteome is quite simple, which reduces 
the possibility of contaminating proteins.  
Transfer DNA into plants cells can result in a transient or stable expression of 
the introduced DNA.  
Stable transformation, is often a long process implicating tissue culture 
techniques that facilitate the growth of whole plants from treated cells or tissue 
explants. Because of its stable transformation, the introduction of DNA is 
integrated into the DNA of the host cell and is thereby suitable to be pass on to 
the next generation (Newell, 2000).  
Transient expression, as his name advocates, usually lasts for only a few days, 
and represents a useful tool in such areas as development of transformation 
methodology or metabolic studies since it permits the effects of experimental 
manipulation to be seen quickly.  
Both stable transgenic plants (Shinmyo and Kato, 2010) and plant-based 
transient expressions methods (Komarova et al., 2010) have been used to 
produce recombinant peptides. Characteristically, transient expression produces 
higher yields and allows more rapid accumulation, whereas transgenic plants can 
provide an almost limitless source of uniform material expressing the target 
molecule (Obembe et al., 2011). Different features need to be considered the 
DNA’s size, the time and the economic supplies needed, the transformation 
efficiency, the rang of transformable plants species, the type of explants of the 
host organism to realize the transformation.  
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Plant-cell-suspension culture  
Like mammalian cell culture, it is possible to use plants cell suspension, to 
produce several different biopharmaceuticals. Plants cell suspension is a 
convenient substitute in molecular farming, considering a single purification 
practice and easygoing downstream processing procedure. However, a high level 
of sterility is needed in order to avoid contamination. Moreover, compared to a 
plant-cell culture system, a plant cell suspension does not require a regeneration 
procedure; this is essential to guarantee a fast production of molecules. Despite 
having numerous advantages, plant-cell suspension cultures have been used for 
few botanical species, e.g. Tobacco, carrot, Arabidopsis and rice. Besides, this 
system presents an increasing proteolytic activity, which leads to a low 
concentration of the recombinant proteins, during the late stationary phase. 
Based on these concerns, plants cell suspension remains a challenging method 
for protein expression (Obembe et al., 2011). 
1.3.1-Stable expression in transgenic plants  
Different approaches can be used for a stable expression of recombinant proteins 
into plants tissues. Stable transformation of plants is reached mainly through 
agro-infection or through a biolistic method. However, Agrobacterium 
tumefaciens T-DNA normally integrates into random sites of the plants genome.  
Agrobacterium tumefaciens 
Agrobacterium tumefaciens is a soil pathogen that colonizes injured plant cells 
and induces the development of a tumor (or crown gall) that creates special 
amino acids byproducts called opines, which the bacteria are able to use as a 
carbon and nitrogen source. The capacity of virulent Agrobacterium strains to 
stimulate tumor growth and opine synthesis, and the capacity to use opines, is 
given by a resident tumor-inducing plasmid (Ti-plasmid). During the 
colonization process, a segment of DNA from this plasmid called T-DNA is 
shifted to the plants nuclear genome. The T-DNA encodes enzymes that 
synthesize auxins and cytokinins, which brings to an unregulated cell 
proliferation, and enzymes that synthesize opines from standard amino acids 
(Gelvin et al., 2003). The Ti plasmid is a naturally occurring vector for plant 
transformation, but wild type Ti-plasmids are not appropriate vectors for genetic 
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engineering in plants since they are too large to manipulate, and the oncogenes 
contained in the T-DNA because uncontrolled proliferation of transformed plant 
cells and prevent efﬁcient regeneration. The T-DNA must therefore be moved to 
a smaller, more suitable vector, and neutralized by deleting the oncogenes, and 
including the appropriate molecular construct. A marker gene must also be 
incorporated to allow transformed cells to propagate. T-DNA transfer is 
controlled by approximately 30 genes situated in a separate virulence (vir) region 
of the Ti plasmid, and these must be supplied in trans using a binary vector 
system if the T-DNA is placed on a smaller plasmid. Contemporary binary 
vectors comprise numerous unique cloning sites within the T-DNA, a lac-Z 
marker gene for blue-white selection of recombinants, and a choice of selectable 
markers to recognize the transformed plant cells (Hellens et al., 2000). The T-
DNA is surrounded by a 25-base-pairs (bp) imperfect direct repeats known as T-
border sequences, which are not transferred to the plant genome intact, but they 
are needed for the transfer process. T-DNA transfer is interceded by the virA and 
virG gene products, which transduce external signals and activate other vir genes 
resulting in the construction of a pilus for DNA transfer, and the release of the 
T-DNA by an endonuclease comprising the products of the virD1 and virD2 
genes (Figure 1). 
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Figure 1: Scheme representing agroinfection process. 
A comparative analysis in Arabidopsis and rice revealed that T-DNA inserted 
randomly in the Arabidopsis genome (which is globally gene-rich, with little 
repetitive DNA) but homed in on 10–20% of the rice genome known to be rich 
in genes, while escaping the more prevalent heterochromatic regions (Barakat et 
al., 2000). It has also been advocated that T-DNA integration occur favorably in 
regions displaying micro-homology to the T-DNA borders (Matsumoto et al., 
1990), which may also be enriched in the transcribed part of the genome. 
Agrobacterium-based transformation methods have proven to be useful 
approaches to genetically modified plants of various levels, including model 
plants such as Medicago trunculata, Arabidopsis thaliana, Nicotiana tabacum, 
Nicotiana banthamiana. Nonetheless, wild-type Agrobacterium tumefaciens is 
a pathogen of dicotyledonous species and the effectiveness of the 
Agrobacterium–based genetic transformation of monocotyledonous plants is 
still restricted due to the little integration percentage (Abiri et al., 2016). Novel 
approaches were developed to increase transformation efficiency in 
monocotyledonous such as maize, rye, barley wheat and rice.  
Biolistics 
Particle bombardment, or biolistics, is a frequently used method for genetic 
transformation of plants and organisms. Millions of DNA-coated metal 
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particles are shot at target cells or tissues by a biolistic device or gene gun. 
The DNA elutes off the particles that reside within the cells, and a part may 
be stably incorporated in the host chromosomes (Kikkert et al., 2005). This 
physical direct technique is used for the genetic transformation of several 
organisms. Plants transformation using particle bombardment follows the 
same steps as the Agrobacterium-mediated transformation method:  
 Isolation of chosen genes from the source organism  
 Development of a functional transgenic construct including the selected gene 
of interest ; promoters to drive expression; modification of the codon, if 
needed to increase successful protein production and marker genes to 
facilitate tracking of the introduced genes in the host plants  
 Insertion of the transgenic construct into a useful plasmid  
 Introduction of the transgenes into plants cells  
 Regenaration of plants cells  
 Testing of the performance of the traits or gene expression under in-vitro, 
greenhouse or field conditions.  
In the particle bombardement method, 1-2 mm tungsten or gold particles (called 
microprojectiles) coated with genetically engineerd DNA are enhanced with air 
pressure at high speeds and shot into plant tissues on a Petri-plates, as shown in 
Figure 2.  
 
 
 
 
 
 
 
Figure 2: Schematic representation of biotistic tool for plant transformation 
 
Plastic disc with DNA coated gold particles 
DNA coated gold particles  
Plastic disc stopped by screen coated 
Target plant cell 
Gene gun barrel   
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This is the second most used method, after Agrobacterium mediated 
transformation, for plants genetic transformation. The device accelerates 
particles in one of the two ways: by means of pressurized helium gas or by the 
electrostatic energy released by a dropet of water exposed to high voltage. 
Particle bombardment methods are also useful in the transformation of 
organelles, such as chloroplasts, which enable engineering of organelle-encoded 
herbicide or resistance in crop plants and to study photosynthetic processes. 
Restrictions to the particle bombardment method, compared to Agrobacterium 
mediated transformation include frequent incorporation of multiple copies of the 
transgene at a single insertion site, rearrangement of the inserted genes and 
insertion of the transgenes at multiple insertion sites. These multiple copies can 
be associated with the silencing of the transgene in subsequent progeny. The 
target tissue may often be damaged due to lack of control of the bombardment 
velocity. 
The microcarriers (or microprojectiles), the tungsten or gold particles coated 
with DNA are inserted by macrocarriers wich are then introduced into the 
apparatus and pushed downwards at high speeds. The macro-projectiles are 
stopped by a perforation plate, allowing the microprojectiles to be propelled at a 
high speed into the plants cells on the other side. As the micro-projectiles enter 
the plants cells, the transgenes are freed from the particles surface and can be 
inserted into the chromosomal DNA of the plant cells. Selectable markers give 
the opportunity to identify those cells that take up the transgene or are 
transformed. The transformed plant cells are then regenerated and developed 
into whole plants by using the tissue culture technique. 
1.3.2-Transient expression in transgenic plants  
Another useful method to obtain biopharmaceuticals from plants is called 
transient transformation. This method is faster compared to stable transfection, 
considering that it often takes six months to a year or more to produce transgenic 
plants. In addition, several generations are required to generate plants that are 
homozygous for the transgene. Most transformation technologies also result in 
the gene being inserted randomly into the plants genome. By using the transient 
transformation, a large quantity of biopharmaceuticals can be created in less than 
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five days (Andrews et al., 2005; Catrice et al., 2015); especially when compared 
to the stable transformation method. 
Scientists joining and viruses achieved one of the most efficient methods to 
produce biopharmaceuticals in plants in a short time. The key of this method is 
to transfer specific components of the viral expression platform by mixing a 
dissimilar Agrobacterium strain harboring portions of the viral machinery, with 
recombination occurring within the cells once infection has occurred. The well 
mixing between viral codons and classic eukaryotic introns leads to a significant 
increase in efficiency of gene delivery and the required amount of the essential 
infectious Agrobacterium reduces. Transient transfection has been developed for 
small or medium-scale PMF (plant molecular farming) production.  
For example, Mason et al. (2010) developed a highly efficient, bean yellow 
dwarf virus (BeYDV) based single-vector DNA replicon system, which 
incorporated multiple DNA replicon cassettes. They produced 0.5 mg of 
antibody per gram leaf (fresh weight) in tobacco leaves within four days 
following infiltration (Figure 3) 
 
 
 
 
 
 
 
 
 
 
Figure 3 A: Plant-based transient expression system. A: Infiltration of Agrobacterium carrying 
the GFP transgene (Left); and transient expression of GFP (Right). Infiltrated leave can be 
examined with a UV lamp at four days’ post infiltration. B: Diagram of the pBY030.2R vector 
used by Mason et al. (2010) for the transient expression of GFP.   
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Mapp Biopharmaceutical Inc. using similar methodology, transiently expressed 
the humanized antibodies, MB-003 and ZMab, in tobacco leaves. MB-003 and 
ZMab were later combined and designated as ZMapp. The use of these 
antibodies as a pharmaceutical drug cured 100% of Ebola infected rhesus 
macaque’s primates (Huang and Arzten, 2010) as previously described. Based 
on the latter, it is clear that this method is useful, productive and cheap compared 
to other systems. For example, 1 liter of a bacterial overnight culture could be 
used to infect about 1000 kg of tobacco leaf tissue, yielding up to 4 kg of 
recombinant protein at 40% TSP (Marillonnet et al., 2005). This manner, which 
has just been discovered, to maximize protein yields while reducing the input 
costs, results in an expected $1/kg of recombinant protein or $50/kg of purified 
protein (Abiri et al., 2016). Generally, transient expression has two main 
problems, those being the high technical requirements for the induction and the 
high risk of accidentally spreading the infection to wild species. In addition, this 
system remained restricted by laborious scale-up and by controlled conditions, 
such as those of a greenhouse or laboratory. 
Root-absorption. 
The pharmaceutical proteins can be efficiently expressed in plants via virus 
vector infection. However, previously mentioned issues prevent development 
and exploitation for the industrial –scale expression of heterologous proteins.  
In a recent paper, the authors described a simple system named "root absorption" 
to effectively express foreign proteins in plants (Yang et al., 2008). It has been 
shown that the green fluorescence protein (GFP) was expressed in tobacco plants 
by root absorbing the Agrobacterium suspension containing the TMV-based 
P35S-30B-GFP vector. Various factors influencing the gene expression were 
studied including Agrobacterium cell density, seedling age, plant materials and 
inoculation conditions. This system benefits of advantages such as simple and 
convenient work processes, ease to scale-up and higher level of expression than 
leaf infiltration. Remarkably, GFP was expressed at 24h post-absorption. We 
assume that the root absorption system will ease the large-scale production of 
the recombinant pharmaceutical proteins in plants by means of transient 
expression. Briefly: Agrobacterium suspension containing P35S-35S-30B 
vectors was placed into a 5 ml Eppendorf tube, and then the root part of each 
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plant was placed into the induction medium (1x MS salt, 10 mM MES, 200 µM 
acetosyringone, 2% sucrose [MMA]) in the tube and cultured at 25±3 C° in a 
growth chamber under 16h light/8h dark cycles. Compared with the leaf 
infiltration technique, this new method is a simple and convenient process, and 
ease to scale-up. Moreover, the expression level obtained by root absorption was 
higher than the leaf infiltration method. It is assumed that the root absorption 
system may facilitate a rapid, large-scale and high expression level manner for 
the production of recombinant proteins in plants in the future. 
Air-brushing  
A further transient expression system for large-scale production of recombinant 
protein in plants is based on “air-brushing” an Agrobacterium suspension. In a 
paper published in 2015 Yang and his colleagues described a more convenient 
system than root absorption for the transient expression of foreign proteins in 
plants. The Nicotiana benthamiana leaves were agro-inoculated with an 
Agrobacterium suspension. The Agrobacterium-suspension was placed into an 
airbrush tube and then sprayed onto the leaves using the airbrush method. 
Whitman et al. (1999) at a 75-80 psi export pressure during spraying. The 
inoculated plants were covered with black plastic bags for 24 h for recovery. 
Next, they were cultured at 25±3°C in a growth chamber under 16h light/8h dark 
cycles. The proposed system is advantageous because it presents a fast, simple 
work procedure. For instance, when the Agrobacterium suspension is prepared 
beforehand, it only takes 20 minutes to spray hundreds of plants with suspension. 
Therefore, it is clear that when a large numbers of plants need to be agro-
inoculated, the new system permits more advantageous and applicable for 
transiently expressing extraneous proteins (Jin et al., 2015). 
Vacuum infiltration 
Vacuum infiltration of Agrobacterium for transient gene expression in whole 
plant leaves is a fast, scalable, and useful approach for the production of foreign 
proteins with no need to generate transgenic plants (Fisher et al., 1999). During 
vacuum agro-infiltration, plants are set upside down and aerial parts submerged 
in Agrobacterium suspension. Then vacuum is applied causing gases to evacuate 
from leaf intercellular spaces through stomata. Rapid re-pressurization following 
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release of the vacuum results in the infusion of the Agrobacterium suspension 
into the leaf. Following vacuum infiltration of Agrobacterium, plants are further 
cultivated and target expression is monitored. The highest levels of target 
expression are typically observed 2-3 days’ post-infiltration (dpi) with a binary 
vector and 4-7 dpi with a launch vector, after which the expression level typically 
decreases (Musiychuk et al., 2007). Agrobacterium tumefaciens is the most 
widely used vehicle for delivering a gene of interest into a plant for protein 
production. Agro-infiltration works extremely well in N. benthamiana but 
relatively poorly in most other plants, including Arabidopsis thaliana. 
1.4-New advances in crop genetic engineering tools 
The stable and gradual improvement in molecular biology has led to the 
advancement of new technologies to engineering plants. Traditional methods of 
crop transformation like Agrobacterium-mediated and particle bombardment are 
dependent on the random insertion of multiple copy of transgene into plant 
genome that may lead to gene silencing and unpredictable expression pattern. 
Because these restrictions, screening of stable transgenic lines with the desired 
level of transgene expression is labor intensive, slow and expensive (Ow, 2005). 
Many researches had focused on the deletion of random DNA integration and 
the reduction of the frequency of multi-copy transgene insertions and overll on 
techniques with a graeter consumer acceptance. 
Recombinase technology 
Site-specific recombinase systems were discovered in bacteria, yeast, and found 
to facilitate a number of biological functions. Site-specific recombination occurs 
at a specific sequence or recognition site and involves cleavage and reunion 
leading to integration, deletion or inversion of a DNA fragment without the gain 
or loss of nucleotides. Site-specific recombination (SSR) is a promising 
technology that can help to bypass most difficulties in genetic engineering. Since 
the 90s, three SSR systems have been described: the Cre-lox from Escherichia 
coli bacteriophage P1, the FLP-FRT from S. cerevisiae, and the R-RS from 
Zygosaccharomyces rouxi. This technology is reasonable to produce marker-free 
transgenic crop plants; but it may not be ideal due to constraints on time, labor 
and the substantial financial resources needed. Generation of transgenic crops in 
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this way necessitates multiple generations and may not be practical in species 
with longer generation times such as trees, or in other crops such as potato, which 
are propagated asexually. However, in 2006 Monsanto developed a first 
commercial marker-free corn LY038 based on Cre-lox system (Ow, 2007), 
which consists in a high content of lysine used as feed for poultry and swine. 
Recombinase-mediated excision has also been used in numerous crop plants 
such as wheat (Srivastava et al., 1999) and rice (Chawla et al., 2006) to determine 
complex insertion sites, containing multiple transgenes, down to a single copy. 
This also decreases the effort needed to screen the total number of transgenic 
plants to find a suitably expressing single copy line that is heritable. Rates of 
integration have been documented from ~33% in tobacco (Albert et al., 1995; 
Day et al., 2000) to almost 50% in rice (Srivastava et al., 2004).  
Cisgenesis/intragenesis 
The term "cisgenic plant" has been introduced a few years ago and it refers to "a 
crop plant that has been genetically changed with one or more genes” (containing 
introns and flanking regions like native promoter and terminator regions) 
selected from a crossable donor plant (Schouten et al., 2006a). It denotes that the 
genetically modified cisgenic crop encompasses genes maintaining their natural 
genetic composition, i.e. a perfect complete copy of a natural gene with all its 
regulatory elements. The font of a cisgene is the same plant species or a sexually 
compatible species as used for traditional breeding. However, contrasting 
traditional breeding, cisgenic crops contain solely the gene or genes of interest 
and no undesired genetic elements (Kamthan et al., 2016). 
On the contrary, intragenesis indicates GMOs where the introduced gene 
originates from the identical species or a crossable species, but in contrast to 
cisgenes, intra-genes are hybrid genes, which can have genetic elements from 
diverse genes and loci (Rommens et al., 2007). As a result, the expression of a 
certain gene could be modified by using a different promoter or terminator 
regions. 
The scientific community has interest in promoting less stringent regulations for 
cisgenic/intragenic crops. For instance, the European Commission (EC) 
requested the European Food Safety Authority (EFSA) to determine the hazards 
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of cisgenic/ intragenic crops compared to transgenesis or traditional breeding 
(EFSA Panel on Genetically Modified Organisms, 2012). Up to date, numerous 
traits have been incorporated into relevant crops by cisgenic or intragenic 
approaches. These species comprise potato (de Vetten et al., 2003; Rommens et 
al., 2005; Rommens et al., 2006; Rommens et al., 2008; Haverkort et al., 2009), 
apple (Joshi et al., 2011; Vanblaere et al., 2011), strawberry (Schaart et al., 
2004), alfa-alfa (Weeks et al., 2008), perennial ryegrass (Bajaj et al., 2008), 
poplar (Han et al., 2011), barley (Holme et al., 2012) and durum wheat (Gadaleta 
et al., 2008). Recently, both intragenesis and transgenesis have been applied to 
different cultivated crops. Intragenic potato has been developed to produce high 
amylopectin content (De Vetten et al., 2003). An intragenic method also aimed 
to produce scab resistance in apples. Modification of tree architecture and 
growth rates is a major issue for the wood plant business. Based on the latter, a 
cisgenic method developed in poplar seeds to address both issues (Han et al., 
2011). Until now, application of cisgenesis and intragenesis as alternatives to 
conventional transgenesis is limited to a few species, mainly because of the lack 
of knowledge of the regulatory sequences required. For several relevant crops, 
the current knowledge of full genomic sequences has opened up new 
possibilities to use genes and their native regulatory sequences to improve 
important traits (Espinoza et al., 2013). 
Genome engineering/editing.  
One of the newest approaches in engineered plants is genome editing. This 
method could be used first to determine the desired modification in plants and 
then to introduce chosen genetic variation in a rapid and accurate manner. The 
idea is to introduce targeted double-strand breaks (DSB) at a desired locus, 
which can be efficiently used to modify the genome of plants. Targeted DSBs 
can be realized using sequence-specific nucleases (SSNs) that are capable to 
recognize and split the selected locus with high specificity. What concerns the 
latter, four main classes of enzymes can lead to genome engineering: engineered 
homing endonucleases or mega-nucleases, zinc-finger nucleases (Kim et al., 
1996), transcription activator-like effector nucleases (Christian et al., 2010), and 
clustered regularly interspersed short palindromic repeats (CRISPR)/Cas9 
reagents. The latest addition to the family of sequence specific nucleases is the 
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CRISPR/Cas, which is proving to be the nuclease-of-choice for plant genome 
engineering. The innate defense system of prokaryotes involving CRISPR and 
Cas9 against an invading DNA element such as a virus or plasmid has been 
engeneered to versatile plug and play tool for genetic engineering. 
Table 5: Summarizes various approach than can be applied to generate genetically improved 
crop varieties and can be used in molecular farming (Kamthan et al., 2016). 
1.5-Plastid transformation  
Plastids are a group of organelles existing in the cells of plants, algae, and several 
protists and are crucial for viability (Waters and Pyke, 2005). The plastid 
genome provides an alternative site for the stable insertion of transgenes in plants 
and is frequently considered an ‘environmentally friendly’ form of plant genetic 
engineering, as plastid DNA (in most crops) is largely omitted from pollen. 
Chloroplast transformation was first proved for the unicellular green alga 
Chlamydomonas reinhardtii (Boynton et al., 1988) followed by the higher plants 
tobacco (Svab et al., 1990a) and tomato (Ruf et al., 2001). Since then, the 
chloroplast genome has been manipulated to produce vaccine antigens, 
commercial enzymes, hormones, antibodies, pharmaceuticals, and biomaterials, 
and engineered to deliver different agronomic traits, including resistance against 
various biotic (viral, fungal, and bacterial diseases) and abiotic (e.g. salt, 
drought, heavy metals) factors (Table 6). However, the number of crop plants in 
which chloroplast transformation has been reported remains very low and the 
technology has not yet reached success in the field. 
 
Approaches  
 
Examples  Advantages  Disadvantages  
 Conventional breeding 
Stable transfection  
 
Agrobacterium tumefaciens  
Biobalistic 
Plastids 
Plants-cell suspension  
Efficient, effective to improve 
many traits. 
Inheritance of non-desired traits 
Time cosuming  
Random insertion of exogenous 
DNA 
Transient 
expression 
 
More targeted and rapid  
Introducing a transgene from 
an organism to host organism 
that cannot be crossed  
Biosafety issues, environment and 
health hazards   
Cisgenesis/ 
intragenesis 
 
Greater consumer acceptance  
Environmental friendly  
Require efforts to look for 
compatible gene pool  
Recombinase 
technology  
Cre-lox 
FLP-FRT 
R-RS 
Site specific integration of 
transgene 
Merker-free plants  
Not suitable for all species  
Screening of transformed plants is 
laborious and time consuming  
Genome editing  
Meganucleases  
Zinc finger 
TALEN /TALE 
CRISP/Cas9 
Targeted and precise  
Engineering complex traits  
Useful for gene stacking  
Focused to knockout gene  
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Table 6: Enzymes, biomaterials, vaccine antigens, and agronomic traits engineered via 
transformation of the higher plant chloroplast genome (modified from Ahmad et al., 2016). 
This feature offers possibility to use chloroplast transformation to introduce 
natural and artificial operons into the plastome in a single transformation step. 
Nevertheless, post-transcriptional processes inside the chloroplast, such as RNA 
editing, removal of introns, processing of mRNA ends, and cleavage of larger 
mRNA transcripts (reviewed by Bock, 2015) should be taken into account. In 
addition, there are several factors limiting the technology.  
Routine chloroplast transformation is currently limited to dicotyledonous plants 
and mainly members of the Solanaceae family, even if transformation of several 
crop plants has been successfully demonstrated, it is still not available for 
monocotyledonous plants except for rice (Lee et al., 2006). 
Another important limitation is that expression of transgenes in non-green 
plastids is not as efficient as in green plastids (chloroplasts). Although the 
plastome is quite small, its contribution to the protein expression in 
photosynthetically active tissues can reach up to 50% of the total leaf protein 
content. In contrast, expression levels are considerably lower in non-green 
plastids (Zhang et al., 2012), which can result in a lower expression of foreign 
proteins. 
Enzymes/protein Gene 
Host 
plants 
Expression 
(%TSP)  
References 
Biopharmaceuticals  
Α 1-antitrypsin SERPINA1 Tobacco 2  Nadai et al., 2009.  
Aprotinin  APR Tobacco 0.5 Tissot et al., 2008. 
Coagulation factor IX CTB-FIX Tobacco 3.8 Verma et al., 2010b. 
Human serum albumin  Has Tobacco 11 Fernandez et al., 2003. 
Human somatotropin  hST Tobacco 7 Staub et al., 2000. 
IFN- GUS-IFN-g Tobacco 6 Leelavathi et al., 2003. 
Enzymes/biomaterial  
Cellulases Bgl1-,cel6B Tobacco 5-40 Petersen and Bock 2011. 
Trp Asa2 Tobacco ND Zhang et al., 2001. 
B-glucosidase Bgl1 Tobacco ND Jin et al., 2011. 
Pectin lyase PecA Tobacco ND Espinoza-Sanchez, 2015 
Bacterial      
Anthrax antigen  pa Tobacco 2.5-4. Gorantala et al., 2014. 
PWD FaeG Tobacco 1% DW Kolotilin et al., 2012. 
Viral     
Human papilloma virus GUS E7 Tobacco 3-4 Morgenfeld et al., 2014 
HIV  C4v3 Tobacco 25mg FW Rubio-Infante et al., 2012 
Rotavirus Vp6 Tobacco 15 % TLP Inka-Borchers et al., 2012 
Agronomic traits     
Herbicide resistance  aroA bar     
Abiotic stress tolerance g-TNT  7.7%TLP Lin and Daniell., 2014  
TLP:  total leaf proteins; TSP: total soluble proteins; ND: not determined; DW: dry weight; FW: fresh weight 
(all concentrations in w/w). 
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Transgene containment in the chloroplast genome is not total. The desirability 
to use plants as ‘green factories’ lies in their scalability. Although plastids 
generally provide a degree of natural gene containment due to their maternal 
mode of inheritance, this containment is not absolute, as mentioned before. 
Absence of glycosylation: plastids are capable of carrying out many of the post-
translational modifications (PTMs) indispensable for the production of a 
physiologically active protein, such as the disulphide bond formation, lipidation, 
multimerization, and N-terminal methionine excision (Rigano et al., 2012). 
However, chloroplasts do not have the necessary machinery to carry out the 
glycosylation, very important PTMs in eukaryotes (Paul and Ma, 2013). The 
deficiency of glycosylation in chloroplasts may therefore be a bottleneck for the 
synthesis of those proteins that rely on this PTM for their correct functioning. 
1.6-Optimization of the expression in host plants 
Heterologous proteins are divided into three main groups: therapeutic proteins 
or those used for clinical diagnosis, proteins used as reagents for research and 
study commitments and proteins with different industrial purposes. Among these 
proteins, proteins used for therapeutic purposes constitute a singular class with 
the stringent quality standards and therefore require high value. A valuable 
expression system should (i) be capable of producing the needed protein with 
right conformation, (ii) have good productivity, (iii) be easy to handle and 
maintain, (iv) be safe and cheap, and (v) demand easy downstream processing. 
For the expression of required proteins in plant, DNA sequences can be 
integrated into the plants nuclear DNA through a suitable vector using 
appropriate transformation technologies. The gene should then be transcribed 
and translated. Ultimate expression of proteins is a quite complex process 
performed by many enzymes, co-factors, regulators, and compartmentalized in 
several sub-cellular organelles. In the last years, few steps have been identified 
as rate limiting which can be improved to increase expression of a desired 
transgene (Table 7). 
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1. Transformation and integration 
Attachment of SAR to DNA 
Increased expression of GUS gene in 
tobacco cells up to 140-fold 
Allen et al., 1996 
2. Transcription 
Addition of Myb and leucine 
zipper 
Increased expression 
Boulikas et al., 
1994 Hurst et al., 
1994) 
Hybrid promoter (Mac), of 
CaMV 35S and mannopine 
synthetase 
GUS gene expression was increased 3–5 
fold in leaves and 10–15 fold in 
hypocotyls and roots in tobacco and 
tomato plant, resp. 
Comai et al., 1990 
Addition of Intron 2 and 6 of 
maize alcohol dehydrogenase-1 
Increase the expression of CAT 
(Chloramphenicol acetyl transferase) 
gene by 12-fold and 20-fold respectively 
in maize protoplasts 
Mascarenhas et 
al., 1990 
3. Translation  
Changing initiation codon 
context 
GGUUUAUGU to 
CCUCCAUGU 
Increased expression 
Gallie, 1993 
Codon optimization in tobacco 
and tomato plants 
Increase expression of cryIA (b) 
(Bacillus thuringiensis) up to 100-fold 
Perlak et al., 1991 
4. Final yield or protein accumulation 
Targeting to sub-cellular 
compartments e.g. apoplast 
104-fold higher Expression of human 
epidermal growth factor (hEGF) was 
obtained in tobacco 
Wirth et al., 2004 
Table 7: Strategies used for enhancing expression of transgenes in plants. 
Sometimes, a problem, which occurs in engineered plants, is the genetic 
expression level and the non-functional proteins production. This is generally 
observed with multiple copy integration at one or more sites, different base 
composition between foreign DNA and the integration site, detrimental effects 
of sequences adjacent to the foreign DNA integration site, and over expression 
effects. 
1.6.1-Optimization by Codon Usage  
The redundancy of the genetic code means that most amino acids are encoded 
by multiple synonymous codons. In all domains of life, a biased frequency of 
synonymous codons is observed at a genomic level, in functionally related genes 
(e.g. in operons), and within single genes. Although translation initiation is a 
fundamental step in protein synthesis, it is generally accepted that codon bias 
contributes to translation efficiency by tuning the elongation rate of the process. 
It is generally known that the genes in bacteria, mammals or humans are not very 
active in crop plants, in molecular farming become pivotal adjusting the DNA 
code to suit the “codon bias” typical of the crop plant species into which genes 
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from bacteria or mammals are introduced. Complete codon engineering by 
replacing codons with more favorable codons through the whole gene could 
generate partially or completely modified synthetic genes, which can improve 
the expression levels of the transgene (Sutton et al., 1992). This approach 
improved the expression levels of the transgenes “winter flounder antifreeze 
protein” (AFP) in corn (Georges et al., 1990), the porcine alpha lactalbumin gene 
in the seeds of transgenic maize and the B-subunit of heat labile enterotoxin of 
Enterotoxigenic E. coli (LT-B) (Lauterslager et al., 2001; Streatfield et al., 
2002). Optimization of plant mRNA processing by replacing the AAT codon to 
GTG surrounding the translation initiation site of LT-B gene resulted in 5-40 
fold higher quantity of LT-B expression level when transformed in potato 
(Mason et al., 1998). Different software programs are accessible for the 
optimization of codon usage, such as Gene Designer (Villalobos et al., 2006) and 
OPTIMIZER (Puigbò et al., 2007). Moreover, numerous strategies are used to 
inactivate the foreign DNA at an integration level: screening and selection for 
plants with single-copy integration, omitting repetitive homologous sequences 
and flanking exogenous DNA with the Scaffold Attachment Region (SAR). 
SARs are DNA sequences that stay specifically associated with the scaffold once 
the digestion of the chromatin with restriction enzymes occurs. SAR elements 
are common among different species and it is demonstrated that they are 
functionally preserved throughout evolution (Cockerill and Garrard, 1986a).  
1.6.2 Synthetic biology 
Recent progresses in genetic engineering made it possible to effect previously 
unobtainable genetic changes in most organisms, exposed to breeding, like 
plants. The genetic distance between the engineered organism and the source of 
the new genetic variation would be a functional measure for assessing the 
newness of the presented genetic changes. A more accurate and explicit 
nomenclature based on the genetic distance associated with the introduced 
genetic modifications is illustrated in table 8. 
In order to increase and maximize expression of exogenous proteins in 
engineered plants synthetic genes can be used (xenogenic modification) as 
explained in Nielsen et al. (2003).  
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Categories Source of genetic modifications Genetic variability 
via conventional 
breeding 
Genetic distance  
Intragenic Whitin genome Possible LOW 
 
 
 
 
HIGH 
Famigenic Species in the same family Possible 
Linegenic Specied in the same lineage Impossible 
Transgenic Unrelated species Impossible 
Xenogenic Laboratory designed genes Impossible 
Table 8. Proposed categories for organisms currently designated ‘transgenic’ or genetically 
modified (Nielsen et al., 2003). 
The aim of synthetic biology is to design artificial biological systems for novel 
applications. From an engineering point of view, construction of biological 
systems of defined functionality in a hierarchical way is essential to this 
emerging field. Neilsen et al. in a review published in 2013 described cells and 
the use of regulatory networks to execute computational operations to answer to 
their environment. Reliably manipulating such networks would be precious for 
many applications in biotechnology; for example, in having genes being 
expressed only under certain circumstances or applying dynamic or temporal 
control of expression, building such synthetic regulatory circuits is still one of 
the most challenging tasks in genetic engineering and as a result, they have not 
found extensive applications (Nielsen et al., 2003). New gene elements have 
been identified, remodeled or designed, which are further merged to build 
artificial biologic systems with specific purposes. From an engineering point of 
view, the design of a biologic system requires the appropriate disintegration of 
the design task into gene elements and their basic combinations able to operate 
in forms of circuits, devices and modules, and then uses a bottom-up 
methodology to further assemble them into more complex systems in an 
hierarchical manner. Ten years after the first two synthetic elements were 
introduced in this field (Elowitz and Leibler, 2000; Garden et al., 2000), 
synthetic biologists have made advancements to engineer a huge assortment of 
artificial gene parts to enlarge their functionalities and applications. The goal of 
synthetic biology is to extent or change the behavior of an organism and engineer 
them to make them execute a new task. Recent developments in synthetic 
biology towards engineering complex living systems thought novel assemblies 
of biological molecules. Recent advances have demonstrated successes in the 
design of some genetic circuits, devices and modules, especially those for the 
regulation of the genes expression. However, these designs are predominantly 
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for proof of concepts and far from generalization and rationalization. A more 
focused and targeted attempt on the design parts list could ease the 
standardization of design parts. Future work could be focused on systematically 
mapping functional motifs and calculating the effects of their combinations as 
linear signal cascade and in the framework of complex connections (Zhang et 
al., 2010).  
1.6.3-Optimization of Promoters  
The upstream element of a gene called promoter is an essential part in the 
gene expression, because of the presence of sites with a specific core 
sequence to which RNA polymerase and transcription factors bind. By using 
different promoters, the regulation of protein synthesis in plants can be 
improved. Table 9 shows several promoters used in molecular farming. 
Table 9: Most frequently used promoters in plant transformation (Desai et al., 2010). 
The promoter is a genetic element that regulates when and where the 
transcription occurs. Generally, the promoters are constitutive, inducible and 
specific for a certain tissue. Based on these issues is it possible to maximize the 
expression levels of a certain protein. Constitutive promoters deliver high 
expression levels. The most common used constitute promoters are the 
cauliflower mosaic virus 35S (CaMV 35S) promoter and the maize ubiquitin-1 
(used in dicots and monocots, respectively) promoter. These promoters have a 
viral origin and deliver an increase in the expression of a selected gene. 
However, also some harmful effects such as gene silencing via co-suppression 
have been reported (Sutton et al., 1992). With the help of constitutive promoters, 
Promoters Origin Type of 
promoter 
Reference 
CaMV 35S Virus Constitutive Odell et al., 1985 
C1 
Cotton leaf curl multan 
virus 
Constitutive Xie et al., 2004 
Polyubiquitin-1 Maize Constitutive Christensen et al., 1992 
Actin Rice Constitutive An et al., 1996 
Pristinamycin-
responsive 
Virus Inducible Frey et al., 2001 
In2-2 Maize Inducible De Veylder et al., 1997 
Nopaline synthase Agrobacteria Inducible Shaw et al., 1984 
Mannopine synthase Agrobacteria Inducible Langridge et al., 1989 
Patatin Potato Tuber specific Liu et al., 1991 
GBSS Potato Tuber specific Visser et al., 1991 
Maize globulin-1 Maize 
Embryo 
specific 
Belanger & Kriz, 1991  
Β-Conglycinin Soybean 
Embryo 
specific 
Chen et al., 1986 
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extensive expression of foreign genes in plant cells can be obtained and this 
could lead to an amassing of recombinant proteins in the cells, which at the end 
leads to be toxic for the cells. This problem can be skipped by employing 
inducible or tissue specific promoters (Majumadar, 2013). 
Wound inducible defiance gene originating promoters are known to be used for 
the expression of recombinant proteins in plants (Cramer et al., 1996; Hansen et 
al., 1997). In plants tissue specific promoters can be used and to target the 
expression in certain tissues that have a lower metabolic activity such as seed 
embryos or endosperm. This is an advantage in the downstream purification 
process. The maize globulin-1 promoter used to target the protein expression to 
the embryo of monocots (Belanger et al., 1989) is a popular tissue specific 
expression promoter. Other tissue specific promoters like the sps1 promoter for 
leaf-specific expression (Chavez-Barcenas et al., 2000), the patatin promoter for 
tuber-specific expression (Park et al., 2002), are well known. There are several 
other reported seed specific or embryo specific promoters (Majumadar, 2013). 
In particular, in the case of the development of an oral vaccine where edible parts 
of plants are directly used for the immunization, tissue specific promoters 
represent the main choice. The expression levels in the seeds of monocots using 
seed-specific promoters are higher than those obtained when using constitutive 
promoters.  
1.6.4-RNA processing, intron mediated enhancement and stability  
RNA processing steps such as capping, splicing and poly-adenylation can have 
an impact on the expression levels of therapeutic proteins. Sequences 
downstream to stop the codon are critical for the processing and should 
incorporate signals targeting the message for poly-adenylation. Poly-adenylation 
sites also influence the solidity of the message and the protein expression levels 
in plants (Lin et al., 2009). After the transcript is being synthesized, the RNA 
stability is important to achieve a high expression level. There are specific 
recognition sites that reduce the RNA’s half-life (Sullivan and Green, 1993). 
Some of these sites are known and probably correspond to specific binding sites. 
To increase the accumulation of recombinant proteins, it could be necessary to 
identify, modify or delete them. 
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1.7-Targeting protein 
As explained before, it is possible to target the expression of proteins in a specific 
organelle or specific part of the plant. Protein targeting is important and should 
be optimized to get a better output. After translation, proteins are folded and then 
moved to intercellular locations through molecular chaperones, which protect 
the native protein from degradation. Protein targeting is needed for its stability, 
modification and for the survival of the plant. Proteins secreted in cytosol are 
often degraded by proteases and until today protease free plant lines are is still 
not possible to establish. Glycosylation and disulfide bridge formation in the 
recombinant protein is only possible in the endoplasmic reticulum (ER) and in 
the Golgi apparatus of plant cells. Therefore, after translation, the glycoproteins 
need to be transported to ER or Golgi apparatus (Ituriaga et al., 1989; Horvath 
et al., 2000). Targeting proteins to intracellular organelles (such as the ER, the 
chloroplast, and the vacuole) or secretory pathway (like the ER or the Golgi 
apparatus) eases the proper folding of proteins, which is crucial for their 
appropriate functioning and increased expression levels (Pelham et al., 1990; 
Schouten et al., 1996). By incorporating C-terminal ER retention signal, 10-100 
fold increases in the target protein yield is achievable as when targeting them to 
the secretary pathway (Conrad and Fiedler, 1998). Improved accumulation of 
LT-B in tobacco and potato has been observed by directing the recombinant 
protein to the microsomes (Mason et al., 1995). As mentioned before, targeting 
the production of proteins in endoplasmic reticulum is more convenient 
compared to the cytosol. Certain ER retention signal sequences like the KDEL 
and the HDEL are used to minimize eventual protein degradation, since the ER 
comprises very small amounts of proteases and offers a quite protective 
environment. 
1.8-Seed based platforms  
Recently, most pharmaceutical proteins are produced in leafy crops for obtaining 
great biomasses. However, leaf proteins during harvest are easier degraded with 
proteolytic enzymes in plants. In addition, long-term storages of leaf material 
are also tricky. Based on preceding experiences, overexpression of foreign 
proteins in leaf cells can also result in necrosis and cell death (Phoolcharoen et 
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al., 2011). Seed-based systems have extra advantages because they exploit the 
natural storage properties of seeds to ease batch processing and distribution. The 
stabilizing effect of seeds after harvest permits the recombinant subunit vaccines 
and antibodies to be transported via the mucosal route, as they are more able to 
survive the harsh environment when protected by the plants matrix. Seeds have 
proven to be adaptable hosts for recombinant proteins of all types, including 
peptides or short and long polypeptides as well as complex, noncontiguous 
proteins such as antibodies and other immunoglobulins. The extraction and 
recovery of recombinant proteins from seeds is greatly assisted by their 
dormancy properties, since this allows a long-term stability of stored products 
including recombinant proteins and a separation of the processing from the 
growth and harvest cycles. Furthermore, the low water content and relatively 
low bio load of seeds help in designing relatively cheap manufacturing processes 
for the desired active pharmaceutical ingredient (Boothe et al., 2010). Seeds 
offer themselves to many applications in the area of molecular farming. A vast 
number of species have been investigated including Arabidopsis, barley, 
Brassica spp, corn (Streatfeld et al., 2002), pea (Perrin et al., 2000), rice (Szarka 
et al., 2006) and soya bean (Philip et al., 2001). In rice for example, the use of 
storage protein promoters to coordinate the expression of genes for mammalian 
proteins such as human lysozyme, resulted in an average expression level of 
13%–14% of the total soluble protein (Huang, 2004), which is quite good within 
an economic threshold for the target protein. Antibodies and scFv proteins in a 
variety of seed production hosts accumulate at levels of about 1%–5% of the 
total seed protein (Fiedler et al., 1997). The use of seeds for the recovery of a 
recombinant protein is advantageous also in other ways as the scale of 
production increases. Firstly, the intrinsic bioburden on seeds is lower than in 
vegetative structures such as leaves. Although neither seed nor leaf extraction 
can be performed at a large scale under aseptic conditions, most seeds can be 
subjected to a surface ‘sterilization’ technique, which reduces bio-load to 
industrially accepted standards for a raw material. A further example described 
by Virdi et al. (2013), is about anti-F4+ ETEC antibodies in seeds of Arabidopsis 
thaliana, whose transformation is easier compared to that of feed crops, and 
sufficient antibody-producing seeds can be up-scaled in greenhouses in a quite 
short time. The seeds provide an antibody production platform with ease of 
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storage at high concentrations in a confined space, and convenience of oral 
administration, which is considerably advantageous for large herds of piglets 
(Lau et al., 2009). More importantly, the crushed seed matrix could protect the 
antibodies from gastric digestion by outcompeting proteases, as proved in the 
study of in-pea-seed–produced anti-Eimeria antibodies administered in chicken 
fodder (Zimmermann et al., 2009).  
1.9-Suitable host and model organism in Molecular 
Farming 
1.9.1-Arabidopsis thaliana  
Arabidopsis thaliana has been historically the foremost used plant for genetic 
transformation. Among the traits of Arabidopsis, there are some interesting 
characteristics that have led scientists to exploit this model plant such as: the 
short generation period, a small genome size, a presence of a self-pollination 
mating system, an ease of in-vitro culturing, easy regeneration and in-vivo 
transformation, as well as its lack of food and feed applications (Koornneef and 
Meinke, 2010). In particular, Arabidopsis is capable to produce significant yields 
of seeds over a short period. This ability makes it particularly suitable for the 
production of many compounds (such as nutraceuticals, therapeutic human 
proteins, vaccines, and antibodies). Arabidopsis should be transformed during 
its early growth stages, since its development towards the flowering phase could 
increase the risk of environmental contamination (Ruebelt et al., 2006). High 
levels of recombinant protein accumulation in Arabidopsis seeds have been 
achieved by employing a seed-specific expression cassette (Van Droogenbroeck 
et al., 2007). It is a non-food/feed crop for which a very efficient and easy in-
vivo transformation method has been developed, known as floral dip (Clough 
and Bent, 1998). A. thaliana’s fast generation cycle in combination with prolific 
seed production turns it into a very adaptable production system. Therefore, it 
can be used for the quick production of stable homozygous lines (about nine 
months) and very fast production of diverse recombinant proteins.  
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1.9.2-Cereals and legumes  
Cereals and legumes are extremely suitable for the production of a lot of useful 
protein compounds. Xue et al. (2003) investigated the use of barley as a 
bioreactor to produce a highly active and thermo-stable hybrid cellulase (1-4b–
glucanase). Barley is also an important host for the production of valuable 
compounds like serum albumin, lactoferrin, lysozyme, human antitrhombin III 
(Sthal et al., 2002). Barley is suitable for the production of biopharmaceuticals. 
The recombinant single-chain Fv antibody has been produced in order to control 
carcinoembryonic antigen in wheat as well as in rice and in both crops the 
proteins could be conserved for up to 4 or 5 months at room temperature without 
any reduction in activity of the product (Stoger et al., 2000; Ma et al., 2003). The 
successful employment of cereal crops is due to the long-term storage of proteins 
whit an appropriate biochemical environment, a low water content and low 
protease activity. The lack of phenolic components is another advantage of 
cereals seeds compared to other plants, such as tobacco. Generally, the 
downstream process of depleting phenol from the products is a too long and 
expensive process (Ma et al., 2003). In addition, using cereals and legumes in 
molecular farming is disliked by “Public Opinion” because they are a valuable 
resource for feeding people and animals. The challenge described above appear 
both companies’ business strategies and focus of innovation. Important changes 
identified include a shift away from major food crops. 
Comparing MMF activities at present to a couple of years ago, reveals a 
noteworthy shift from food crops to non-food crops or minor food crops. As 
illustrated in table 10 the number of field trials with major food crops went down 
since 2003 in particular field maize which was considered to be the most 
valuable source for feeding in human and animals. 
Plant Number of applications for field trials 
Up to 2003 Update from 2004 onwards 
Maize 72 14 
Soybean 12 0 
Rice 8 18 
Barley 1 0 
Wheat 1 0 
Table 10: Food crops species used for MMF (by Spok and Karner, 2008). 
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1.9.3-Vegetables and Fruits 
Notably, fruits, vegetables are consumed in the form of moderately processed or 
entirely raw foods. These type of plant products are normally free of toxicants 
and are rich in nutrients, which make them particularly suitable to produce 
recombinant vaccine subunits, antibodies, and food additives for active 
immunotherapy (Ma et al., 2003). Potatoes have been frequently used because 
of the transformation protocols to generate transgenic lines, which are 
established. Tuber extracts from the transgenic lines expressing the S1 
glycoprotein gene of infectious bronchitis virus (IBV) have been demonstrated 
to protect the chickens from clinical diseases, as well as virus shedding when 
challenged (Zhou et al., 2003). Potatoes have been used extensively for the 
production of plant-derived vaccines, which have been administered to humans 
in many clinical trials. Among several other antigens expressed in potatoes for 
human trials, the enterotoxigenic E. coli (ETEC) labile toxin B-subunit (LTB), 
one powerful oral immunogen (Tacket et al., 1998) and Norwalk virus capsid 
protein (NVCP) (Tacket et al., 2000) had noticeable success. A recent trial using 
LTB expressed in processed corn seeds produced quite similar results to those 
of the potato study (Tacket al al., 2004). Besides, the risk of outcrossing in the 
open field production is low as the plant can be clonally propagated. In addition, 
as the industrial processing of tuber is established, the cost of downstream 
processing can be reduced. However, potato tuber has a relatively low protein 
content (Mason et al., 2002) and it is not palatable although to be eaten raw. 
While cooking can improve its palatability, it might lead to the denaturation of 
the foreign protein, thus resulting in poor immunogenicity if it has to be used to 
produce vaccine antigens (Gunn et al., 2012). Another candidate crop are 
tomatoes. Tomatoes have become a more attractive alternative system, since 
they are palatable and can be eaten raw with no need to be cooked. Thus, vaccine 
antigens expressed in them do not risk to be denatured by heat treatments. The 
first vaccine candidate used for expression in tomatoes was the rabies virus 
glycoprotein (McGarvey et al., 1995). Furthermore, they had been used to 
express the capsid proteins VP2 and VP6 of rotavirus, which were immunogenic 
to mice by intraperitoneal delivery (Saldaña et al., 2006) The inherent high 
amounts of vitamin A in tomatoes could also help in amplifying the immune 
responses (Gunn et al., 2012). Tomatoes have an established industrial 
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cultivation and processing system just like potatoes. However, the fruits have 
also a quite low protein content and must be chilled after harvest in order to 
avoid spoilage. Although the freeze and drying technology is available to 
preserve the fruits, this adds an additional cost to the processing. 
Among the fruits, banana is a significant one with many advantages. Bananas 
are consumed as staple food, are available at low cost in tropical and subtropical 
countries and are also palatable and easily digestible.  
1.9.4-Nicotiana tabacum  
Nicotiana tabacum is a largely used host system in MMF (as well as Arabidopsis 
thaliana). Nicotiana tabacum is a model organism and an extremely adaptable 
system for all the main aspects of cell and tissue culture researches. Tobacco is 
a natural allotetraploid generated through two hybrids between two diploid 
progenitors, Nicotiana syslvestris and Nicotiana tamentasiformis which 
occurred approximately 6 million years ago (Okamura et al., 1985). Nonetheless, 
the application of tobacco in smoking, it has many unique advantages compared 
to other plant species for the production of pharmaceutically important proteins. 
Scientists generally think that the role of tobacco in recombinant-protein 
investigations is close to that of the white mouse in mammalian studies of the 
last 20 years. As a leafy species, tobacco has numerous advantages compared to 
other plants, which have encouraged researchers to focus on this plant as an 
undeniable alternative for recombinant protein expression. This herb can 
produce a biomass of up to 100 ton/ha and tobacco is a very prolific seed 
production of about 1 million seed/plant (Ganaphati et al., 2004). Moreover, it 
is a well-established system to transform tobacco that results in high levels of 
soluble protein. The potential of utilizing various strategies for the expression of 
proteins in a stable or transient manner using this species, as well the option to 
utilize chloroplast genome-based methods using Agrobacterium or viral 
induction are its other advantages (Karg and Kallio, 2009). Tobacco is not a feed 
or food crop, and this decreases the odds of its contamination within the feed or 
food chains. In addition, tobacco can produce a large number of therapeutic 
immune-modulatory molecules, like cytokines, vaccines and antibodies 
(Tremblay et al., 2010). The high concentrations of alkaloids and nicotine in 
some tobacco varieties are disadvantageous for the usage of this plant for 
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molecular farming. These last characteristics have been compensated by 
breeding new cultivars such as “81V” (Ma et al., 2003). In addition to avoid this 
problem, seed-based products in tobacco are developed instead of leafy products. 
In table 11, biopharmaceuticals products in tobacco plants are shown. 
Type of protein Name Reference 
Monoclonal 
antibodies 
Anti-PA (Protective antigen)  
Anti-BoNT/A scFv (botulinum 
neurotoxin/antibody single chain variable 
fragment) idiotype specific antibodies 
 
Anti-Anthrax Hull et al., 2005 
Cancer B-cell lymphoma Young et al., 2009 
Breast and colon Brodik et al., 2006 
Cysteine proteases 
Der p 1 (Dermatophagoides pteronyssinus 
allergen) 
Johnston et al., 2009 
Der p 2 Lienard et al., 2007 
Proteins 
Ebstein-Barr virus  
HIV p24 capsid protein Zhang et al., 2002 
Tet-C Tetanus toxin fragment C 
Tregoning et al., 
2009 
UreB urease subunit beta Gu and Glatz, 2007 
Glycoprotrein Interleukin 13 
Thompson and 
Debinski, 1999 
Growth hormone Human somatotropin Staub et al., 2001 
Anticoagulant Human protein C Crammer et al., 2002 
Table 11: Main biopharmaceutical products in tobacco plants. 
  
The availability of various tobacco expression systems with their particular 
strengths is another advantage of this model plant over other plant species. 
Nuclear transformation is the appropriate method to achieve the long-term 
production of glycoproteins, such as antibodies. Alternatively, chloroplast-based 
expression systems allow the production of large amounts of proteins that 
require certain types of post-translational processing. Tobacco is amenable to 
several different simultaneous applications and has the potential to excel at each 
of them. When a product that requires rapid modification, as in the case of the 
abovementioned idiotypic anti-cancer vaccine, transient expression can be 
anticipated to produce the appropriate quantities of the chosen protein within a 
short period (Tremblay et al., 2010). By using transient protein-expression 
systems, researchers can produce significant amounts of recombinant protein 
during a short period, which is essential for the rapid response to a disease 
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outbreak, as is the situation when a new influenza appears, e.g., during the 
A/H1N1 pandemic, as well as for patient-specific cancer cures. 
1.10-Edible Vaccines  
Vaccines are a biological preparation that provide active acquired immunity to 
a particular disease. A vaccine typically contains an agent that resembles a 
disease-causing microorganism and is often made of weakened (i.e. attenuated) 
or killed (i.e. inactivated) forms of the microbe, its toxins or one of its surface 
proteins. The agent stimulates the body's immune system to recognize the agent 
as a danger, dismantle it, and keep a memory of it so that the immune system 
can more easily recognize and destroy any of these microorganisms that it could 
encounter subsequently (Abbas et al., 2015). Vaccination has greatly lowered 
the burden of infectious diseases and has led to the eradication of smallpox, near 
eradication of polio, and the prevention of huge numbers of deaths (Plutkin et 
al., 2008). Traditional vaccines, attenuated or inactivated, present the risk of 
reversion into pathogenic forms, thus the production of these vaccines usually 
requires high-level biosafety facilities. For these reasons in the last two decades, 
subunit vaccines are developed and used widely. Subunit vaccines are composed 
by major antigen components of the disease-causing organism complexed with 
adjuvants. After the administration, subunit vaccines will provoke immune 
response in the host. Subunit vaccines can be given to animal or human with 
weakened immune systems. The potential advantages of using subunits as 
vaccines are the increased safety and less antigenic competition, ability to target 
the vaccines and differentiation of vaccinated animals from infected animals is 
easy. Since only a few components are included in the vaccine ability to target 
the vaccines at the site where immunity is required is possible. Potential 
disadvantages of subunit vaccines are that they generally require strong 
adjuvants with possible tissue reactions. The duration of immunity is generally 
shorter than the live vaccines. 
Most currently available vaccines are delivered by injection, which makes mass 
immunization more costly and less safe. Oral vaccines, needle-free, have several 
attractive features compared with parenteral vaccines, in particular to protect 
against mucosal transmitted pathogens. Orally delivered vaccines are processed 
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and presented by the digestive tract's immune system, often referred to as the 
gut-associated lymphoid tissue (GALT). The GALT is a complex system 
consisting of inductive sites (where antigens are encountered and responses are 
initiated) and effector sites (where local immune responses occur) linked by a 
homing system, whereby cells induced by antigen in the GALT migrate to the 
circulation and, subsequently, colonize the mucosa. As a result, oral vaccination 
can induce immune responses locally in the gut and at distant mucosal sites, as 
well as systemic humoral and cellular immune responses. Oral vaccination 
typically generates a large amount of secretory IgA (sIgA), which plays a major 
role in mucosal defense. Accordingly, studies have focused on pathogens that 
enter the body through mucosal surfaces and cause diseases of the intestinal, 
respiratory and genital tracts.  
Edible vaccines (oral vaccines) are transgenic plants expressing a virus or 
bacterial antigens (subunit vaccines), that can be administered raw with no need 
to be previously processed and act as a vaccine inducing a sufficiently protective 
mucosal immune response versus a particular disease (Dus Santos and 
Wigdorovitz, 2005). Several benefits are related to edible vaccines, e.g. they 
represent a suitable method of administration; moreover, the oral administration 
via food or feed, allows the activation of mucosal immune response where the 
major pathogens gain access to the body. Plant-based edible vaccines do not 
require a cold chain to preserve the vaccine; hence, the technology is very useful 
for vaccines to be used in countries without concrete health infrastructure (Third-
World countries). Plants or plant products, which are edible, provide the 
additional unique opportunity to serve as vehicles for oral delivery of the 
vaccines.  
During the past twenty years, plants drove the attention in vaccinology as both 
production hosts and delivery vehicles. Looking to minimize costs, the 
production of subunit vaccines becomes advantageous if a vegetable organism 
is used as the expression host for the recombinant vaccine and if its biomass can 
support a straightforward formulation of an oral vaccine. In terms of easy 
administration and immune protection at local mucosal tissues, oral vaccination 
is an attractive approach to fight against several diseases, particularly in poor 
countries where vaccines are more needed.  
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After 25 years of exploring the concept of plant-based vaccines, several edible 
plants have been used to develop plant-based vaccine candidates. The main 
attribute is that edible plant tissues are very cheap to produce in a process that 
can be easily scaled-up. Plant cells can be genetically engineered to transiently 
or stably express antigens in the nucleus or in the chloroplast. Nuclear expression 
offers high biosynthetic capacity because complex post-translational 
modifications take place. A myriad of proof-of-concept have been published in 
the last years. Several vaccine prototypes were thoroughly analyzed at the 
preclinical level targeting virus (Yusibov et al., 2002), bacteria (Lakshmi et al., 
2013; Uvarova et al., 2013; Zhang et al., 2013), and parasite pathogens as well 
as autoimmune diseases (Ruhlman et al., 2007). Many preclinical studies against 
several diseases are going on with the aim to enter clinical trials or trials in 
definitive animal hosts for veterinary species (Yuki et al., 2013; Lindh et al., 
2014, and Hayden et al., 2015). Remarkably, several clinical trials have been 
executed to verify the safety and immunogenicity of oral plant-based vaccines 
including antigens from HBV, delivered in potato (Thanavala et al., 2005); 
enterotoxigenic E. coli, delivered in maize (Tacket et al., 2004), Newcastle 
disease virus, in potato (Tacket et al., 2000); and rabies virus, in spinach. The 
findings reflect a potential to induce specific humoral responses in humans. The 
first plant-produced biopharmaceutical approved for human use (taliglucerase 
alfa for Gaucher’s disease treatment, named ELELYSO®) was produced in 
carrot, and this species provides an excellent platform because of the experience 
gained in terms of production at the industrial level and, moreover, the 
establishment of proper conditions that meet the regulations governing 
biopharmaceuticals for human use. 
1.11-Challenges of Plant-Based Vaccines 
Although many plant-based vaccines that have been created are still in phase 1 
clinical trials, some vaccines have advanced or completed phases II and III trials 
(Mardanova et al., 2015). Nevertheless, until today, there is no plant made 
vaccine that has been approved to be marketed for human or animal 
consumption. Thus, it is worthwhile to note that even though the production of 
plant-based vaccines had been initiated almost two decades since 1989 (Almada 
et al., 2015), a few challenges still have to be achieved in order to develop them 
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into highly efficient vaccines. The issues that need to be addressed could start 
from the upstream processes to the implementation of the vaccines. Generally, 
the three main challenges are: the selection of the antigen and the plant 
expression host, the consistency of the dosage, and the manufacturing of 
vaccines according to Good Manufacturing Practice (GMP) procedures. 
1.11.1-Selection of Antigen and Plant Expression Host 
The first issue is the selection of an antigen and the right plant expression host. 
This stage is very important in developing a vaccine that is able to fulfill all the 
requirements needed because not all antigens are well-matched with the selected 
host plants (Arnold et al., 2012). The correct and careful selection, will not only 
help to determine the safeness of the vaccine produced, it can also be utilized to 
produce thermal-stable vaccine (Arnold et al., 2012). Meanwhile, the 
identification of antigen candidates of poorly characterized pathogens with 
promising characteristics can be done by applying genomics or proteomics 
approaches (Bader et al., 2012). 
1.11.2-Consistency of Dosage 
The consistency of dosage is another challenge that the researchers have to face 
as dosage produced may vary within the plants of the same species, from fruit to 
fruit and from generation to generation due to the size and ripeness of the fruits 
or plants. The transgenic plants show intrinsic variability in the antigen 
expression due to the position and pleiotropic effects caused by generic 
integration of the transgene within the host plants genome (Foged, 2012). On top 
of that, it is also quite difficult to evaluate the required dosage for every patient. 
Levels of innate and adaptive immune responses generated in different 
individuals may vary based on the types of antigens being exposed in the body. 
Between two patients with different body weight as well as their age, the dosage 
of plant-based vaccine required will be different. If this issue is not well -
monitored, an immunological tolerance will be induced when the patient is 
overdosed while reduction in antibody production will occur when the patient is 
under dosed (Arnold et al., 2012). Besides that, gene silencing might be induced 
due to the increase of mRNA in the transgenic plant cells as the growth of the 
plants is stopped and the fruit formation is reduced whereas the antigen content 
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is increased (Berhate et al., 2014). In such cases, consumption of plant-based 
vaccines may induce allergic reactions and few side effects such as toxicity on 
central nervous system, cytokine-induced sickness, and autoimmune diseases. 
1.11.3- Manufacturing of Vaccines according to GMP Procedures 
The ultimate goal of plant-based vaccines is to produce stable transgenic 
vaccines, which are safe for consumption while reducing the production cost. 
Besides all the underlying issues, that may affect the efficacy of plant-based 
vaccines, the manufacturers shall ensure their responsibility to follow the Good 
Agricultural Practices (GAP) and Good Manufacturing Practice (GMP) so that 
the upstream to downstream production of plant-based vaccines is strictly 
controlled for quality management. Generally, to produce a plant product that 
could meet the quality standard, the bio manufacturing facilities must be well 
equipped so that complete processing cycles of the plant vaccines could be 
accomplished. The facilities include equipment for plant and bacterium 
cultivation, infiltration, plant harvest, and protein purification (Ma et al., 2014). 
Takeyama et al. (2016) also summarized a few GMP plants that produce various 
vaccines such as influenza HA antigen, Norovirus capsid protein subunit 
vaccine, and rice-based cholera vaccine (Ma et al., 2014). Concurrently, 
Kashima et al. (2016) reported that in order to produce a plant vaccine that meets 
the governmental regulatory requirements, many steps and precautions need to 
be taken into consideration. During the production of a rice-based oral cholera 
vaccine, MucoRice-CTB, the biomanufacturing agency successfully established 
specific techniques to maintain the seed of MucoRice-CTB. The agency further 
evaluated the seed’s propagation and stored seeds were renewed periodically to 
maintain the good quality. Furthermore, cultivation of the plant using a closed 
hydroponic system helps to minimize the variations in vaccine production. The 
rice produced was polished, powdered, and packaged to make the MucoRice-
CTB drug substance. A final control on the identity, the potency, and the safety 
of the MucoRice-CTB product must be executed and only the products that 
satisfy the quality requirements will be released (Su et al., 2015). It remains a 
great challenge to maintain the GMP standard for the product in plant-based 
vaccine industry. Besides the equipment, facilities, and method used to produce 
the vaccine, there are other considerations that have to be taken into account like 
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those stated in the GMP guideline published by WHO (Govea Alonso et al., 
2014; Valdez et al., 2014). GMP for biological products guideline stated that 
some particular precautions are necessary for the manufacture, control, and 
administration of biological products as procedures and processes used in the 
production usually lead to high variation in the quality of products. Thus, the 
precautious steps should start from the very beginning of the production 
processes. However, in-process control is also important during the 
manufacturing of the biological products. Skillful staff is required to run the 
production processes and thus the bio manufacturing agency should provide 
necessary training to the staff. Buildings for the vaccine production must be 
designed in a way that operations can be carried out smoothly. A special design 
is required for plant vaccine production, in which the seed lots should be stored 
separately from other materials. Some other general rules of GMP shall be 
followed to maintain the quality standard of the vaccine products. These include 
the facts that standard operating procedures shall be implemented for all 
manufacturing operations, all products shall be clearly labelled, lot processing 
and distribution records shall be properly kept, and quality assurance and control 
shall be in place in monitoring the product quality. 
Many medicinal products including edible vaccines are derived from proteins, 
e.g. insulin, vaccines and antibodies and has been extensively studied, as 
application of Molecular Farming, due to the high value of these recombinant 
proteins. In Europe, legislation (Council Directives 2001/82/EC and 
2001/83/EC) defines a medicinal product for both human and veterinary use as 
“Any substance or combination of substances presented for treating or 
preventing disease. Any substance or combination of substances which may be 
administered to human beings with a view to making a medical diagnosis or to 
restoring, correcting or modifying physiological functions in human beings is 
likewise considered a medicinal product”. All medicinal products (with or 
without genetic modifications) have to be tested thoroughly prior to 
commercialization.  
a. Clinical trials for human use  
After mandatory preclinical research and animal trials, there are three clinical 
phases for experiments on human subjects. In a first phase, the safety of a 
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medicinal product is tested on a small group of healthy people. In the next 
phase, the optimal dose is defined for a group of patients. Finally, in a third 
clinical phase the activity of the medicinal product is tested. All tests from 
the preclinical research until commercialization of a new pharmaceutical can 
easily last from 10 until 12 years. Directive 2001/20/EC regulates clinical 
trials with medicinal products for human use. At the start of a clinical trial, 
the subject has to provide his free and informed written permission, and an 
ethical commission has to give a positive advice. In addition, the minister of 
public health has to give his written permission for clinical trials with 
medicinal products containing GMOs. The clinical trial also has to comply 
with Council Directives 2009/14/EC and/or 2001/18/EC, respectively for 
contained use and/or deliberate release into the environment. At the 
European level, it is not clear yet when a clinical trial is part of contained 
use, but for now all clinical trials performed in the hospital itself are 
subjected to Council Directive 2009/14/EC concerning the contained use of 
GMOs.  
b. Clinical trials for animal’s use  
There is no separate legislation for clinical trials for veterinary use, but they have 
to comply with chapter II of the RD of 21 February 2005 concerning the 
deliberate release of GMOs into the environment. The only difference is that the 
competent authority taking the decision is the Federal Agency for medicines and 
health products. In addition, permission from the ethical commission is needed 
before initiating the trial.  
c. Commercialization  
Regulation (EC) no 726/2004 regulates the procedures for permits and 
supervision of medicinal products for human and veterinary use. A medicinal 
product made with recombinant DNA technology or controlled expression of 
genes for biologically active proteins in prokaryotes and eukaryotes can only be 
commercialized when a permit of the Community is granted. The permit will be 
valid in all member states of the EU. The procedures for medicinal products for 
human and veterinary use are quite similar. A permit request is applied at and 
evaluated by the European Medicines Agency (EMEA). If the advice is positive, 
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the dossier is provided to the European Commission, which can grant 
permission. This permission is valid for five years. Afterwards, the permission 
can be extended after an evaluation of advantages and risks by EMEA. This 
extended permit is unlimitedly valid. To obtain permission for the use of 
medicinal products for veterinary use, which will be used for food, some specific 
regulations need to be applied (Regulation EC no 2377/90). 
1.12-Edible Vaccines in Veterinary Medicine  
Recently, the World Health Organization, the UK government and the G8 
governments have emphasized the need for judicious use of antibiotics in 
agriculture as a key element of strategies to prevent or delay the onset of 
antibiotic resistance (G8 Science Ministers Statement, 2013, UK Department of 
Health, 2013 and World Health Organization, 2016). These initiatives, coupled 
with a growing public demand for animal-based food, which is “produced 
without antibiotics”, will undoubtedly constrain the availability and routine 
practice of using antibiotics for growth promotion and prophylaxis in livestock, 
poultry and fish production. Within this context, it is imperative to devise cost-
effective strategies for the intensive production of livestock and fish using fewer 
antibiotics. Increased use of vaccines and immunotherapeutic agents will be a 
cornerstone of these strategies (Topp et al., 2016). Vaccination of animals 
against an infectious disease is a control method that has been practiced for over 
a century with remarkable success. Prior to the past two decades, most veterinary 
vaccines were either inactivated products formulated with an oil-based adjuvant 
or live attenuated vaccines. The field of biotechnology and molecular 
immunology yielded rapid advancements starting in the 1980s, including the 
ability to produce subunit antigens in a cost effective fashion for the veterinary 
market. However, protection of animals against infection remains a major 
challenge in most of the developing countries, especially in the surge of drug 
resistant strains. Vaccine targets are also changing, with non-infectious disease 
targets representing a considerable growth area. For example, these include 
molecules to control fertility, behavior and production by immunization against 
hormones or hormone receptors. In addition, protein-misfolding targets such as 
prion diseases are of significant interest for the control of Bovine Spongiform 
Encephalopathy (BSE), Chronic Wasting Disease (CWD) and scrapie, largely as 
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a means of mitigating the threat of transmission to humans or trade barriers 
(Gerdtsa et al., 2013).  
As mentioned before edible vaccines are plants, or part of them, engineered for 
the expression of antigens. After the oral administration, they induce a protective 
mucosal immune response. Oral delivery offers ease of application and 
protection against pathogens interacting with host mucosal surfaces via the 
induction of mucosal immunity (Streatfield et al., 2005). Plant-based expression 
systems represent an interesting production platform due to their reduced 
manufacturing costs and high scalability (Clemente et al., 2012). The cost for 
vaccine injections in animal livestock is related closely to the productivity of the 
industry, plant-based edible vaccines represent a viable alternative from the 
perspective of production cost (Virdi and Depicker, 2013). The obtained 
recombinant antigens retain the same structural integrity and activity. These 
transgenic plants safely and effectively deliver non-replicative subunit vaccines 
through the consumption of edible parts (Hefferon, 2010). 
Mucosal surface, which covers the digestive, respiratory and reproductive tract, 
is the largest immunologically active tissue in the body (Tacket et al., 1999). 
Edible vaccines can stimulate both mucosal and humoral immunity.  
The antigens in transgenic plants (in particular in seeds), are delivered through 
bio-encapsulation, i.e., the tough outer wall of plant cells, which protects them 
from gastric secretions and finally break up in the intestine. The released 
antigens are then taken up by M cells, present over Peyer's patches and over gut 
associated lymphoid tissue (GALT). These antigens are subsequently passed 
onto macrophages, other antigen presenting cells and local lymphocytes. This 
triggers formation of specific serum IgG, IgE and local IgA antibodies and 
memory cells. These antibodies can neutralize the target molecule of the parasite 
on subsequent exposures (Lal et al., 2007). So many trials have been conducted 
to express either target antigen or antibody in edible part of the plants. These can 
be fed to animals directly without any further purification as crude extract or by 
minimal processing. As described by Topp et al. (2016) to be competitive, 
veterinary vaccines need to have a number of desirable attributes, many of which 
are met using plant-based production. Many candidate subunit vaccines have 
been produced in plants (Table 12) and tested in target animals with positive 
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outcomes (Kolotilin et al., 2004). Based on these considerations, it is indeed 
surprising to see that 26 years down the road only two recombinant protein 
products from plants had made it through the regulatory processes to be licensed: 
monoclonal antibody against HBs-Ag and poultry vaccine against NDV. The 
idea of plant-made vaccines as edible vaccines has received much publicity and 
enthusiastic development since the first proof of concept recombinant plant-
derived pharmaceutical proteins was reported. However, the progress made was 
not without hurdles. Although the reports of successful expression of target 
antigens of interest were numerous, many of these failed to achieve expression 
levels suitable for commercialization. Besides, the use of food plants for 
production of vaccine antigens has sprouted fears of contamination of the human 
food chain. Worries about regulatory issues have also deterred the development 
of plant-made vaccines.  
 
Characteristic 
of  efficacy 
Comments The plants advantages References 
Subunits antigens Eliminate safety risks from 
attenuated live vaccines 
Reduced risk of zoonotic 
pathogens in vaccine 
Soria-Guerra et al., 
2010 
Particulate 
antigens 
Compared to soluble antigens 
more efficient uptake by antigen 
presenting cells. Better stability 
following administration 
Ability of plants to produce 
VLPs and multimeric 
protein aggregates /protein 
bodies 
Rosales –Mendoza., 
2014 
Persistence in 
the gut  
Protein needs to tolerate low 
gastric pH 
Plant matrix can confer 
protection 
Pelosi et al., 2012 
Ability to cross 
epithelial 
barrier 
Need to get from GI tract into 
tissue for antigen presentation 
Subunit vaccines can be 
engineered with cell 
penetrating moiety or 
ligands binding to enterocyte 
receptors 
Devriendt et al., 2013 
Monoclonal 
Antibodies 
Polyclonally antibodies have 
batch to batch variability 
Antibodies can be 
engineered –e.g. nanobody, 
glycosiliation , grafting to 
animal specific Fc 
Virdi et al., 2013 
Adjuvancy Increases responses Subunit vaccines 
engineered with adjuvant 
moiety 
Rosales Mendoza., 
2014 
Mode of 
administration 
Oral or nasal easier than 
parenteral and more effective for 
mucosal immunity 
Plants expressing vaccine 
antigen offer potential for 
oral vaccine ; dose 
calibration is challenging 
with oral delivery in feed  
Mason and Herbst-
Kralovetz, 2012  
Shelf life Stable under challenging 
conditions of temperature , 
moisture 
Longer shelf life  Kwno et al., 2013b  
Cost-benefit Return on investment out weight 
cost  
Low unit cost of plant-
based unpurified , orally 
administred product  
Xiao et al., 2015  
Table 12: Desirable characteristics of veterinary vaccines and immunotherapy agents (Kolotilin et al., 
2004)  
However, the regulatory pathway for plant molecular farming of vaccine 
antigens for veterinary use is far shorter when compared to products intended 
for human use. 
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1.12.1-Plant–based vaccines against parasitic diseases 
The health and well-being of food-bearing animals is major preoccupation for 
any livestock producer.  
In developing, an edible vaccine is fundamental choosing suitable antigenic 
proteins expressing in plants. Animal parasitic diseases are an effective problem 
in livestock and appropriate strategies on order to avoid outbreaks of serious 
illness are needed. Several parasitic diseases can be kept under control using 
plant- based vaccines. The various reports in this regard can be summarized as 
follows. 
Fasciola hepatica 
Fasciolosis caused by Fasciola gigantica and Fasciola hepatica is a relentless 
constraint on the growth and productivity of cattle, buffaloes and sheep (Mehra 
et al., 1999; Yamasaki et al., 2002). Among the various subunit-vaccine 
candidates’ cysteine proteases (CP) remains the most promising. CP released by 
Fasciola spp. plays a key role in feeding and in the migration through host tissues 
and immune evasion (Tort et al., 1999) could induce high levels (>70%) of 
protection in cattle. Recently, Legocki et al. (2000) engineered a 981 nucleotide 
cDNA fragment encoding the catalytic domain of the cysteine protease of F. 
hepatica into plant transform. After estimating antigen concentration, transgenic 
alfa-alfa and lettuce were fed model mice in order to assess their ability to 
perform as an edible vaccine as well as to find out safety index. They have 
immunized mice twice per month with 2 μg of cysteine protease. After the 
second immunization, there was a significant increase in antigen specific IgG 
and IgA antibodies in serum. The results suggest that the orally administered 
antigen in lettuce and alfa-alfa was able of inducing an effective immune 
response in mice.  
Taenia solium 
T. solium cysticercosis is a major parasitic disease of global proportion that poses 
a very serious threat to human. Vaccination of pigs, the only intermediate host, 
could impede the parasite transmission, thus reducing human infection and 
increase swine health status (Sciutto et al., 2000). Various whole or subunit 
vaccine candidates with promising protective effects against porcine 
55 
 
cysticercosis have been reported, but their effectiveness has been assessed 
experimentally rather than under complex field conditions (Wang et al., 2002; 
Gonzales et al., 2005). A vaccine based on 3 synthetic peptides, KETc1, KETc12 
and GK1 consisting of 12, 8 and 18 amino acids, respectively (designated 
S3Pvac) was shown to be effective in mice against Taenia crassiceps (Toledo et 
al., 1999; Toledo et al., 2001) and in pigs against T. solium (Huerta et al., 2001). 
These peptides are present in all stages of development of T. solium. S3Pvac is 
the only field trial-tested vaccine candidate against cysticercosis, which was 
originally, identified in T. crassiceps by screening the cDNA library of T. 
crassiceps with sera from T. solium infected pigs. S3Pvac is capable of inducing 
significant protection against cysticercosis in vaccinated pigs, both 
experimentally and in the field where transmission conditions are most pressing 
(Sciutto et al., 2007). Insights in cysticercosis prevention and in the development 
of new antigen delivery systems is useful for the design of more effective and 
affordable oral subunit vaccines to be feasible applicable in the endemic 
countries stringent economies. 
Ascaris suum 
A. suum has been identified as a ubiquitous roundworm of swine. Recent studies 
have emphasized its importance as a zoonotic parasite (Nakamura-Uchiyama et 
al., 2006). Protection of animals from A. suum infection by immunization with 
third stage larvae (L3) or their cuticle component led to the discovery of a 
protective 16-kDa antigen (As16) of A. suum L3. This antigen was later found 
to be expressed in the intestine, hypodermis, and cuticles of both larvae and 
adults (Tsuji et al., 2003). Following these findings, Matsumoto et al. (2015) 
expressed As16 as a chimeric fusion protein with B-subunit of cholera toxin 
(CTB) in rice endosperm under the control of endosperm-specific glutelin-GluB-
1 promoter. This led to the accumulation of the chimeric fusion protein in seeds 
up to 50 μg per gram. However, when the transgenic rice seeds were fed to mice 
they could get only a weak immunogenic response. Therefore, future studies 
should be directed towards the improvement of in-vivo immunogenic potential 
of this transgenic vaccine. 
 
56 
 
Eimeria tenella 
Coccidiosis caused by intracellular protozoan parasites belonging to the genus 
Eimeria is recognized as an important disease having the greatest economic 
impact on poultry production. The first live vaccine released to challenge this 
disease was in 1956. Although vaccination strategies with a-virulent or 
attenuated Eimeria strains have been routinely used for 50 years, the large-scale 
production is relatively laborious and expensive. Limited progress has been 
achieved towards the development of subunit or recombinant vaccines, the major 
hurdle being the identification of protective antigens and delivery of 
recombinant vaccines (Shirley et al., 2005; Dalloul et al., 2005). Sathish et al. 
(2011) expressed one of the microneme proteins, EtMIC2 of E. tenella in 
tobacco leaves using Agrobacterium. Feeding of this transgenic plant in poultry 
resulted in high antibody production along with the reduction in oocytes output. 
Moreover, the weight gain was considerably higher in these birds compared to 
control.  
Here is increasing evidence that orally applied recombinant antibodies have the 
capacity to reduce the infectious load in animals following oral administration. 
Issues such as stability in the gut, tissue penetration, clearance, general 
immunogenic effects as well as technical issues and commercial applicability 
have to be addressed in future. Current results indicate that there is no generally 
applicable “ideal” plant system for the expression of antibodies and antibody 
fragments, but such systems must be carefully chosen and tailored to the specific 
type, and even to the specific sequence, of the antibody under study. 
1.12.2-Plant-based vaccines (PBV) against bacterial or viral 
diseases  
Oral vaccination has been traditionally viewed as the panacea of plant-produced 
vaccines in terms of their use as an approach to disease control. In livestock the 
disease, outbreaks represent significant economic loss not only due to mortality 
of the animals, but also for the reduction of the growing performance, and of the 
feed efficiency, the increase of therapeutic costs and labor. Moreover, in case of 
zoonotic agents, the potential risk to consumers from contaminated food is an 
important public health concern. Nevertheless, an estimated 9.4 million cases of 
57 
 
illnesses due to the consumption of food contaminated with known pathogens 
occurs annually in the United States (Scallan et al., 2011).  
1.12.3-PBV against zoonotic diseases  
Several plant-employed as edible vaccines were developed and studied against 
important zoonotic agents. Below some examples are reported. 
Viral diseases: 
 Rabies virus  
Rabies is a major public health concern in developing countries as it caused 
55000 deaths annually according to WHO report and millions of death in animals 
(Loza-Rubio et al., 2012). Rabies virus that belongs to the family Rhabdoviridae 
is the major cause of spread infection. Currently, available vaccines are almost 
useful, however the maintained cold chain at 4 C make this vaccine expensive 
and present serious limitations in developing countries. Plant-based vaccines 
give potential solutions to these critical issues (Loza‐Rubio et al., 2012). 
Nucleoprotein of rabies virus transiently expressed, had high-level expression 
and was antigenic in mice conferring protection against rabies viral challenge 
(Arango et al., 2008).  
 The swine flu virus  
One of the most problem in the livestock is swine flu disease in pigs. The virus 
responsible of infection belongs to the family Flaviviridae. Influenza is also a 
burden for the public health in humans. In fact, has been estimated that millions 
of people each year need vaccination against flu-virus. Influenza virus infects 
farm animals and transmits to humans either by direct contact or through 
contaminated food. Many cases were reported where pig farmers showed 
symptoms similar to swine influenza after interaction with infected pigs. Oral 
and plant-based vaccines offer alternative solutions (Jung et al., 2014). E2 
structural protein expressed in tobacco chloroplasts conferred protective 
immune response in mice upon oral delivery (Shao et al., 2008). A further 
research evidenced that transgenic rice calli expressing E2 structural protein 
have protective effect in immune system, in orally immunized mice; also pigs 
develop a specific and systemic immune response against E2‐antigenic protein. 
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 Avian influenza  
Avian influenza is a highly infectious and contagious disease that can cause 
100% mortality in livestock. As this disease is usually spread in large farms, 
massive vaccinations are needed to control disease in birds and animals. Plant‐
based vaccines offer the best solution to control this disease in large animal farms 
(Firsov et al., 2015). Antigenic protein HA was expressed in endoplasmic 
reticulum from avian influenza, HPA1 resulted in high level expression; 
immunogenicity of transgenic Arabidopsis was confirmed from orally 
immunized mice with high level HA specific systematic IgG and mucosal IgA, 
strong Th-1 responses together with IgG2b production and 72% of immunized 
mice were protected after viral challenge (Lee et al., 2015). 
Bacterial diseases. 
Several serious illnesses are also zoonotic infections caused by bacteria. When 
pathogens gain access to the body serious illness can occur. Routinely the first 
aim of bacteria is multiplying and crowd out healthy bacteria, after infection 
bacteria are able to grow in tissues that are normally sterile. Harmful bacteria are 
particularly able to produce dangerous toxins that damage cells and tissues. 
Common pathogenic bacteria and the types of zoonotic disease are listed below: 
 Anthrax. 
An important zoonotic agent related also to the terrorism risks is Bacillus 
anthracis. It is worth to mention that Anthrax outbreaks have been continuously 
recorded in Asia, Africa and South America. Anthrax is an animal disease, but 
humans get often the infection during hunting, eating contaminated food or 
direct contact with animals. Nowadays vaccines against human and animal 
anthrax are injectable and derived from protective antigen from obtained culture 
filtrate of Bacillus anthracis. There are several limitations to this vaccine, 
including requirement of several boosters (up to eight) and withdrawal of certain 
batches due to toxin contamination in the culture filtrate (Koya et al., 2005). 
Transplastomic tobacco expressing the anthrax protective antigen (PA) was 
observed to be protective against infection in immunized mice. The animals 
challenged producing high‐titer IgG antibodies against anthrax (1:320000) and 
get 100% protection after challenge with lethal dose of Bacillus anthracis. 
Protective immune response was confirmed by oral feeding with transgenic 
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plants and challenge with lethal dose of Bacillus anthracis. Orally immunized 
mice produced IgA, IgG1, IgG2a titers and showed 60%–80% protection after 
challenge (Gorantala et al., 2014). 
 Tuberculosis  
Tubercolosis (TB) is a zoonotic disease that causes serious illness. TB has 
bacterial origin in both animals and humans. In 2010, TB affected 8.8 million 
people and resulted in 1.5 million deaths. TB has a high mortality rate and 
represents a severe unhealthy status in humans and animals. In evolved 
countries, TB has been mostly eradicated. However; it remains a problem in 
most of the poor countries. Mycobacterium tuberculosis is the etiological agent 
of TB in humans, on the other hand bovine get TB infection with M. bovis. Both 
species are closely related. M. bovis is risky in humans as 10% TB infection in 
humans is zoonotic due to M. bovis (Müller, 2013). The only available vaccine 
for tuberculosis is BCG, but several limitations remain. The major challenge is 
drug‐resistant TB. Plant-based vaccines could offer potential solutions. 
Transgenic modified carrot with Mycobacterium tuberculosis genes cfp10, esat6 
and dIFN produced very low levels of antigen (0.035% TSP), and orally 
immunized mice with transgenic carrot produced both cell‐mediated and 
humoral immune responses (Permyakova et al., 2015). Chloroplast 
transformation of CTB fused ESAT6 and Mtb72F in tobacco and lettuce leaves 
produced much higher level of expression (up to 7.5% TSP) and lyophilized 
plant cells could be stored at ambient temperature for several months, thereby 
eliminating the cold chain and this could facilitate development of an affordable 
vaccine (Lakshmi et al., 2013). 
 Listeriosis 
Listeria monocytogenes is responsible to induce Listeriosis, an infectious 
zoonotic disease in humans and animals. Listeriosis is a serious illness caused 
by a bacterium. This disease is transmitted to humans through contaminated or 
raw food. The infection is particularly serious in newborn, pregnant women and 
immunosuppressed people. The infection can induce complications such as 
encephalitis. Listeriosis is an overlooked zoonotic pathogen and plant‐based is a 
promising way to overcome this disease, and to find the best solution. Transgenic 
potato based vaccine against Listeriosis showed a very promising result in 
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immunized mice. A significant reduction of numbers of bacteria was observed 
in spleen and liver. The immunized mice get better healthy status, even if an 
infection of Listeria occurs (Ohya et al., 2005). 
1.12.4-PBV against specie-specific pathogens  
The goal for researchers is a great reduction of animal morbidity and mortality 
and the use and employment of good production practices. The production 
system “drives” the use of best manufacturing practices. Nowadays, a problem 
in animal health toolbox are antibiotics. It can be reasonable to assume that the 
availability of antibiotics will become increasingly constrained as legitimate 
public alarm. Public opinion and the governements of several countries fear the 
onset of catastrophic antibiotic resistance in human and veterinary medicine. 
Based on some issues it becomes pivotal developing new vaccines and 
immunotherapeutic agents. The use of these new therapies could evolve in a new 
strategy to challenge diseases. Without using antibiotics against disease, in 
addiction offer veterinary practitioners much needed tools (Potter et al., 2008). 
Edible vaccines offer several advantages over conventional methods of vaccine 
delivery. Edible vaccines induce primary the lining of the digestive tract, thus 
enabling them to stimulate both mucosal and systemic immunity, the former of 
which is a response that is notoriously difficult to achieve through injections, 
which bypass mucosal barriers. In part, this accounts for the reason as to why 
the efficacy of injectable vaccines against intestinal pathogens has generally 
been quite poor. Edible vaccines also have positive implications for livestock 
welfare, as they could be administered directly in the diet, eliminating the need 
to confine the animal, or the need to breach the skin through injection, a practice 
that can promote secondary infections. Oral administration of vaccines 
eliminates the risks that injection-based methods pose on meat quality as a result 
of intramuscular administration (Kolotilin et al., 2004).  
Below some examples of innovative plant based vaccines that are developed and 
studied against common animal pathogens are reporded. 
 Foot and mouth disease 
Rao et al. (2015) produced a bivalent vaccine against foot and mouth diseases 
expressing VP1 structural protein from two serotypes A and O. The pigs 
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administered with transgenic plants developed specific humoral immune 
response. Sera from immunized pigs when challenged with FMDV neutralized 
the virus with no cytopathic effect on BHK‐21 cells (Rao et al., 2015). A further 
proof, VP1 protein was expressed in tobacco chloroplasts (Lentz et al., 2010). In 
addiction in several published papers we can found new strategies to express 
BVDV in tobacco (Nelson et al., 2012), alfa-alfa (Aguirreburualde et al., 2013) 
and Panax ginseng (Gao et al., 2015). The immune studies in different animal 
models showed promising results. 
 Canine parvovirus 
Causes infection in dogs and particularly in puppies. Currently live and killed 
virus-based vaccines offer the only solution to treat dogs with CPV infection. 
Live vaccines are always associated with pathogen of low virulence that can be 
hazardous for dogs with weak immune systems. Many efforts in the field of 
plant‐based vaccines have been made to find alternate solution to treat or prevent 
CPV in dogs. Immunization of mice with CTB 2L21 and GFP 2L21 peptide from 
(CPV) VP2 protein (Molina et al., 2004) and 2L21-TD (Ortigosa et al., 2010) 
expressed in chloroplasts generated high titers of IgA, IgG1 antibodies against 
viral VP2 protein. 
 Transmissible gastroenteritis coronavirus (TGEV) 
The use of maize seeds as an edible delivery vehicle has been extensively 
studied. The envelope spike protein was used as an antigen to raise neutralizing 
antibodies and the efficacy of this plant-made vaccine has been presented in 
experiments with piglets (Lamphear et al., 2004). In addition, it was found that 
the antigen was stable during storage in various conditions and authors were able 
to concentrate the antigen using milling techniques. 
 Bovine Rinderpest virus  
Transgenic peanut plants expressing hemaglutinin raised immune responses in 
cattle (Khandelwal et al., 2003) This oral vaccine was able to raise virus-specific 
antibodies which also neutralized the virus in-vitro. Immunogenicity of a 
Tobacco mosaic virus (TMV)-based vaccine against bovine herpes virus (BHV) 
was studied in cattle (Perez et al., 2003). Immunogenic glycoprotein D was 
produced as a by-product in TMV-inoculated tobacco plants, and the crude plant 
extract emulsified in oil and subsequently injected into cattle was able to raise 
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specific humoral and cellular immune responses. Most importantly, cattle were 
protected against BHV to similar levels as those vaccinated with the commercial 
vaccine. As mentioned before, plant-made oral vaccines possess exceptional 
skills against serious illness in human and animals the most desirables attributes 
are long-term storage and stability at room temperature and are needles and 
syringes free. New techniques and concepts are needed to contribute to this 
growing field of Molecular Farming. In table 13, an overview of vaccines 
antigens against zoonotic and non-zoonotic diseases is reported. 
Table 13: Vaccines antigens against zoonotic and non-zoonotic diseases. PA: protective antigen. 
TSP: total soluble proteins. 
 
Disease  Expressed 
antigen  
Expression 
system  
Host  Expression 
level  
Immune response  Ref. 
Rabies Virus  -PA  
-G-protein 
of RV 
Transplantomic  
 
Transgenic  
Lettuce  
Carrot  
7%  TSP 
 
0.4- 1.2% 
TBS  
66% of immunized 
mice showed 
protection against 
virus challenge  
Rasoulicet 
al., 2014 
-G-protein 
fused with 
CTB, 
-G protein  
Transient  
 
Transgenic  
Tobacco 
 
Maize 
0.4% TBS 
 
25.1g/g of 
fresh seeds  
50-83% protection 
was observed in 
immunized sheep 
Loza 
Rubio et 
al., 2012  
Swine flu  -E-2 
glycoprotein  
Transgenic  Tobacco  1-2%  TSP Orally immunized 
(mice) : no specific 
response  
Sc: CSFV‐specific 
serum IgG 
Shao et 
al., 2008 
Bird flu Avian 
Influenza Virus 
(AIV) 
-NA gene of 
H1N1 
Transgenic Lettuce 0.018%–
0.045% TSP 
Orally immunized 
(mice): anti‐NA 
antibodies at third 
booster; no virus 
challenge assay was 
performed 
Liu et al., 
2014  
Newcastle 
Disease Virus 
(NDV) 
-HN gene Transgenic Tobacco 0.069% TSP anti‐HN serum IgG, 
no virus challenge 
study was performed 
Hahn et 
al., 2007  
Antrax (Bacillus 
antracis) 
-PA  Transplantomic Tobacco  4.5%TBS Immunized mice 
produce antibodies 
against rabies. and 
Protection: 66% 
immunized mice  
Koya et al. 
2005 
Tuberculosis 
(Mycobacteriu
m tuberculosis) 
Ag85B, 
MPT83, 
MPT64, 
ESAT6 
Transgenic Potato Not reported Immunized mice 
produced high‐titer 
IgG and IgA 
antibodies against 
antigens, and 
stimulated CD4+ and 
CD8+  
Zhang et 
al., 2012  
(Listeriosis) 
Listeria 
monocytogenes 
IFN‐α Transgenic Potato Not reported Orally immunized 
mice with transgenic 
IFN‐α showed its 
ability to reduce 
bacterial burden  
Ohya et 
al., 2007  
Pasteurellosis GS60 Transgenic/Tr
ansient 
Alfalfa/
Tobacco 
0.02% TSP  Immunized rabbit 
with transgenic alfa-
alfa produced 
antibodies against 
GS60 
Lee et al., 
2008  
Brucellosis U‐Omp19 Transient Tobacco Not reported Immunized mice 
produced specific 
response 
Pasquevic
h et al., 
2011 
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1.13-Escherichia coli infections in pig livestock 
The pathogenic strains of Escherichia coli recovered from the intestinal tract of 
animals fall into categories called enterotoxigenic (ETEC), enteropathogenic 
(EPEC), enterohemorrhagic (EHEC) and necrotoxigenic. The pathogenicity of 
these strains is determined by the presence of certain genes that encode adhesins 
and toxins, are generally organized in large blocks in chromosomes, large 
plasmids or phages, and are often transmitted horizontally between strains.  
ETEC strains are equipped with adhesion factors and enterotoxins: they are heat-
labile and heat-stable. The EPEC strains also produce intestinal lesions, but act 
through mechanisms distinct from those of ETEC and EHEC. EHEC strains are 
so called because the prototype of this group, serotype O157: H7, causes in 
humans, hemorrhagic colitis. As it produces cytotoxic toxins (Verotoxin, VT), 
the term "enterohemorrhagic" (EHEC) and "verocitotoxic" (VTEC) were often 
overlapping.  
Among VTEC, serotype O157:H7 has been closely associated with the sporadic 
and clinical outbreaks of hemorrhagic colitis, hemorrhagic uremic syndrome, 
and thrombotic thrombocytopenic purpura in human beings (Croxen et al., 
2010). Although ruminants, primarily cattle, have been suggested as typical 
reservoirs of STEC, many food products of other origins, including pig products, 
have been confirmed as vehicles for STEC transmission. In swine, STEC plays 
an important role in the pathogenesis of enterotoxiaemiae. In particular, a Shiga 
toxin subtype, named stx2e, it is considered as a main factor responsible in the 
damage of swine endothelial cells. On the contrary, stx2e-producing Escherichia 
coli has rarely been isolated in humans, and usually only from asymptomatic 
carriers or from patients with mild symptoms, such as uncomplicated diarrhoea. 
In fact, the presence of gene stx2e, encoding for stx2e, has rarely been reported 
in STEC strains that cause HUS. Moreover, stx2e-producing STEC isolated from 
humans and pigs were found to differ in serogroups, their virulence profile and 
interaction with intestinal epithelial cells. Because of the limited epidemiologic 
data of STEC in swine and the increasing role of non-O157 STEC in human 
illnesses, the relationship between swine STEC and human disease needs to be 
further investigated (Ercoli et al., 2015).  
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From the clinical point of view, the swine colibacillosis can be divided into 
intestinal and extra- intestinal infections (Table 14). The first manifest 
themselves in the form of diarrhea (neonatal and pre-or post-weaning), of 
hemorrhagic gastroenteritis or in enterotoxaemia form. The latter include instead 
septicemia and polyserositis or, rarely, mastitis, cystitis and pyelonephritis 
(Zavanella et al., 2009).  
Pathology Strains 
Neonatal diarrhea O8, O9, O101 O20, O64, O147, O149, O157 
Pre-weaning diarrhea O8, O115, 0147 
Post-weaning diarrhea O8, O9, O115,0138, O139, O141, O147, O157 
Hemorrhagic gastroenteritis O8, O149, O157, 
Oedema diesasse O138, O139, O141 
Table 14: Strains of E. coli associated to the diseases in pigs (Zavanella et al., 2009) 
In particular, regarding the enterotoxaemia, attributable to verocytotoxic E. coli 
(VTEC) strains, it occurs in piglets (about one or two weeks after weaning, while 
they are six-fourteen weeks old) but it is also reported in adult pigs.  
PWD is caused by F4+ and/or F18+ enterotoxin-producing E. coli (ETEC), while 
OD is the result of an infection with verotoxin-producing F18+ E. coli (VTEC). 
Up to now, no vaccine protecting piglets against these infections is available and 
treatment relies upon the use of antimicrobials.  
1.13.1-O138 verocytotoxic E. coli in weaned piglets  
Among the different phases of production, the weaning transition is a 
particularly complex period, during which the piglets are confronted by multiple 
stressors. Weaning involves complex social changes, including abrupt 
separation from the sow, a new housing system, separation from littermates and 
mixing with other litters in a new environment. Diet composition also changes 
at weaning: the liquid highly digestible milk from the sow is replaced by a less 
digestible and more complex dry feed. Early weaning (21 days or before) in 
intensive production systems is more likely to exacerbate the level of general 
stress, contributing to increased mortality, decreased growth performances and 
abnormal behavior of piglets (Kil et al., 2010). 
The immediate effect of weaning is a dramatic reduction in feed intake and a 
consequent ‘growth check’ (Pluske et al., 1997), which continues to represent a 
major source of production losses in commercial piggeries. Weaning is a critical 
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stage of pigs production and is associated with changes in the structure and 
function of the gastrointestinal tract. Intestinal alterations often seen in newly 
weaned piglets include reduction in villous height and increased crypt depth, 
reduced activities of intestinal digestive enzymes, disturbed intestinal 
absorption, secretion and permeability (Boudry et al., 2004; Lalles et al., 2004). 
Different stressors, related to the management may affect the immune fuction 
and the intestinal microflora of pigs, increasing the risk of enteric disorders.  
After the ban of in-feed antimicrobial growth promoters (AGP) in 2006, 
traditionally used in newly weaned pigs to control enteric pathogens, new 
strategies are required. E. coli is one of the main causes of important economic 
losses in the livestock industry, especially for the pigs: a group of diseases 
related to many factors, such as environmental, managerial, hygienic, and 
nutrition. 
Verocytotoxigenic E. coli (VTEC) was the first identified as a distinct group of 
E. coli named as verocytotoxigenic E. coli (VTEC), which had the ability to 
produce toxins with profound and irreversible effect on Vero cells (Reuter et al., 
2016). VTEC is also termed as Shiga-like toxin producing E. coli or Shiga toxin 
producing E. coli or STEC. Acronym STEC is derived from the fact that the 
toxins are Shiga like that is similar to those produced by Shigella dysenteriae 
Type 1 (O’Brien et al., 1987).  
Clinical signs of enterotoxaemia occur with oedema disease, intense diarrhea, 
and dehydration: the perineum looks yellowish and watery feces smeared; the 
stomach looks distended and contains undigested milk, the intestine is dilated 
and with a thickened wall, filled with clear liquid, and the mucosa is reddened 
and full with watery material containing. 
In farming industry verocytotoxic Escherichia coli (VTEC) is an important 
pathogen, causing serious mortality and severe production losses (Rossi et al., 
2013). Two crucial virulence factors are present: (1) adherence factors (often 
fimbriae) in order to mediate the attachment to specific receptors, usually 
glycans, followed by colonization of the intestinal tract and (2) the production 
of one or multiple toxins that induce disease symptoms. In piglets, VTEC strains 
expressing F18 fimbriae (Figure 4) are associated with post-weaning diarrhea 
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and enterotoxiaemia. The major protein of the F18 fimbria, FedA, is not 
sufficient for recognizing the F18 receptor (Imberechts et al., 1992). Two 
additional genes from the fed gene cluster, fedE and fedF, have been described 
as essential for fimbrial adhesion and fimbrial length (Imberechts et al., 1996). 
However, so far it has not been possible to assess F18 adhesion function with 
regard to either of the two gene products.  
 
Figure 4: E. coli expressing adhesive F18 fimbriae (electronic microscopy), (Imberechts et al., 
1996). 
After the initial adherence step via the F18 fimbriae VTEC strains produce and 
secrete the heat-labile (LT) and/or heat-stable enterotoxins (ST), thereby 
stimulating the secretion of electrolytes and water and resulting in dehydration 
of the enterocytes and watery diarrhea (Sears et al., 1996; Nagy et al., 2005) 
(Figure 5).  
 
 
 
 
 
 
 
Figure 5: Shiga-like toxin. The toxin has two subunits designated A-B. The B subunit is a 
pentamer that binds to specific glycolipids on the host cells, a globotriaosylceramide (Gb3). 
Following this, the A subunit is actuve enzimaticaaly (Rao et al., 2011).  
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O138 E. coli is a F18 positive VTEC strain producing the Shiga toxin Stx2e. 
Damage to the vascular endothelium eventually results in edema, hemorrhage 
and microthrombosis, and will be fatal in 90% of all affected animals.  
F18 fimbriae are assembled by dedicated machinery, the chaperone/usher (CU) 
pathway, which is distributed among genera of the phyla Proteobacteria, 
Cyanobacteria, and Deinococcus-Thermus. Essential to the CU pathway are a 
periplasmic chaperone protein and an outer membrane pilus assembly platform, 
termed usher (Busch et al., 2012). Fimbriae subunits or pilins are stabilized by 
the chaperone and complemented in the final quaternary structure by an N-
terminal donor strand of the following subunit. The usher both acts as a building 
platform and anchors the fimbriae to the cell surface (Phan et al., 2011). Crystal 
structure of the FimD usher binds to its cognate FimC-FimH substrate. The two-
domain tip subunit often harbors the adhesive properties and thus determines the 
host tropism of the bacteria (De Greve et al., 2007). It features a typical two-
domain organization comprising an N-terminal receptor-binding domain linked 
to a C-terminal pilin domain that forms the connection to the fimbrial shaft. F18 
fimbriae are comprised of the major subunit FedA (Imberechts et al., 1992), the 
minor subunit FedE and the tip-adhesin FedF (Smeds et al., 2001), which binds 
to glycosphingolipids having A/H blood group type 1 core antigens (H: 
Fucα2Galβ3GlcNAcβ3Galβ4Glc;GalNAcα3) that are present on enterocytes of 
the small intestine (Coddens et al., 2002). Two subtypes of the F18 fimbria are 
distinguishable by serologic methods: F18ab (formerly, F107 fimbria) and 
F18ac (formerly, 2134P, 8813, or Av24 fimbria) (Rippinger et al., 1995).  
Both F18 fimbrial subtypes appear correlated with different pathovars and O 
antigens. O antigens are constituted by certain sugar residues of 
lipopolysaccharides present in the outer membrane of Gram-negative bacteria. 
Although O antigens appear not directly involved in bacterial virulence, 
serotyping is often used in routine diagnostics for presumptive identification of 
virulent strains among porcine E. coli isolates (Gyles et al., 2010). While F18ab 
fimbriae have been found predominantly in STEC exposing the O138 or O139 
antigen on the bacterial surface, F18ac fimbriae were reported dominant in 
ETEC strains of serogroups O141, O147, and O157 (Hyde et al., 1995; Nagy et 
al., 2005). 
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Pathogenesis  
After birth, suckling piglets are protected from F18+ VTEC by specific 
antibodies in the sow colostrum. Vaccination of the sow can enhance the 
protection and so far, several maternal vaccines are available on the market (Cox 
et al., 2002). At weaning this lactogenic immunity is lost and together with the 
stress associated with the weaning period the piglet will become highly 
vulnerable to infection.  
VTEC can survive the high acidity of the stomach and with such small numbers 
capable of causing disease, infection can occur without any growth of the 
bacteria in food. The incubation period for VTEC infection ranges from 1–8 days 
but is typically between 2 and 4 days (Maule, 2000). The relatively long 
incubation period of VTEC has significant implications for investigation. It 
makes recall bias (inability to remember accurately what foods were eaten or 
where the patient was during the possible exposure period) more likely (report 
of the Health Protection Surveillance Centre (HPSC) subcommittee on 
verotoxigenic Escherichia coli, 2005). 
Ingestion of VTEC is followed by colonization of the intestine in pigs in which 
intestinal epithelial cells carry receptors for the F18 pili. Expression of the 
receptors is related with age; in fact, younger pigs are less susceptible to 
colonization than older pigs. Some pigs with a specific mutation in a gene that 
codified the receptors are resistant to infection. Resistance/susceptibility is 
established by a single locus with a dominant susceptibility allele and a recessive 
resistant allele; it is allowing selection of resistant pigs, which can be analyzed 
by a simple PCR test that identifies the presence or absence of the specific 
mutation. Some ideas about selection for resistance to F18+ E. coli has been 
expressed, because a very high association between the presence of the marker 
for resistance to F18+ E. coli and the presence of the marker for stress 
susceptibility was shown in Swiss Landrace pigs.  
VT2e proteins in the intestine of colonized pigs are responsible for the major 
clinical signs and pathology symptoms. O138 E. coli may colonize the 
mesenteric lymph nodes and produce VT2e there. In addiction, this site the toxin 
is absorbed into the bloodstream. The VT2e toxin binds readily to pig RBCs, 
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which may deliver the toxin to various sites in the body. Sites highly susceptible 
to the toxin include the submucosa of the stomach, the colonic mesentery, the 
subcutaneous tissues of the forehead and eyelids, the larynx, and the brain. 
Damage to vascular endothelium results in edema, hemorrhage, intravascular 
coagulation, and microthrombosis.  
High-protein diets increase the susceptibility of pigs to the disease. Factors 
associated with weaning, including the stresses of mixing pigs, changes in diet, 
and the loss of milk antibodies from the intestine, appear to be important 
elements in enhancing the susceptibility of weaned pigs to the disease.  
Currently, no vaccine is available to protect pigs against VTEC. Expressed 
antigens in plants against post- weaning disease offer potential solutions. Orally 
immunized mice and pigs with tobacco seeds expressing VT2e-B and FedA 
conferred protective immune response against O138 E. coli, and immunized pigs 
showed protection against O138 E. coli infection (Rossi et al., 2014).  
In this study, two proteins actively involved in the pathogenesis of the disease 
were selected as potential immunogens against O138 E. coli infection: the F18 
fimbria, responsible for the adherence of the bacteria on small intestinal 
enterocytes, and the B subunits of VT2e, responsible for binding the toxin to 
specific receptors on the cells surface.  
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2-AIM OF THE STUDY 
This work focused on Nicotiana tabacum-based vaccines engineered for the 
expression of antigens against verocytotoxic Escherichia coli (VTEC strain). In 
a previous study, tobacco plants of Nicotiana tabacum specie were transformed 
via agro-infection for the seed-specific expression of the antigenic proteins. 
The general aim was to define the strategy to induce effective local immune 
response in weaned piglets by oral administration of engineered tobacco seeds.  
In particular, the following issues have been investigated: 
 Evaluation of germination, growth and development of vaccinal plants in 
Fitotron and greenhouse: seeds of two antigenic lines (F18+ and VT2e-B+) and 
wild-type of tobacco were seeded and monitored.  
Optimization of harvesting seeds practices and quantification of seeds from 
transgenic tobacco plants. 
 Chemical, molecular and morphological evaluation of engenireed plants. 
In particular, the stable integration of transgenes, their expression and their 
influence on principal morphological characteristics were investigated.  
 Definition of experimental conditions in order to perform the oral 
immunization of piglets. In particular, the palatability, dosage, texture, milling 
procedures were investigated. 
 Evaluation of the protective effect of immunogenic seeds throught in-
vivo trial (ethical authorization: 102/2015PR – Health Ministry) carried out at 
the experimental animal research and application Centre of the University of 
Milan in Lodi. 
In order to examine in depth, the aspects related to local immunity, an 
independent project to characterize the effects of different mucosal bacterial 
pathogens (two strains of H. influenzae, M. catarrhalis and S. aureus) on the 
isotype of antibody production from human B cells has been developed. The 
potential “decoy” stimulation by surface bacterial proteins that is proposed to 
stimulate B cells non-specifically by cross-linking surface antibody by the 
constant Fc region rather than binding these bacteria by the antigen-specific Fab 
variable region. This part of the study has been conducted in collaboration with 
the Department of infectious diseases, University of Denver, Colorado. 
71 
 
3-MATERIALS AND METHODS 
ABBREVIATIONS: 
dNTPs  deoxynucletide triphosphate  
IPTG   Isopropyl β- D -1-thiogalactopyranoside 
SDS  Sodium dodecyl sulfate 
RT   room temperature  
o/n  over night  
bp  base pairs  
rpm   revolutions per minute 
OD600 Optical Density, of a sample measured at a wavelength of 600  
nm  nanometer 
PBS-t  Phosphate Buffered Saline adding of the detergent Tween 20 
LB  Luria-Broth 
KAN  Kanamycin 
kDa  KiloDalton  
TMB  3,3',5,5'-Tetramethylbenzidine 
BSA  Bovine Serum Albumin  
NDF  Neutral Detergent Fiber  
ABTS  2, 2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) 
BHI  Brain Heart Infusion  
IFN-  Interferon- 
PBMC  peripheral blood mononuclear cell 
IL-21  Interleukyn-21 
TSB  Tryptic Soy Broth 
HRP  Horseradish Peroxidase  
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3.1-Vaccinal biomass production  
In the present study, two lines of Nicotiana tabacum plants, previously 
engineered for the seed-specific expression of the major subunit Fed-A of the 
F18 adhesive fimbriae and VT2e B-subunit genes respectively, were considered 
as model of edible vaccines against porcine verocytotoxic E. coli (Rossi et al., 
2013). Briefly, tobacco plants were transformed via Agrobacteium tumefaciens 
with chimeric constructs containing structural parts of genes under control of a 
seed specific GLOB promoter (Figure 6). 
Figure 6: Chimeric constructs used for Agrobacterium tumefaciens EHA105 transformations. 
Transgenes were inserted under control of the GLOB promoter and NOS terminator. (A) 
pBIpGLOB-VT2e-B was 13800 bp. (B) pBIpGLOB-F18 was 14049 bp. 
3.1.1-Seeding  
Three lines of tobacco seeds (Nicotiana tabacum L., cv. Xanthi), two transgenic 
(F18+ and VT2e-B+) and one wild type used as control, were seeded in three 
seedbeds with growing soil (sphagnum, peat, lapilli and pumice) previously 
wetted for 24 hours on 2 cm of water.  
In particular, three tobacco seeds were potted in each pots of seedbed, using 
spatula and microscope (Figure 7). After sowing directly onto soil, the seeds 
were wetted with normal water three days a week to keep them humid. 
A total of 80 pots per each vaccinal line (F18+ and VT2e-B+) and 56 pots for 
wild type were seeded.  
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Seeds were maintained in a Fitotron® growth chamber in controlled 
environmental condition (25°C ± 2°C; 14 hours of light by 400 W high-pressure 
sodium lamps and 10h dark). 
 
A                                          B                                           C      
 
 
 
 
 
Figure 7: Times of seeding of transgenic seeds and wild type seeds. A: seeds were selected by a 
spatula and using microscope; B the seedbed with commercial soil; C: Fitotron growth chamber 
at optimal growth conditions 
 
3.1.2-Germination and morphology evaluation 
The germination was determinate by index. The germination index was 
measured with the following formula to evaluate and compare the germination 
value and time of control, F18 and VT2e-B plants. 
% of germinate plants= number of germinated plants/total number of pots 
After the germination the height of the out-soil part of the plants were monitored 
weakly for 50 days.  
3.1.3-Cultivation in the greenhouse  
80 plants for each vaccinal line (height 15 cm) were transferred at the Orto 
Botanico G.E. Ghirardi in Toscolano Maderno (Brescia), a botanical garden of 
the University of Milan, in collaboration with the Department of Bioscience. The 
plants were maintained in a greenhouse using biosafety level 1, according to the 
98/81/EC Directive.  
In the greenhouse, plants were stored and isolated from the environment by the 
polyethylene monofilament to avoid cross-pollination and to provide protection 
against aphids, white fly and Bemicia tabaci, as shown in Figure 8. 
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The environmental conditions were maintained: temperature between 25-30°C, 
80-85% atmospheric humidity, a low level of nitrogen in the soil, a photoperiod 
of 14h light and 10h dark by a specific lamp. The plants were treated with water 
containing 20% of total nitrogen, 20% of Phosphate (P2O5) and 20% of Soluble 
Potash (K2O) Peters Professional® (by Scotts Company).  
 
A                                          B                                        C     
 
 
 
 
Figure 8: Level 1 of containment in the greenhouse. A: experimental plants harvested under 
a polyethylene monofilament that provides protection from aphids, white fly and Benicia 
tabaci; B: Sheet for insect killer; C: The plants growth in separate room to avoid cross-
pollination. 
 
3.2-Seed collection  
After the flowering period, brown ovaries were cut off and collected. Seeds 
ovaries were stored in a cool, dry place to air dry for 7-10 days. After this period, 
each ovary was opened in order to collect transgenic seeds. The harvest of seeds 
was performed in different rooms to avoid contamination between two vaccinal 
lines: F18+ and VT2e-B+. 
Seeds were sifting and separated from debris and residual part of ovary with 
Vibroscreen Retch by using sieves with different diameter (Figure 9) for 4 
minutes and amplitude 50. The seeds were stored for next experimental trial and 
to confirm the presence of the transgene in the progeny (R3). 
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Figure 9: Vibroscreen used after seed collection in order to separate seeds from capsulaes.  
3.3-Chemical analyses of principal components of vaccinal 
tobacco seeds 
The chemical analysis of tobacco seeds was performed to measure the principal 
components: Crude protein (CP), according to the official method of Analysis 
of Association of Analytical Communities, procedure 2001.11 (AOAC, 2005); 
dry matter (dm), according to procedure 930.15 (AOAC, 2005); fat (EE) 
according to DM 21/12/1998; crude fiber (CF), according to procedure Ba 6a-
05 of the official method of the American Oil Chemists Society (AOAS, 1998); 
ash, according to procedure 942.05 (AOAC, 2005). 
3.4-Molecular Analyses of tobacco plants 
3.4.1-DNA extraction from seeds and leaves 
In order to confirm the presence of F18 and VT2e-B genes in the two vaccinal 
lines and the absence of the genes in the controls, DNA was extracted from 
leaves and seeds (20% of growing plants and 20% of obtained vaccinal seeds).  
In particular, 40 mg of each sample was grinded into a fine powder freezing it 
with liquid nitrogen by mortar and pestle. For the isolation genomic DNA from 
plants, tissues and seeds, the Wizard® Genomic DNA Purification Kit by 
Promega (Promega Corporation 2800 Woods Hollow Road Madison, WI 53711 
USA) was used. Extracted DNA was quantified by a 0.8%-1.5% agarose gel and 
by a spectrophotometer. In the agarose gel, DNA samples were compared with 
PCR 100 base pairs (bp) Low Marker (SIGMA-Aldrich, St. Louis MO USA). 
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3.4.2-Detection of F18, VT2e-B and NOS genes  
F18 gene was detected with PCR using the two primers reported in table 15. 
PCRs were performed in 25-μl volumes containing 5 μl of DNA template, 0.2 
mM concentrations of deoxynucleoside triphosphates, 2.5 μl of 10X PCR buffer 
II, 3 mM MgCl2, 1 μM concentrations of each forward and reverse primer, 1.25 
U of AmpliTaq Gold (Perkin Elmer). The thermal cycling conditions were as 
follows: 1 cycle of denaturation at 95°C for 5 min; 35 cycles of melting at 95°C 
for 1 min, annealing at 56°C for 1 min 20 s, and elongation at 72°C for 1 min 30 
s; and a final extension at 72°C ∞. 
Table 15: Sequences of oligonucleotides for F18 detection. 
VT2e-B gene was detected by polymerase chain reaction using two primers 
reported in table 16. PCRs were performed in 25-μl volumes containing 5 μl of 
DNA template, 0.2 mM concentrations of deoxynucleoside triphosphates, 2.5 μl 
of 10X PCR buffer II, 3 mM MgCl2, 1 μM concentrations of each forward and 
reverse primer, 1.25 U of AmpliTaq Gold (Perkin Elmer). The thermal cycling 
conditions were as follows: 1 cycle of denaturation at 95°C for 5 min; 35 cycles 
of melting at 95°C for 1 min, annealing at 50°C for 1 min 20 s, and elongation 
at 72°C for 1 min 30 s; and a final extension at 72°C ∞. 
Table 16: Sequences of oligonucleotides for the VT2e-B detection. 
Primers HA-NOS118-f and HA-nos118-r (Lipp et al., 2001), reported in the 
table 17, were used for the detection of the NOS terminator. Amplification of 
the NOS terminator will result in the production of a DNA fragment of 118 bp. 
Table 17: The oligonucleotide sequences for NOS detected by PCR. 
PCRs were performed in 50-μl volumes containing 15 μl of DNA template, 0.2 
mM concentrations of deoxynucleoside triphosphates, 5 μl of 10X PCR buffer 
Gene  Oligonucleotide sequences PCR product size (pb) 
F18 
adhesive 
fimbriae 
313 F 
314 R 
5’ggatccatgaaaagactagtgtttatttcttttg  
3’cgaatgcgccaatgaatgttcattctcgag  
519 
gene  Oligonucleotide sequences PCR product size (pb) 
VT2e-B 
subunit  
307 F  
308 R 
5’ ggatccatgaagaagatgtttatagcgg 
3’ aacgggtccacttcaaatgattctcgag 
270 
gene  Oligonucleotide sequences PCR product size (pb) 
NOS terminator 118 F 
118 R 
5’ gcatgacgttatttatgagatggg  
3’ gacaccgcgcgcgataatttatcc   
118 
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II, 3 mM MgCl2, 1 μM concentrations of each forward and reverse primer, 1.25 
U of AmpliTaq Gold (Perkin Elmer). The thermal cycling conditions were as 
follows: 1 cycle of denaturation at 95°C for 10 min; 50 cycles of melting at 95°C 
for 25 s, annealing at 62°C for 30 s, and elongation at 72°C for 45 s; and a final 
extension at 72°C ∞. 
PCR-product were evaluated on agarose gel (F18 0.8%, NOS: 1%; VT2e-B: 
1.5%). 
3.5-Evaluation of the expression of antigenic proteins in 
seeds 
The seed expression of antigenic proteins was evaluated through ELISA assay 
in collaboration with PLANTECHNO S.R.L. 
3.5.1-Positive controls: purified antigens  
The F18 protein was purified according to the protocol previously described by 
Goddeeris et al. (2002). Briefly, O138 E. coli strain (F18 positive) was cultured 
in Tryptone Soya Broth at 37° C and 85rpm for 18 h. Subsequently, the bacteria 
were collected by centrifugation (3000×g; 35min) and washed in PBS, after 
which the F18 fimbriae were isolated by heat shock (60° C for 20 min). Larger 
fragments were removed by centrifugation (10,000×g; 20 min) and the 
supernatant was further purified by a subsequent centrifugation (20,000×g; 40 
min), both at 4°C. The solubilized F18 fimbriae was precipitated with 20% (w/v) 
ammonium sulfate and the pellet was dissolved and dialyzed overnight against 
ultra-pure H2O.  
VT2e-B protein was produced by pET-system (Novagen) in E. coli BL21 as 
described in Rossi et al. (2013). In particular, E. coli BL21 competent cells 
(Novagen) were transformed with the expression plasmid pET-28a containing 
the VT2e-B gene and selected on LB-Kan plates (kanamycin 30 ug/mL). A 
single recombinant colony was inoculated with 5mL of the LB medium 
containing kanamycin (37°C, o/n). A total of 1 mL of the pre-inoculum was 
added to 100 mL of the LB medium in a 1L flask, and incubated with shaking 
(175 rpm at 37°C) until the OD600 reached 0.6. Isopropyl-Beta-D-thiogalactoside 
(IPTG) was added to the culture to a final concentration of 0.1 mM and the 
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incubation was continued for another 2 h. The culture was incubated for an 
additional 3 h and then collected by centrifugation. The soluble protein fraction 
and inclusion body proteins were eluted separately in columns with a specific 
resin. The proteins were resolved by 10% polyacrylamide gel electrophoresis. 
Detection was performed by Coomassie blue staining. The purified VT2e-B 
protein was concentrated in a 4M urea elution buffer with a centrifugal filter 
(10kD molecular weight cut-off, Centricon). The transgenic protein VT2e-B was 
expressed in inclusion bodies about 1 mg /100 mL of induced culture, after 
renaturation the purity of the polypeptides reached >80%. 
F18 and VT2e-B proteins were evaluated on an SDS page. The purified proteins 
were stored at −80 °C.  
3.5.2-Specific antibodies against antigens 
Anti-F18 antibody was produced by GenScript (GenScript 860 Centennial Ave. 
Piscataway, NJ 08854 USA). The sequence of F18 antigenic protein (Table 18) 
was analyzed by Genscript's Peptide Antigen Database. Three peptide antigens 
were identified across the target protein sequence (Table 19). In some instances, 
peptide antibodies failed to recognize the folded conformation of the native 
protein. However, generating antibodies against multiple antigens can 
significantly increase the success rate of endogenous protein detection. 
Table 18: The aminoacid sequence of F18 antigenic protein. 
Table 19: Aminoacid sequences of thee peptides chosed for the production of specific antibodies. 
Using these peptides, the PolyExpress™antibody services can produce high 
quality polyclonal antibodies with guaranteed ELISA titer >1:64000.  
Anti-VT2e-B polyclonal antibodies were kindly purchased and produced by 
Plantechno s.r.l. The specific antiserum was obtained through the immunization 
of New Zealand rabbits with VT2e-B protein expressed by pET-system 
(Novagen) in E. coli BL21 (DE3) as described by Rossi et al. (2014). 
Sequence of F18 protein 
MKRLVFISFVALSMTAGSAMAQQGDVKFFGNVSATTCNLTPQISGTVGDTIQLGTVAPSGTGSEIPF
ALKASSNVGGCASLSTKTADITWSGQLTEKGFANQGGVANDSYVALKTVNGKTQGQEVKASNSTV
SFDASKATTEGFKFTAQLKGGQTPGDFQGAAAYAVTYK 
Antigen Designed:  
peptide 1--> AQLKGGQTPGDFQG : 
peptide 2--> LTEKGFANQGGVAN : 
peptide 3--> TGSEIPFALKASSN  
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3.5.3-Set-up ELISA assay 
The total proteins were obtained from all mature transformed tobacco seeds by 
homogenization with liquid N2 in a mortar and protein extraction with the 
extraction buffer (50 mM Tris, pH 8.5 mM EDTA, 200 mM NaCl, 0.1% Tween 
20). Protein content was estimated by a Bradford assay (BioRad, Hercules, USA) 
using bovine serum albumin as the standard. An indirect ELISA was developed 
to quantify the best concentration for the coating and titration of immunogenic 
proteins VT2e-B and F18. 
3.5.4-Quantification of F18 in vaccinal seeds 
The coating was performing at room temperature for 2 h in carbonate buffer 
(50mM, Ph 9.6) We have tested serial dilutions starting from an initial 
concentration of 2 g/mL to 60 ng/mL, from 1 to 6 (Table 20), the line 7 
represented the negative control. Different dilutions of the primary antibody 
were tested, starting from a 1:1000 up to a 1:64000 (line A-G) negative control 
(line H) without antibody. The conditions of the secondary antibody (anti-rabbit 
peroxidase conjugate) are fixed, dilution 1: 15000, as suggested by the 
manufacturer (Sigma). 
Table 20: ELISA plate serial dilutions for coating of F18 antigenic protein (mL**ng/mL). 
100 mg of seeds were homogenized in extraction buffer (TRIS-HCl, pH 7.5) 
then centrifuged, from the supernatant. The extracted proteins were estimated 
about 1.8g /L (Bradford assay). 100l of each of the five standard and 100 
mL of each sample were added into tubes. 100 l of primary antibody was added, 
diluted in PBS buffer 1:12000. The samples were leaved an hour at RT. 100 l 
was transferred of the previous competition reaction in the wells of the strip 
Col 1 
2* 
2 
1* 
3 
0.5* 
4 
0.25* 





A 3.394 3.362 3.330 3.279 3.130 3.027 0.093 
B 3.343 3.314 3.266 3.205 3.044 2.795 0.138 
C 3.253 3.228 3.217 3.132 2.915 2.677 0.112 
D 2.952 2.981 2.897 2.724 2.483 2.104 0.091 
E 2.422 2.361 2.241 2.190 1.874 1.512 0.086 
F 1.821 1.781 1.644 1.469 1.281 0.982 0.090 
G 1.201 1.239 1.070 0.951 0.828 0.639 0.080 
H 0.095 0.122 0.114 0.112 0.115 0.089 0.063 
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ELISA (Coating 0.5 g / mL) for an hour at RT. Then, the wells were washed 
three times with 1X PBS buffer. The secondary antibody (1: 15,000 in 1X PBS) 
was added and incubated for 30 minutes at RT. After washing the plates, l 
of TMB were added to each well and manteined in the dark for 15 minutes. The 
reaction was stopped with HCl 0.4 N and the optical density was measured at 
450 nm. 
3.5.5-Quantification of VT2e-B in vaccinal seeds 
The coating of antigen was performed overnight (o/n) at 4°C in carbonate buffer 
(50mM, pH 9.6). Serial dilutions, starting from 10 g/mL to 10 ng/mL, were 
tested starting from line 1 until line 12 as shown in the table 21; line 7 is the 
negative control (without antigen). 
Different dilutions of the primary antibody starting from a 1:400 dilutions up to 
a 1.25000 dilution (line A-G) (line H negative control) without antibody were 
tested (Table 21). The conditions of the secondary antibody (anti-rabbit 
peroxidase conjugate) were fixed, dilution 1: 15000, as suggested by the 
manufacturer (Sigma). 
Table 21: Serial dilutions for coating of VT2e-B protein *: g/mL**:ng/mL. 
The best concentration for the coating was 0.6 g/mL-10ng/mL and 1:6000 for 
the primary antibody. Based on the yield putatively contained in seed, five 
standards were determined from 0 to 80 ppm. 100 mg of seeds were 
homogenized in an extraction buffer (TRIS-HCl, pH 7.5). After centrifugation 
(5,000 rpm for 10 minutes), the supernatant was collected. The total extracted 
proteins were about 1.8 g/mL (Bradford assay). The samples were finally 
quantified. l of each of the five standard and l of sample were putted 
into tubes. 100 l of primary antibody (1:12,000 PBS buffer) were added for one 
hour at RT. 100 l of the previous competition reaction were added in the wells 
Cal 























A 3.27 3.39 3.37 3.26 3.27 3.28 3.14 3.04 2.91 2.67 1.661 0.821 
B 3.16 2.97 3.10 3.15 3.11 3.03 2.94 2.88 2.62 1.96 1.67 0.81 
C 2.92 2.60 2.64 2.51 2.85 2.59 2.65 2.42 1.93 1.60 1.27 0.58 
D 2.58 2.05 1.97 2.07 2.08 1.71 1.77 1.842 1.697 1.29 1.13 0.39 
E 1.55 1.37 1.43 1.42 1.49 1.41 1.09 1.028 0.974 0.801 0.705 0.28 
F 1.14 1.06 1.039 1.12 1.06 0.84 0.71 1.03 0.71 0.49 0.44 0.23 
G 0.78 0.75 0.78 0.83 0.68 0.67 0.61 0.61 4.46 0.33 0.34 0.22 
H 0.53 0.49 0.53 0.71 0.62 0.46 0.45 0.49 0.45 0.49 0.31 0.25 
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of the strip ELISA (coating 0.6 g/mL) for an hour at RT. The samples were 
washed with 1X PBS buffer. The secondary antibody (1:6,000 PBS) was added 
and incubated for 30 minutes. l of TMB were added into tubes for 15 
minutes without lightning. The reaction was blocked with HCl 0.4 N and the 
optical density was evaluated at 450 nm. The samples were analyzed with 
ELISA device at a wavelength of 450 nm, the calibration curve was calculated 
with the "Curve expert 1.3" program. 
3.6-Microscopical evaluation of plants  
We have performed analysis by optical and electronic microscopes in different 
phases of the plants growth in collaboration with the Department of Biosciences, 
Università degli Studi di Milano. Samples were fixed in 2% formaldehyde and 
0,2% glutaraldehyde (in Hepes 50mM, pH 7,4) overnight at 4°C, repeatedly 
rinsed in Hepes 50mM, pH 7.4, dehydrated with increasing concentrations of 
ethanol and embedded in LRGold resin at -20°C. 
3.7-In-vivo trial: evaluation of the oral administration of 
tobacco seed as edible vaccines in weaned piglets 
3.7.1-Animals, Housing conditions  
Thirty-six piglets (Landrace x Large White) were selected from a conventional 
herd free from diseases according to the A-list of the International Office of 
Epizootic, and from Aujeszky’s disease, atrophic rhinitis, transmissible 
gastroenteritis, porcine reproductive and respiratory syndrome and 
salmonellosis, without history of PWD and OD and with bacteriological analysis 
of the feces negative for hemolytic E. coli (IZSLER).  
Piglets, homogeneous per weight, age and gender (50% male, 50% female), 
weaned at 21 days (to ensure the animals’ sensitivity upon experimental 
infection) were transported to the Experimental Animal Research and 
Application Centre (pigs sector) in Lodi of the University of Milan. 
Animals were allocated in individual pen, under the same environmental 
conditions (temperature 29 °C and humidity 60 %), with water and feed ad 
libitum, the animals were identified by auricular tag. The in vivo trial was 
approved by ethical authorities (102/2015 PR Health Ministry) in accordance 
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with the European regulations (European Union Directive 2010/63/UE). The 
piglets were fed a basal diet without antibiotics, provided by Ferraroni S.p.A 
(Bonemerse CR, Italy) (Table 22). 
The experimental diets were analyzed for the principal chemical components: 
crude protein (CP), according to the official method of Analysis of Association 
of Analytical Communities, procedure 2001.11 (AOAC, 2005); dry matter (dm), 
according to procedure 930.15 (AOAC, 2005); fat (EE) according to DM 
21/12/1998; crude fiber (CF), according to procedure Ba 6a-05 of the official 
method of the American Oil Chemists Society (AOCS, 1998); ash, according to 
the procedure 942.05 (AOAC, 2005).  
The animals were divided in two experimental groups, controls group (CG; 
n=18) and treated group (TG; n=18) randomly. 
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Table 22: Basal diet and high proteins diet. 1Palm oil, salts of fatty acids (sodium butyrate 30%), 
calcium carbonate. 2Providing the following nutrients (per kg of air-dried diet): Vitamin A, (E 
672) 4000000 UI/Kg; Vitamin D3, (E 671) 400000 UI/Kg; Vitamin E, (3a700) 40000 mg/Kg; 
Vitamin B1, 1200 mg/Kg; Vitamin B2, 4000 mg/Kg; Calcium D-pantothenate, (3a841) 10865 
mg/Kg; Vitamin B6, (3a831) 2400 mg/Kg; Vitamin B12, 16 mg/Kg; niacinamide, (3a315) 14000 
mg/Kg; Vitamin K3, 2000 mg/Kg; Folic acid, (3a316) 600 mg/Kg; D-Biotin, 80 mg/Kg; Choline 
chloride, (3a890) 90000 mg/Kg, Fe (FeO), 45000 mg/Kg; Cu (CuSO4), 8000 mg/Kg; Zn (ZnO), 
52200 mg/Kg; Mn (MnO), 16000 mg/Kg; I (Ca(IO3)2), 240 mg/Kg; Se (Na2SeO3), 120 mg/Kg. 
3Phytase (EC 3.1.3.26) minimum: 10000 Fytα-phytase/g 4 Endo-1,4β-Xylanase (IUB/EC 3.2.1.8) 
minimum 1000 FXU/g.5 Ortophosphoric acid 33.5%, Calcium formate 32.38%, Citric acid 7.8%, 
Fumaric Acid 5%, Silicic acid 6%. 
  
Item Basal diet High protein diet 
Ingredient, g/kg 
Barley 228.000 161.880 
Wheat flakes 168.000 119.280 
Wheat meal 134.000 95.140 
Maize flakes 112.000 79.520 
       Barley flakes 72.600 51.546 
Soy protein concentrate 70.000 49.70 
Soybean  meal  - 28.000 
Whey  55.600 39.476 
Maize meal 52.000 36.920 
Fish meal (herring) 39.700 28.187 
Monohydrate dextrose 37.100 26.341 
Spray-dried plasma 27.100 19.241 
Coconut oil 27.000 19.170 
Soybean oil 16.000 11.360 
Dicalcium phosphate 5.200 3.692 
Calcium carbonate 1.100 0.781 
Sodium butyrate 30%1 2.190 1.555 
L-Lys 6.700 4.757 
DL-Met 3.220 2.286 
L-Thr 3.040 2.158 
L-Trp 1.220 0.866 
Vitamin/mineral premix 2 3.270 2.322 
Vitamin E 50% 0.140 0.099 
Additives: phytase3, xylanase4, acidifiers5, 
feed flavors.  
16.55 11.750 
Chemical composition 
DM  90,332 88.5 
CP 17,80 25,42 
Fat 5,87 4,57 
Crude Fiber 2,19 3,20 
Ash 4,46 5,17 
Starch + sugar 51,51 38,88 
Lysin 1,48 1,73 
NE Mc/Kg 2,60 3,56 
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3.7.2-Experimental design  
The work was divided in three phases: 
1. Phase I-Immunization (Days 0-20): administration of vaccinal seeds by 
oral route (day 0, 1, 2, 5, 14). 
2. Phase II -Challenge (Day 20): experimental infection. 
3. Phase III- Observation (Days 21-29): sample collection, zootecnical 
and clinical evaluation 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Scheme of experimental design. 
3.7.3-Treatments 
Tobacco seeds were ground with a suitable mill to obtain a uniform powder using 
a 0.75 mm grid (Figure 11) controlling the temperature (max 50° C). 
 
 
 
 
 
 
 
Figure 11: ZM 200 Ultra Centrifugal Mill, Retsch® for fine grinding of N. tabacum seeds. 
During the immunization phase (on days 0, 1, 2, 5, 14), the tobacco seeds were 
administered with a commercial milk replaced powder (LACTOSOL) by mixing 
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in a 1:2 ratio (weight/weight) in order to guarantee the complete consumption 
(Table 23). 
Table 23: Chemical component of LACTOSOL TV, used for the treatment preparation. 
The TG received vaccinal Nicotiana tabacum seeds (F18s + VT2e-Bs) on days 
0, 1, 2, 5 and 14. In particular, each treatment was represented by 10g of F18s 
(containing about 7 g of FedA protein), 10g of VT2e-B (containing about, 35 
g of VT2e-B) and 40g of milk replacer powder. At the same time CG received 
20g wild type milled tobacco seeds mixed with 40g of milk powder (Table 24). 
Table 24: Treatments received during the trial by the experimental groups. 
3.7.4-Challenge  
Six days after booster immunization, on day 20th, 24 piglets (TG, n: 12; CG, n: 
12) were orally challenged with O138 Escherichia coli strain, provided by 
Lombardia AND Emilia Romagna Experimental Zootechnic Institute (IZSLER) 
(Table 25). 
Table 25: Distribution of piglets in the experimental groups during the phase I and III. 
Analytical components Nutritional additives (/kg) 
Crude protein: 20.5% Vitamin A (E672): 50.000 I.U. 
Vitamin D3 (E671): 5.000 I.U. 
3a700 Vitamin E (all-rac-alpha-tocopher 
l acetate): 100 mg 
Vitamin C (E300): 100 mg 
E1 Ferrous sulphate monohydrate: 304 mg 
E2 Anhydrous calcium iodate: 1.5 mg 
E4 Copper sulphate pentahydrate: 31 mg 
E5 Manganous sulphate monohydrate: 169 mg 
E6 Zinc sulphate monohydrate: 192 mg 
E8 Sodium selenite: 0.55 mg 
Oils and fats: 20.0% 
Crude ash: 9.5% 
Crude fiber: 0.1% 
Sodium: 0.8% 
Lysine: 1.7% 
Methionine: 0.8% 
Name of group  Number of 
animals 
Treatment Dose 
Treated group 
(CG) 
18 10 grams F18 and 10 grams 
VT2e-B 20 grams of milk 
powder 
7 g F18 
35 g VT2e-B  
Control group 
(TG) 
18 20 grams of WT milled 
tobacco seeds 20 grams 
powder milk 
0 g 
Days  Control Group (CG) Treated group (TG) 
0-20 
(Phase I) 
N= 18 N= 18  
20-29 
(Phase 
III) 
Challenge 
group (CC) 
Unchallenge 
group (UC) 
Challenge 
group (CT) 
Unchallenge 
group (UT) 
N= 12  N= 6 N= 12  N= 6  
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Sixty minutes before challenge, piglets were sedated with azaperon (StresnilTM, 
Janssen Cilag SpA, 2 ml/head), thereafter 30 mL of a 10% bicarbonate solution 
(SIGMA, Italy) was orally administered in the attempt to neutralize gastric acid 
and to increase the survival rate of challenger strain in the stomach (Madec et 
al., 2000, Jensen et al., 2006).  
After 10-15 min, the inoculum was given via oral route in a single dose of 5 mL 
of bacterial medium with 1*1010 colony forming units (CFU) of challenger 
strain, using 16G catheter. Animals were fasted 3 hours before and 3 hours after 
challenge. 
For each group, six animals were not challenged and housed in pens separated 
by means of two empty pens from the infected group, so that physical contact 
between challenged and not challenged piglets was excluded.  
From the day of challenge until the second day after challenge, the same 
antimicrobial-free diet, containing 27% of crude protein on dry matter, was 
administered to all experimental groups.  
Before the administration, chemical analysis of the diet was performed to 
confirm its high protein level and to measure its principal components: crude 
protein (CP), according to the official method of Analysis of Association of 
Analytical Communities, procedure 2001.11 (AOAC, 2005); dry matter (dm), 
according to procedure 930.15 (AOAC, 2005); fat (EE) according to DM 
21/12/1998; crude fibre (CF), according to procedure Ba 6a- 05 of the official 
method of the American Oil Chemists Society (AOCS, 1998); ash, according to 
procedure 942.05 (AOAC, 2005). 
3.7.5-Sample collection and zootecnical evaluation 
Blood samples were collected from the jugular vein of each animal to determine 
the hematocrit value on days 0, 7, 14, 21, 25, and 29.  
In phase I, fecal samples were taken from rectum weekly on 0, 7, 14, 21 days to 
determine total and specific IgA levels, as described below.  
In phase III fecal samples were collected in order to evaluate the shedding of the 
challenger strains in collaboration with IZSLER. 
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Rectal temperature was daily recorded and the clinical signs of the disease in 
particular: palpebral Edema, epiphora, vitality, respiratory and neurological 
problems - were daily checked and scored using the specific point scales reported 
below: 
Respiratory score: 0 = normal; 1=slightly quick; 2= quick. 
Edema score in palpebra: 0= normal; 1=mild; 2=severe. 
Epiphora score: 0= normal; 1=mild; 2=severe. 
Vitality score: 0= good; 1=loose; 2=bad. 
In the same period, fecal consistency was daily evaluated through a scale of four 
levels: 0= normal feces; 1=soft consistency 2=mild diarrhea; 3=severe diarrhea. 
All piglets were individually weighed weekly during the entire experimental 
period and twice in the week following challenge (25 and 29 days); the feed 
intake (FI) was daily measured weighing the residual feed at the pen level 
(experimental unit for FI evaluation). 
At day 3 post-challenge (23th day), 12 piglets (4 CC, 2 CU 4 TC, 2 TU) were 
euthanized for post mortem examination; the restraint part of animals were 
sacrificed at 29th day.  
3.8-Evaluation of intestinal Immunoglobulin-A titer in the 
immunization phase  
After the extraction of fecal antibodies, the titre of total IgA in fecal samples was 
evaluated through the Pig ELISA quantitation set (Bethyl Laboratories, Inc. 
Montgomery, Texas). Briefly, 0.5 g of feces were diluted in 1 mL of extraction 
buffer and placed for 1 hour in ice. Centrifuged at 2000xg for 15 min at 4°C. The 
supernatant was collected and further centrifuged at 10000xg for 10 min at 4°C. 
The supernatant was then removed and stored at 20°C until use.  
3.8.1-Evaluation of total immunoglobulin A in the immunization 
phase 
 “Pig ELISA IgA quantitation set” was performed to detect and quantify IgA 
fecal samples. Fecal samples were diluted 1:100 for quantification of IgA. Serum 
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samples were diluted 1:100 in Sample Diluent, (“ELISA quantitation set”, 
Bethyl Laboratories, Texas). 
Microtitration 96-well plates were coated for 1 h at RT with 100μl of a solution 
containing 1 μl of affinity purified Pig IgA diluted in 100 μl of coating buffer. 
Then the wells were blocked with 200 μl of Blocking Solution for 30 min and 
then washed five times with 300 μl of Wash Solution. To each well 100 μl of 
standard or sample were added and incubated at RT for 1 hour. After washing 
the plates five times, 100 μl of diluted HRP detection antibody were added to 
each well and incubated at RT for 1 hour. After washing the plate five times, 100 
μl of TMB Substrate Solution were added to each well. The plate was developed 
in the dark at room temperature for 15 minutes, and then reaction was stopped 
by adding 100 μl of Stop Solution to each well. Absorbance was measured on a 
plate reader at 450 nm. For each plate, a standard curve was constructed to 
calculate the IgAs concentration of each sample using “Curva Expert 1.3” 
software. The concentrations determined were expressed as nanograms of IgAs 
per 1 mL. 
3.8.2-Evaluation of anti-F18 IgAs and anti-VT2e-B IgAs in fecal 
samples 
An ELISA method was set up for the titration of specific IgAs for antigenic 
proteins. 
In order to establish specific IgA title (anti-F18 and anti-VT2e-B) previously 
obtained antigens and antibodies were used.  
Extraction of total fecal immunoglobulins 
1g of fresh feces were vortexed (in 10 mL of extraction buffer 0.01M PBS, 0.5% 
Tween, 0.05% sodium azide) and centrifuge at 1,500 xg for 20 min at 4°C.  
2 mL of the supernatant were transferred to a sterile tube containing 20 L of 
protease inhibitor (Roche) and mixed briefly. Finally, the samples were 
centrifuged at 10,000xg for 10 min and the supernatant was recovered in sterile 
tubes.  
For the evaluation of specific IgA (anti-F18 and anti-VT2e-B) a double antibody 
sandwich ELISA system was developed. 
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Pig IgA antibody (Bethyl 1: 500 in coating buffer, 50 mM sodium carbonate pH 
9.6) is made to adhere to an ELISA plate o/n at 4°C. The plates are "blocked" 
with PBSt and 3% BSA to 3 hours at RT.  The total immunoglobulins extracted 
from feces and/or their dilutions (100 mL) were incubated o/n at 4 ° C in the 
wells with the antibody conjugates. After three washes of the wells with PBSt, 
100 L are added to each well and incubated 1 hour at RT, respectively Ab F18 
and Ab VT2e-B (Rabbit). After three washes of the wells with PBST, 100 L of 
anti-Rabbit horseradish peroxidase conjugate were added to each well for 1 hour 
at RT. TMB was used for the colorimetric reaction; the quantification of the 
specific antibodies was out by measuring absorbance at 450 nm. 
3.9-Statistics  
Data were analyzed using IBM SPSS Software (IBM Corporation 1 New 
Orchard Road Armonk, New York 10504-1722 United States). We have applied 
Non-Parametric Tests for Independent Samples, using NPTESTS procedure post 
hoc tests for the Kruskal-Wallis omnibus test. Comparisons of antibody titers 
between groups were done using the Mann–Whitney test after base 10 
logarithmic transformation. A p-value< 0.05 was considered to indicate 
statistical significance. In addition, the one-way analysis of variance (ANOVA) 
with a Dunnett post hoc test in SPSS. The Dunnett test is used when only the 
comparisons between treatments and a control group are of interest. Differences 
between groups were considered significant with a p <0.05. GLM univariate 
with Bonferroni post-hoc test.  
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4-RESULTS AND DISCUSSION 
The health status of food-producing animals is a major challenge on a global 
basis as it affects upon both human health and economics, being a primary factor 
in determining safety, quality and health benefits of food of animal origin. 
Indeed, infectious diseases can spread rapidly with devastating results.  
Traditionally, the control of animal diseases relied upon the use of in-feed 
antibiotics, which have been used in animal production for over 50 years as feed 
additives. However, the use of antibiotics has raised increasing concerns about 
the development of antibiotic resistant bacterial strains, which may impair the 
effectiveness of certain antibiotics in the treatment of human diseases. In the last 
decennium, several innovative approaches were studied and developed. Animal 
nutrition, which for long time was based on the need to avoid deficiency 
symptoms and to support the economically important production criterion, in 
recent years has driven the research of new strategies for disease prevention, and 
a better understanding of the interactions between nutrition and health 
introduced the concept of nutrition-based health for animal production (Adams, 
2006). Considering the pig livestock, various nutritional approaches have been 
tested in the past decades in order to manage critical periods in the lifespan of 
the animal, such as the weaning period of the piglet when the animal is more 
exposed to diseases (Kraeling and Webel, 2015; Moehn et al., 2013). 
In general, it is always preferable to prevent disease rather than having to resort 
to treatment for animals: “Prevention is better than cure”.  
The main theme of this research concerns the nutritional management of some 
health problems frequently occurring during the weaning of piglets, focusing in 
particular on the use of tobacco seeds as edible vaccine against verocytotoxic E. 
coli. In swine livestock, the weaning is a particularly complex period, during 
which the piglets are confronted by multiple stressors. The immediate effect of 
weaning is a dramatic reduction in feed intake and a consequent ‘growth check’, 
which continues to represent a major source of production losses in commercial 
piggeries. Weaning also causes alterations in intestinal architecture and function, 
predisposing to diarrhea and intestinal infections. Verocytotoxic E. coli strains, 
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in particular O138, O139 and O141 serotypes, are an important causes of growth 
retardation and mortality in piglets during the first weeks after weaning.  
Verotoxin-producing E. coli (VTEC) also presents adhesive fimbriae, important 
virulence factor, that is responsible for the adhesion of the bacteria on the 
intestinal wall.  
The weaning process increases the stress on piglets, and thus their susceptibility 
to viral and bacterial infections. Up to now, no vaccine for post weaning 
diarrhea-protecting piglets against these infections is available and treatments 
rely upon the use of antimicrobials. Vaccination of the sow can enhance the 
protection and so far, several maternal vaccines are available on the market (Cox 
et al., 2002). Available commercial vaccines against swine E. coli infection are 
referred to colibacilosis that differs from post weaning diarrhea, because 
maternal immunity can be induced by vaccination and can result in the animals 
protection. 
In recent times, the development of vaccines has rapidly advanced thanks to a 
significant progress made in the use of recombinant gene technologies. Plants 
have been recognized as an expression system for the production of edible 
vaccines thanks to the possibility of introducing antigenic proteins into their 
genome. Stable transformation allows transgene integration into the plant 
genetic material and, consequently, the transfer of the acquired character to next 
generations. 
Delivery of a vaccine to a mucosal surface induces a mucosal immune response, 
providing a first line of defense against infection.  
Several orally delivered vaccine candidates induced mucosal immune response 
in the gastrointestinal tract, such as Dukoral by (SBLvaccine), against cholera 
and Vivotif against rotavirus produced by (SSVI, Berna). However, the most 
promising targets for plant-based oral vaccines may be gastrointestinal 
pathogens (Sirskyj et al., 2016; Banda et al., 2012). 
Many antigens from viral and bacterial origin has been expressed in plants 
against different animals diseases including polio, plague, cholera, malaria, 
canine parvovirus, tuberculosis, antrax, rotavirus (Arlen et al., 2008; Gorantala 
et al., 2014; Lentz et al., 2010; Ortigosa et al., 2010 Shao et al., 2008). 
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The work presented in this thesis is part of a wider project, still in progress in 
our Department, in which Nicotiana tabacum plants were previously engineered 
for the seed-specific expression of the major subunit FedA of the F18 adhesive 
fimbriae, and VT2e B-subunit genes respectively, as model of edible vaccines 
against porcine verocytotoxic E. coli (Rossi et al., 2013). The major subunit 
FedA, the primary pathogenic factor responsible for the adhesion of E. coli 
strains to enterocyte receptors, and the B subunit of the toxin VT2e were chosen 
as antigens. Specifically, the development of toxicity is caused by the extra-
intestinal effects of VT2e toxins, which are bipartite molecules, composed of a 
single enzymatic intracellularly active A-subunit and a pentamer of B-subunits 
associated with receptor binding.  
In the present study, two lines of Nicotiana tabacum plants were previously 
transformed via Agrobacterium tumefaciens with chimeric constructs containing 
structural parts of genes under control of a seed specific GLOB promoter. 
In the first part, the attention was focalized on the production of tobacco seed-
based oral vaccines against verocitotoxic E. coli. Then the vaccinal seeds were 
in-vivo evaluated through a challenge experiment on weaned piglets.  
4.1-Production of tobacco seed-based oral vaccines against 
verocytotoxic Escherichia coli production 
4.1.1-Cultivation and collection of seeds 
The development of vaccines has rapidly advanced thanks to a significant 
progress made in the use of recombinant gene technologies. Plants have been 
recognized as an expression system for the production of edible vaccines thanks 
to the possibility of introducing antigenic proteins into their genome. Stable 
transformation allows transgene integration into the plant genetic material and, 
consequently, the transfer of the acquired character to next generations. 
Transgenic plants would also permit large scale, low-cost expression of selected 
genes and have the potential for crossing transgenic lines to obtain multiple 
proteins production in the same plant. Moreover, they are able to confer heat 
stability to the heterologous protein and, if edible plants are used, the antigen 
can be attractively delivered through oral administration in feed, thus avoiding 
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antigen purification and needle administration (Tregoning et al., 2004). 
Furthermore, plants or plant products, which are edible, provide the additional 
unique opportunity of serving as vehicles for oral delivery of the vaccine.  
Tobacco is a prolific seed producer, about 1 million seed/plant. In agricultural 
practices the production of tobacco seeds is 30-500g/ha, (10000 seeds/gram) and 
140-150T/ha of total biomass (Fogher et al., 2007). 
Nicotiana tabacum is an organism model and extremely versatile system for all 
aspects of cell and tissue cultures research. Tobacco is a natural allotetraploid 
formed through two hybridization between two diploid progenitors, Nicotiana 
syslvestris and Nicotiana tamentasiformis approximately 6 million years ago. 
Based on some issues the optimization of cultivation practices of tobacco plants 
had been studied for the purpose of obtaining the maximal seed production with 
high levels of stable transgenes.  
SEED Germination (%)  
WT 78.5 
F18 73.3 
VT2e-B 76,6 
Table 26: Germination index of tobacco plants. 
We had harvested the third generation (R3) of two lines of Nicotiana tabacum 
expressing, respectively, adhesive fimbriae FedA and VT2e-B toxin (VT2e-B) 
in order to obtain an effective quantity to perform an in-vivo trial. Three lines of 
seeds, two vaccinal and one wild type tobacco, were potted in each pots of 
seedbed. No statistical difference was observed in germination index between 
the Nicotiana tabacum control and engineered tobacco seeds (Table 26). 
We had 80 pots for vaccinal tobacco lines and 56 pots for wild type tobacco 
plants grown in a Fitotron® growth chamber. This is in according to the 
observations about plants germination. 80% germination rate, estimating losing 
about 20% during transplanting and even taking in a 10% mortality rate for first 
time growers (source: Seedman .com). 
After 5 weeks from seeding wild type, plants showed a higher height if compared 
to the vaccinal lines (Figure 12). No differences were observed between F18 
positive plants and VT2e-B positive plants. 
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Figure 12: Growth curves of Nicotiana tabacum plants after the seeding (day 0); * p-value: 
<0.05. WT, n:56; F18, n:80; VT2e-B, n:80. 
The data were analyzed by the univariate GLM procedure with estimated 
marginal means and with the Bonferroni post hoc test, profile plots and custom 
hypothesis tests showed that the heights of engineered plants (F18 and VT2e-B) 
and the heights of the control plants did not show statistical differences at T0, T1, 
T2, T3 T4, (p-value > 0,05). The heights of the control plants compared to height 
of transgenic plants (F18 and VT2e-B), instead, was statistical different at T5, 
T6, T7 (p-value<0.05) but the heights of F18 compared with the heights of VT2e-
B did not show statistical difference (p-value = 0,208) during the growth period.  
Considering the day of seeding as day 0, wild type lines germinated at day 6 and 
the two vaccinal plants at day 10 (Figure 13-14) 
 
 
 
 
 
 
 
 
Figure 13: Images representing the beginning of the growth phases of the experimental plants at 
day 6 and at day 10. A: wild type plants; B: VT2e-B; C: F18 plants.  
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Figure 14: Germination time (days after seeding) of wild type and vaccinal tobacco lines. 
Nevertheless, F18s and VT2eBs germinated four days later than wild type, as 
showed in Figure 14. This aspect was probably caused by late metabolic 
employment of inclusion bodies, observed in the vaccinal seeds by 
morphological analyses described below. 
When plants were about 15 cm high, 80 plants for each transgenic line were 
transferred to the “Orto Botanico G.E. Ghirardi” in Toscolano Maderno 
(Brescia). The plants were grown in accordance to a Directive which governs 
(Directive 98/81/EC of 26 October 1998, amending council directive 
90/219/EEC), on the contained use of genetically modified organisms. The 
specific biosafety level of the greenhouse used was level 1. 
Transgenic plants are categorized in this level when both host plant and 
transgenic plant pose little risks for humans, animals, plants or the environment. 
“Environment” indicates the environment, which is likely to be exposed during 
the planned activities. Within the containment of a greenhouse, the exposed 
environment is very limited. 
The greenhouse was previously supplied with polyethylene monofilament that 
provides protection against aphids, white fly and bemicia tabaci and lamp to 
guarantee a photoperiod of 14h light and 10h dark. The environmental conditions 
at the Orto Botanico G. E. Ghirardi were a temperature between 25-30°C for 
adequate growth and flowering, atmospheric humidity between 80 and 85% and 
a low level of nitrogen in the soil. The plants were treated with 2020-20 Peters 
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Professional® Water Soluble Fertilizer containing 20% of total nitrogen, 20% 
of Phosphate (P2O5) and 20% of Soluble Potash (K2O). Also in the greenhouse, 
plants were stored isolated from the environment by the polyethylene 
monofilament to avoid cross-pollination.  
The harvest of the vaccinal seeds occurred when the seeds pod turned brown. 
The harvest has been made from June to October. After harvest, seeds ovaries 
were stored in a cool, dry place to air dry for 7-10 days. After this period each 
ovary was opened in order to collect, transgenic seeds the harvest of seeds was 
performed in different rooms to avoid contamination between the two transgenic 
lines F18 and VT2e-B. Each ovary contains about 100 mg of seeds. Seeds were 
sift and separate from debris and the residual part of the ovary. 
All 80 plants for each line produced good quality seeds without parasites. We 
performed some harvests and in total, we obtained 450 gr for 80 VT2e-B positive 
plants and 470 gr for 80 F18 positive plants. Each plant produced about 5-6 
grams. Considering that each plants was cultivated in 20-25 cm2 the production 
of seeds obtained during the trial was consistent with the space available in the 
greenhouse. In agricultural practices total biomass of tobacco yields on 
unirrigated land is usually 1.100-1.300 kg per four Km2 and irrigated lands can 
produce about 2,000 kg per four Km2 when using the closer commercial spacing 
of 0.5-1 meter between plants, with rows 1.2 meter apart (from Seedman.com). 
The obtained yield of tobacco seeds was lower than commercial productions. It 
could be due to losses related to the manual harvesting. Nevertheless, it was 
sufficient for the further oral immunization trial.  
4.2-Morphological evaluation of plants  
The germination time between wild type tobacco plants and engineered 
tobacco plants was different. Transgenic tobacco plants germinated 4 days 
after the wild type. We have analyzed by optical and electronic microscope 
in different phases of plants growth in collaboration with the Department of 
Biosciences, Università degli Studi di Milano. The germination of transgenic 
seeds occurred four days later than the wild type in two replicated 
experiments, with 12 replicated. This suggested that the random integration 
of exogenous genes by Agrobacterium might influence genes related to 
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germination. For these reasons furthers morphological analyses were carried 
out. In Figure 15, a section of wild type plant embryo contained in seed is 
shown.  
 
 
 
 
 
 
 
Figure 15: Ultra-thin sections (80 nm) of whole embryo of wild type tobacco plant, obtained 
using a Reichert Jung Ultracut E microtome. Semi-fine sections were stained by 1% toluidine 
blue and observed with a Leica DMRB optical microscope. C: cotyledon, hy: ipocotyledon, r: 
radicle. Magnification bar 50 m 
The F18 and VT2e-B engineered seeds (Figure 16) presented many storage 
bodies as protein bodies and lipid bodies that appeared as dark dots inside the 
cells by electronic microscopy.  
 
 
 
 
 
 
 
 
Figure 16: C-D-E.: Ultra-thin sections (80 nm) of whole embryo of F18 transgenic tobacco plant, 
obtained using a Reichert Jung Ultracut E microtome. Semi-fine sections were stained by 1% 
toluidine blue and observed with a Leica DMRB optical microscope. C: cotyledon, hy: 
ipocotyledon, r: radicle. Magnification bar 50 m 
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Plant oleosomes are uniquely emulsified lipid reservoirs that serve as the 
primary energy source during seed germination. These oil bodies undergo 
significant changes regarding their size, composition and structure during 
normal seedling development. Oil bodies—filled with mostly triacylglycerols 
(TAGs) and to a lesser extent sterol ester, diacylglycerols, monoacylglycerols 
and free fatty acids (FFAs) are plant analogues to classical mammalian lipid 
droplets. They provide energy in the form of FFAs for β-oxidation in 
neighbouring glyoxysomes (peroxisomes) during initial seed germination and 
lipids for new cell and organelle membranes (D’Andrea, 2016). The structure of 
oil bodies also resembles lipid droplets. Owing to the initial absence of 
photosynthesis in germination, nearly all energy for initial development in plants 
comes from lipids via lipolysis of TAGs by surface-bound lipases, β-oxidation 
in glyoxysomes and catabolism in mitochondria (Graham, 2008). As a result, the 
density of oleosomes, and correspondingly of oleosins, was initially quite high: 
for instance, oleosins constitute nearly 10% of the total protein mass in 
Arabidopsis thaliana seeds (Hsieh, 2004). Although previous studies have 
shown that oleosin disappears from oil bodies during germination (Chen et al., 
2014; Deruyffelaere et al., 2015) and that oil bodies fuse when oleosin is 
genetically suppressed (Siloto et al., 2006). In the same manner, plants store 
proteins in embryo and vegetative cells provide carbon, nitrogen, and sulfur 
resources for subsequent growth and development. The storage and mobilization 
cycles of amino acids that compose these proteins are critical to the life cycle of 
plants. Mechanisms for protein storage and mobilization serve many different 
developmental and physiological functions. For example, stored proteins 
provide building blocks for rapid growth upon seed and pollen germination. In 
the vaccinal plants, a late metabolic employment of inclusion bodies that is 
probably responsible for the delayed germination in the greenhouse was 
observed. 
4.3-Chemical analyses of principal components of vaccinal 
tobacco seeds 
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Chemical analyses carried out on seeds from, F18 and VT2eB are reported in 
table 27. No differences were observed in the principal nutrient content. For 
these reasons, the vaccinal seeds could be considered substantially equivalent 
to the wild type. 
 
 
 
 
 
Table 27: Chemical composition of F18, VT2e-B Nicotiana tabacum seeds. 
4.4-Molecular Analyses of tobacco plants  
A pivotal aspect of this work was the detection of exogenous genes in the R3 
generation of tobacco plants in order to confirm the stable integration into the 
genome. The PCR products were evaluated on agarose gel (range 0.8-1.5%). 
PCR products of B-subunit of VT2e and the F18 fimbriae compared with the 
marker were respectively identified as bands with a length of 270bp and 
519bp (Figure 17). The NOS gene was identified as a band with a length of 
118bp (Figure 18). 
 
 
 
 
 
 
 
 
 
Figure 17: Agaraose gel of PCR products for the detection of VT2eB and FedA genes. Lanes 1, 
2, 3, are represented by PCR products using oligonucleotides specific for F18 gene; Lanes 5, 6 
7 are represented by PCR products using oligonucleotides specific for VT2e-B gene. Lane 1: 
Genomic DNA from wild type Nicotiana tabacum; Lane 2: genomic DNA from F18 positive 
Nicotiana tabacum; Lane 3: genomic DNA from VT2e-B positive Nicotiana tabacum plants; 
Lane 4: marker (bp); Lane 5: genomic DNA from positive VT2e B line 6: positive control. Line 
7: WT. 
Chemical composition % DM F18 seeds VT2e-B seeds 
Crude protein 26.14 25.4 
FAT 32.77 36.30 
NDF 39.11 37.25 
Ash 8.53 5.47 
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Figure 18: PCR for NOS terminator (118 bp). Lane 1: DNA from VT2e-B positive tobacco 
seeds; lane 2: DNA from F18 positive tobacco seeds; lane 3: negative control; lane 4: marker 
100bp. 
The PCR of NOS gene terminator in our samples is a screening procedure 
used to assess that the exogenous gene of interest were integrated into the 
genome of cultivated tobacco plants. NOS gene derive from the nopaline 
synthase gene of Agrobacterium tumefaciens that is often used as an insert 
for genetically modified organisms (GMOs). PCRs were developed following 
the indications published in the JRC “Compendium of reference methods for 
GMO analysis” (2006). 
Obtained data demonstrated that the genes coding for VT2e-B and the F18, 
representing important antigens and virulence factors of E. coli, could be stably 
incorporated into the next generation of Nicotiana tabacum genome (R3). 
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4.5-Expression and quantification of antigenic proteins in 
tobacco seeds, by ELISA  
We evaluated the expression of antigenic proteins in collaboration with 
PLANTECHNO S.R.L. The F18 and VT2e-B proteins were purified as a 
positive control. 
ELISA assay to quantify antigenic protein F18 in transgenic tobacco line  
Total protein extracted were estimated to be about 1.8g/L. The indirect 
ELISA assay was developed using TMB /HCl and the optical density was 
measured at 450 nm (Table 28). 
Table 28: ELISA plate of FedA antigen. Output of lecture of program “Curva expert1.3” 450 
nm. TQ: without dilution 
The secondary anti-body molecule, which is covalently bound to horseradish 
peroxidase (anti rabbit H2O2–oxidoreductase), was incubated with developer 
(TMB). The developer contains both the substrate and the chromogenic 
reactants. When H2O2 is degrade, by-product causes the chromogen to develop a 
green color. According to the standard curve the amount of FedA subunit 
fimbriae was estimated to be about 66-74 ng per 100 mg of seeds (Figure 19).  
 
 
 
 
 
 
 
 
Std g Lect.1 Lect.2 Lect.3 mean dev std cv % interpol. 
0 2.166 2.129 2.191 2.162 0.031 1.4 0.9 
2 2.073 2.082 2.096 2.084 0.012 0.6 1.9 
10 1.876 1.860 1.923 1.886 0.033 1.7 11.6 
50 1.742 1.711 1.766 1.740 0.028 1.6 45.0 
80 1.664 1.660 1.702 1.675 0.023 1.4 81.4 
F18 TQ 1.987 1.875 1.945 1.936 0.057 2.9 7.4 
F18 50% 2.004 2.050 2.013 2.022 0.024 1.2 3.3 
WT TQ 2.196 2.200 2.234 2.210 0.021 0.9 0.6 
Y= 4E+0.8e-9.2247x 
R2= 0.996 
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Figure 19: Standard curve performed by “curva express 1.3”program of FedA immunogenic 
protein in ELISA assay. 
ELISA assay to quantify antigenic protein VT2e-B in transgenic tobacco 
line  
In the same manner, we have evaluated VT2e-B, as results the best concentration 
for the coating was 0.6 mg/mL-10ng/mL and 1:6000 for the primary antibody. 
The samples were analyzed with an ELISA device at a wavelength of 450 nm, 
(Table 29) the calibration curve (Figure 20) was calculated with the program 
"Curve expert 1.3" The average content of VT2e-B in the 100 mg of seeds is 
equal to 340-370 ng of the immunogenic protein. 
Table 29: ELISA plate of VT2e-B antigen. Output of lecture of program “Curva Expert 1.3”at 
450 nm. 
 
 
 
 
 
 
 
 
Figure 20: Standard curve performed by “Curva express 1.3” program for VT2e-B immunogenic 
protein in ELISA assay. 
Moreover, we performed ELISA assays in order to assess that the nuclear 
apparatus can be able to translate the transgenes in antigenic proteins that were 
estimated to be around 6.6-7.4 g and 34-37 g per 10 g of seeds respectively 
for FedA and VT2e-B. This aspect is particularly important. Notably, during the 
transgene integration following Agrobacterium–mediated transformation, the 
Std g/l  Lect.1 Lect.2 Lect.3 media dev std cv % interpol. 
0 1.445 1.560 1.461 1.489 0.062 4.2 0.5 
2 1.320 1.393 1.283 1.332 0.056 4.2 2.2 
1 1.260 1.157 1.164 1.194 0.058 4.8 8.6 
50 1.029 1.039 0.977 1.015 0.033 3.3 50.9 
80 0.976 1.002 0.918 0.965 0.043 4.5 83.3 
VTe2-B 1.039 1.002 1.100 1.047 0.049 4.7 37.0 
WT 1.586 1.551 1.577 1.577 0.023 1.4 0.2 
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position of transgene integration is essentially random within the genome of the 
plant species. The transgene is thus subject to position effects which may 
inﬂuence its expression, resulting in some cases in transcriptional silencing as 
the new DNA is sequestered into the silenced region There are many factors that 
inﬂuence transgene stability, and these lead to highly variable expression within 
populations of plants generated in the same gene transfer experiment. One of the 
most important factors is the position effect, which reﬂects the inﬂuence of 
genomic DNA surrounding the site of transgene integration (Wilson et al., 1991). 
Another is the structure of the locus, including the number of transgene copies, 
their intactness, and their relative arrangement, which inﬂuences the likelihood 
of physical interactions and further recombination within the locus (physical 
instability) and the induction of silencing through DNA methylation and/or the 
production of aberrant RNA species from the locus (Heinrichs, 2008). 
Based on these issues we assessed the production of vaccinal proteins by the 
nuclear apparatus of both tobacco plants lines. Nicotiana tabacum seeds offer 
the unique opportunity for the production and delivery of oral subunit vaccines. 
In several published papers, authors achieved a good expression of valuable 
proteins. Tackaberry (1999) produced human cytomegalovirus glycoproteinB 
(UL55) in seed of transgenic tobacco. Specific immunoassays of protein extracts 
from seeds of positive plants showed that all were producing antigenic 
glycoprotein B at levels ranging from 70-146 ng/mg extracted protein. Kohl and 
colleagues (2007) investigated the possibility and feasibility of producing the 
HPV-11 L1 major capsid protein in transgenic Arabidopsis thaliana ecotype 
Columbia and Nicotiana tabacum cv. Xanthi as potential sources for an 
inexpensive subunit vaccine. Yields of up to 12 μg/g of HPV-11 L1 NLS- protein 
were harvested from transgenic A. thaliana plants, and 2 μg/g from N. tabacum 
plants. 
The estimated amount of antigens allowed a further in-vivo trial.  
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4.6-In-vivo trial: evaluation of the oral administration of 
tobacco seed as edible vaccines in weaned piglets 
4.6.1-Strategical optimization of vaccinal tobacco seeds 
administration 
The most common uses of tobacco is for cigarettes; nevertheless, tobacco is 
covering important roles also in other holistic sectors  and herbal medine. 
Tobacco plays an important role in the advancement of plant biotechnology, 
it has been found to be an extremely versatile system for genetic manipulation 
and tissue culture research. Oral vaccination, through plant-derived 
immunogens, presents many potential advantages related to the management 
of intensive livestock, if compared with traditional injectable vaccination 
way. Considering the optimization of the oral immunization of piglets with 
tobacco seeds transformed for the expression of antigens against porcine 
verocytotoxic E. coli different aspects must be considered. 
Firstly, the oral immunization through edible vaccines must be start at least 
at the weaning, because of simultaneous decreasing of maternal immunity 
and the exposure to high microbial pressure. During the weaning phase, 
piglets are exposed to several stress factors that may influence the 
establishment of the infections. The loss of the passive protection provided 
by milk, the rise in stomach pH, the slowed gut transit and the morphological 
and physiological changes in the small intestinal tract, which occur at 
weaning, allow bacterial adhesion and colonization. Stresses from mixing and 
moving into a new pen also cause increased transit time and depressed 
immune response through the release of cortisol. Predisposing factors to post-
weaning infections include rearing conditions, in particular environmental 
temperatures, hygiene and dietary composition. Nutrition is obviously a 
critical determinant in the functional development and growth of the 
gastrointestinal tract and the weaning phase represents a critical period. The 
immediate effect of weaning is a dramatic reduction in feed intake and a 
consequent ‘growth check’, which could compromise the effective oral 
immunization. Effective needle-free immunization strategies are needed to 
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accommodate large-scale vaccination programs and avoid injection-related 
risks. Such delivery systems have broad applications for the rapid 
immunization of humans, as well as production farm animals, and may be the 
effective means for immunization of wild animal reservoirs to mitigate 
epizootic disease spread into humans and other animals. Vaccines 
administered at mucosal surfaces can induce local protection at the infection 
sites for many pathogens as well as induce systemic immunity (Ogra et al., 
2001; Streatfield et al., 2006; Arntzen et al., 2003). 
However, direct antigen delivery through an oral or nasal route generally 
leads to weak induction of immunity, if any, or to immunological tolerance. 
A previous study showed that tobacco seeds (Nicotiana tabacum specie) 
present less than 2 μg/kg of nicotine, a toxic alkaloid compound, and can be 
integrated in the feeding of the weaning phase of pig livestock without 
affecting the palatability (Rossi et al., 2007). 
In order to ensure the complete consumption of the treatments in Rossi et al. 
(2013) piglets were fed tobacco seeds mixed with chocolate and water in 
palatable bolus. In this work, we chose to increase the palatability of tobacco 
seeds by adding a specific pig milk replaced powder (composed by dairy 
products, vegetable oils, cereals, sugars and flavoring). The milk replaced 
powder, based on protein content (about 20.5% as fed), was mixed with 
milled tobacco seeds in a 2:1 ratio (weight). 
Moreover, a preliminary study showed that gastric degradation of milled 
transgenic tobacco seeds did not affect the protein signal by western blot 
analyses (Rossi et al., 2011). The ability of specific polyclonal rabbit serum 
to recognize the antigens even after 3 hours of incubation with porcine gastric 
fluid may indicate that the residual amount of transgenic proteins after 
digestion of both milled and whole seeds appears sufficient for their use in 
immunization trials on piglets.  
Nevertheless, the seeds of Nicotiana tabacum are so small that 1 g seed 
contains 10,000-18,000 grains and present an impermeable coat. The 
grounding becomes pivotal for the formulation of the experimental feed, in 
order to guarantee the sufficient antigen exposure in intestinal mucosa. In 
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addition, tobacco has great potential as a vaccine delivery platform because 
of its naturally high protein content, nutritional value and multiple product 
streams. Mature seed contains about 35% (w/w) protein, primarily the 7S 
glycinin and 11S β-conclycinin storage proteins, compared to 8–10% protein 
in maize and rice or 1–2% protein in leaf tissues. Similar to other seed types, 
mature tobacco seed has a low water content that confers storage stability on 
expressed proteins. 
Administration schedule of vaccinal seeds 
To have a complete and mature immune response, the clonal expansion of B-
cells must not only stop but an active process of cell death (apoptosis) must 
also occur. This whole process from vaccination to achieving mature immune 
response homeostasis takes at least 3 weeks. This fully developed mature 
immune response can then be boosted to get a true secondary response, 
typically swine vaccine primary and booster doses are administered at 2 
weeks of interval. In young pigs, this is done to provide an opportunity to 
make sure that the piglets develop a primary response in the face of maternal 
immunity. Protection on mucosal surfaces is due in large part to secretory 
IgA, the route of vaccine administration can be important when attempting to 
induce mucosal immunity. To induce secretory IgA production at mucosal 
surfaces with a subunit vaccine, it is better to present the antigens at the 
mucosal level. We planned multiple oral administration in order to guarantee 
the booster effect at day 0, 1, 2, 5, 14.  
4.6.2-Zootechnical performances 
Piglets were early weaned at 21 days to ensure the sensitivity upon 
experimental infection. At the beginning of the experiment, the animals had 
homogeneous average individual body weight (Figure 21).  
Since the start of experimentation during the first two days of housing, the 
animals were fed vaccinal tobacco seeds mixed with powdered milk 
(treatment). We have done it in order to guarantee the assumption of suitable 
antigenic dose by all enrolled subjects in sperimentation. The individual feed 
intake was measured from day 2nd through the weight of the residue in the 
feeder. The feed intake was reduced in the first days after weaning and then 
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gradually increase in all experimental groups, however no statistical 
differences were observed.  
During the immunization period (days 0-20), after an initial phase of 
adaptation to the solid diet, in which feed intake and weight gains were low, 
the ADG and ADFI (Figure 22 and Table 30) were in line with the standards 
of growth of the piglets in this phase, with no statistically significant 
differences among the experimental groups. As shown by previous studies 
(Rossi et al., 2007), these data confirm that tobacco seeds intake and oral 
immunization had no effect on the zootechnical performances. 
Figure 21: Evaluation of body in the experimental groups. Arrow represents the day of challenge 
CC: challenged control, CT: challenged treatment, UC: unchallenged control, UT unchallenged 
treatment 
Table 30: Average individual FI in days 0-20. CC: challenged control, CT: challenged treatment, 
UC: unchallenged control, UT unchallenged treatment 
  
Experimental groups AFI in the pre-challenge period: day 0-20 (grams) 
CC 328,6 
CT 347,0 
UC 367,0 
UT 362,7 
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Figure 22: Average individual feed intake in the experimental groups during the pre-challenge. 
CC: challenged control, CT:  challenged treatment, UC: unchallenged control, UT unchallenged 
treatment. 
Since verocytotoxic E. coli is responsible for significant economic losses due to 
high mortality and reduction of growth rates of infected piglets, the zootechnical 
parameters were measured during the post-challenge period to assess whether 
oral immunization could reduce the negative impact of E. coli infection on the 
production parameters. As expected, the zootechnical parameters were clearly 
affected by experimental infection. 
The three days after the challenge, a general reduction of feed intake was 
observed in all experimental groups. This is probably due to the high protein 
content diet, administered to all the animals; in fact, it could affect the 
palatability and create enteric disorders. The diet administered during the first 
three days, containing a high level of crude protein, was intended to be a “high-
risk” diet, since several pathogens preferentially ferment proteins and high 
amounts of crude protein in the diet of newly weaned piglets have been identified 
as one of the predisposing factors of E. coli infection. Moreover, the high level 
of crude proteins was due to the presence in the feed of soybean meal, an 
ingredient that seems to allow the occurrence of E. coli infection (Fairbrother et 
al., 2005) 
The experimental infection affected the daily feed intake, in fact challenged 
groups showed a significant lower feed intake if compare with non-challenged 
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groups. CC showed a lower AFI considering both periods after the challenge 
(Table 31).  
Table 31: Comparison of the average feed intake in the three days before challenge (17-20) and 
the periods after challenge (days 21-23; days 21-29). CC: challenged control, CT:  challenged 
treatment, UC: unchallenged control, UT unchallenged treatment. 
Challenge has certainly influenced the average daily gain (ADG) indeed the 
control challenge group and the treated challenge group showed a lower ADG 
during the completely experimental trial when compared with the ADG of 
uninfected groups. Nevertheless, considering only challenged groups, the treated 
challenge group showed a higher ADG than the control challenge group (Table 
32). 
Table 32: Average daily gain in the completely experimental period. Values are expressed as 
grams ± standard deviation. CC: challenged control, CT: challenged treatment, UC: 
unchallenged control, UT unchallenged treatment 
4.6.3-Evaluation of clinical signs  
From the day after the challenge, clinical signs related to VTEC infection were 
observable in infected piglets. Clinical and fecal score related to VTEC 
infection, such as palpebral edema, epiphora, loss of vitality in all challenged 
groups from the day after challenge until day 9-post challenge are shown in table 
33. For each clinical sign "the average total score" that is the sum of the average 
daily score of each group recorded from day 1 to day 9 post-challenge (Rossi et 
al., 2012) was considered. 
 
 
Experimental 
groups 
AFI days 17-20 (g) 
Before challenge 
AFI day 21-23 (g) 
3 days post-
challenge  
AFI days 20-29 
Post-challenge 
period (g) 
CC 563,8 456,9 482,1 
CT 568,4 480,6 521,7 
UC 609,6 530,8 568,5 
UT 575,6 493,1 533,9 
 
ADG 0-29 (g) 
CC 227,34  ±  73,21 
CT 243,31  ± 54,44 
UC 271,96  ± 48,06 
UT 264,47  ± 68,21 
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ATS day 9 Significance 
 T C    
  UT CT UC CC Treat Chall treat 
*chall 
Edema 0.50 1.50 3.25 9.63 <.01 <.01 <.01 
Epiphora 1.75 4.00 5.75 8.38 <.01 <.01 ns 
Vitality 0.50 1 0 4.13 ns <.01 ns 
Hair 2.50 4.50 6.75 11.5 <.01 <.05 ns 
Fecal score 3 7.13 9.00 11.6 <.05 Ns ns 
Table 33: Average daily score of experimental groups of animals at day 9. CC: challenged 
control, CT: challenged treatment, UC: unchallenged control, UT unchallenged treatment 
What regards the palpebral edema, an important symptom related to the VTEC 
infection, CC showed a higher total score compared to UT, CT and UC (p < 
0.01).  
Considering the vitality, treated individuals groups showed a faster recovery 
after the challenge. 
What regards the fecal score, during the nine post-challenge days, challenged 
control groups presented a higher average total score than the other experimental 
groups, without statistical differences. This aspect is probably due to the 
administration of the “high risk” diet during the three days after the challenge 
that could be responsible for enteric disorders as observed immediately after the 
challenge. 
These results demonstrated that the piglets fed with tobacco seeds, which express 
the VTEC antigens, have generally a better clinical condition. This oral 
immunization strategy also seems effective to control the development of the 
clinical signs after the challenge with the O138 E. coli strain.  
The use of the multicomponent vaccine appeared more effective in preventing 
the negative impact of challenge with O138 strain. This vaccination strategy 
probably provided a specific immunocompetence that was activated after the 
exposure to the wild-type pathogen. The protective effect of the vaccine was 
evaluated considering that the immunized piglets were protected, with mild or 
absent clinical symptoms and pathological lesions observed and no bacteremia 
detected, when the challenges were conducted at days 20, postimmunization. 
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After the challenge at 20 dpi, all immunized piglets survived. In addiction, oral 
administration of the vaccine directly in the manger is less stressful for the 
animal than the use of needles and syringes. 
4.7-Evaluation of intestinal Immunoglobulin-A titer in the 
immunization phase  
Many studies have shown that the mucosal immune system, which is 
characterized by secretory IgA (S-IgA) antibodies, as the major humoral defense 
factor, contains specialized lymphoid tissues where antigens are encountered 
from the environment, are taken up and induce B and T-cell responses. This 
event is followed by an exodus of specific lymphocytes, which home to various 
effector sites such as the lamina propria regions and glands. These responses are 
regulated by T cells and cytokines and lead to plasma cell differentiation and 
subsequent production of S-IgA antibodies in external secretions. This 
knowledge has led to practical approaches for oral vaccine construction and 
delivery into mucosal inductive sites in an effort to elicit host protection at 
mucosal surfaces where the infection actually occurs. During the pre-challenge 
time, the piglets had been feeding with transgenic seeds of Nicotiana tabacum, 
expressing the antigenic proteins F18 and VT2e-B (6.6-7.4 µg and 34-37 µg per 
10g seeds respectively).  
The titer of fecal IgA-S was shown in Figure 23 and 24. From day 0 to 21, both 
experimental groups showed a progressive decrease of IgAs titer.  
The luminal level of S-IgA (day 0 to 21) in piglets, probably related to maternal 
immunity, may decrease constantly due to the reduction of milk consumption.  
The yield of IgAs had been measuring in their feces using specific ELISAassay 
as previously described. The results (Figure 23) showed a progressive decrease 
of IgA level in control group and an increase of intestinal IgAs in treated piglets 
from day 0 until 20th days.  
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Figure 23: Evaluation of total mean intestinal IgAs titer of individual fecal samples collected 
from piglets in in pre-challenge period. 
In Figure 24, the IgAs titer in piglets is shown. Each dot in the graph represent 
an individual immunoglobulin value during pre-challenge period. Secretory 
immunoglobulin A (S-IgA) is a protective molecule of the mucosal immune 
system. In the case of pigs, maternal S-IgA is supplied to piglets by the 
maternal colostrum and milk.  
 
 
 
 
 
 
 
 
Figure 24: Evaluation of total intestinal IgAs titer of individual fecal samples collected from 
piglets in in pre-challenge period. CG: control group; TG: treated group. 
However, regarding the treated group, which is different from other pigs in term 
of feed, from day 7th until 20th, the treatment group increased the fecal IgA level. 
Based on the ELISAassays treated group showed a higher fecal titer of IgAs 
0
20000
40000
60000
80000
T0 T1 T2 T3
Ig
A
s 
n
g
/m
l 
Time (days 0-21) 
Total fecal IgAs in piglets 
Control group Treated group
Total fecal IgAs in piglets  
113 
 
(+37%) at day 20th. These data might suggest improvement of the gut mucosal 
immune system and reflect the progressive increase in the local immune 
response actively involved in microbial infection. As observed in Rossi et al. 
(2011) the use of multicomponent vaccine, based on two important virulence 
factors of the VTEC strain, appeared to be more effective for the activation of 
the local immune response. However, fecal IgA titer did not reveal a statistical 
significance between experimental groups. The lack of significance of this 
finding is probably due to the large intra-individual variation in fecal 
immunoglobulin levels observed in our experiment, higher than that observed in 
preliminary studies performed on a mouse model (Rossi et al., 2003b). This 
aspect was influenced by the variability linked to the colostrum intake and by 
the fact that the piglets enrolled in this trial were not specially made for 
experimentation in-vivo. In addition, the number of enrolled animals was 
limited. The individual variation in local immune response is well-documented 
(Crawley et al., 2005). Fritz at al. (2012) also demonstrated the pivotal role of 
IgA+ plasma cells in the local immunity (specific and a specific) in a paper 
published in Nature. 
4.7.1-Evaluation of anti-FedA IgAs and anti-VT2e-B IgAs in fecal 
samples  
The E. coli F18 fimbriae allows adhesion to specific receptors on small intestinal 
villi and consequently the colonization can occur. The presence of the F18 
receptor is genetically determined by an autosomal dominant gene and their 
absence makes pigs resistant to infection. Following colonization, VTEC strains 
produce the Shiga-like toxin type II variant (SLT-IIv), a vasotoxin that acts on 
vascular endothelial cells resulting in edema and subsequent neurological signs 
including ataxia, recumbence, and paddling movements, eventually leading to 
death. Colonization begins after adhesion of the bacteria with their fimbriae to 
the small intestine and stops when anti-fimbrial antibodies can be detected in the 
intestinal lumen of the infected pig. To protect weaned pigs, an oral vaccine is a 
suitable method to induce not only total S-IgA but also specific local immunity, 
since parenteral immunization does not induce protective immunity at mucosal 
surfaces (Bianchi et al., 1996).  
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Van den Broeck et al. (1999) reported that oral immunization of weaned pigs 
with purified F4 fimbriae protects them against subsequent F4+ETEC infection. 
For F18+ E. coli, however, only an infection has been reported to induce 
protective F18-specific antibodies at the small intestinal mucosa.  
Treated group showed at day 20, after the immunization phase, a higher level of 
anti FedA subunit immunoglobulin-A, if compared to controls (Figure 25). 
 
 
 
 
 
 
 
 
 
Figure 25: Evaluation of anti-FedA immunoglobulin A in fecal samples in the pre-challenge 
period.  
Also anti-VT2e-B immunoglobulin-A level resulted at day 20 higher in the 
treated group. These data suggested a specific activation of the local immune 
system against VTEC strains (Figure 26). 
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Figure 26: Evaluation of anti-VT2e-B immunoglobulin-A in fecal samples in the pre-challenge 
period. 
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5-CONCLUSIONS  
 
Medical and Molecular Farming represent a new way to produce affordable 
contemporary drugs and make these globally available. The greatest target of the 
latter will be the prevention of infectious diseases, especially in underdeveloped 
countries where the access to drugs and vaccines has historically been 
inadequate. The idea that “prevent is better than care” gives new stimuli to 
develop innovative techniques in order to avoid outbreaks of infection diseases, 
the abuse of drugs, in particular antibiotics. As we move into the 21st Century 
and the demands for animal food products increase to meet the nutritional needs 
of a growing world population, alternative strategies to prevent and control 
animal diseases is a global issue and a critical component of efforts to promote 
global food security, and global health security. 
This work was focused on the production of tobacco seeds as a model of edible 
vaccines against verocytotoxic Escherichia coli (VTEC) in piglets. Two lines of 
Nicotiana tabacum respectively engineered for the seed-specific expression of 
VT2e-B and F18 adhesive fimbriae, were previously obtained (Rossi et al., 
2003a) as a model of edible vaccines against VTEC by agroinfection 
(Agrobacterium tumefaciens EHA105) using pBIpGLOB binary vector. 
Nicotiana tobacco is a model plant that makes it suitable as a model for edible 
vaccine. A first finding of the study was that engineered tobacco are able to 
produce an adequate amount of vaccinal seeds. The vaccinal seeds were seeded 
and cultivated in a Fitotron® growth chamber in optimal conditions. Analyses 
have been executed on the germination index of the plants and on the chemical 
composition of the seeds. It was evidenced that both the germination and the 
chemical composition have been proved to be congruent with the wild-type 
plant. However, considering the germination time, the engineered tobacco seeds 
have germinated four days after the wild-type plants. We hypothesized based on 
morphological analyses that this is probably because the engineered tobacco 
plants did not use inclusion bodies such as protein and lipid bodies. As expected, 
it could be that the random integration of gene into plant genome interrupted the 
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sequence of some genes involved in the metabolism or on the use of substances 
useful for the growth of the plant. 
After the seed-collection period, it has been possible to obtain 450 gr of VT2e-
B seeds and 470 gr of FedA seeds. The optimization of cultivation practices of 
tobacco plants had been studied for obtaining the maximal seed production. 
Anyhow, the obtained quantity of seeds results to be lower compared to a 
standard in-field collection, also the losses, related to the manual harvesting must 
be taken into account. Nevertheless, the obtained quantity was enough for further 
in-vivo-trials. Molecular analyses performed with the PCR technique that 
confirmed the presence of bacterial genes incorporated into genome of 
engineered plants. 20% of plants were screened, 100% of the enrolled samples 
resulted positive to the PCR. Further analyses with ELISA-assays confirmed the 
vaccinal antigens in seeds that make possible to perform the in-vivo trial. We 
then focused on strategy to administrate the seeds to the piglets. To guarantee a 
complete assumption of the treatment, the piglets have been fed with a mixture 
made of seeds and milk replaced powder directly placed in the trough to simulate 
a possible treatment in livestock. Since the tobacco presents an impermeable 
coat, the grounding became pivotal for the formulation of the experimental feed 
in order to assure a sufficient antigen exposure in the intestinal mucosa. The seed 
grounding has been performed at a low temperature to prevent protein 
degradation, which could occur at high temperatures (about 50°C). The efficacy 
of tobacco seeds-based oral vaccines directed against VTEC infection 
(authorization: 102/2015-PR) was evaluated through an in-vivo trial carried out 
in the Experimental Animal Research and Application Centre (pigs sector) in 
Lodi of the University of Milan. We found that piglets fed tobacco seeds 
expressing VTEC antigens have over all a better growth performances and 
clinical status after challenge with the O138 VTEC E. coli strain, compared to 
the controls. The oral delivery strategy appeared effective in reducing the 
development of clinical signs (respiratory, palpebral oedema, epiphora, vitality, 
fecal consistency, and rectal temperature) after challenge with O138 VTEC E. 
coli strain. We also found that total IgA and the specific IgA anti FedA and anti 
VT2e-B in piglets. At day 20 (the end of immunization period) in the piglets 
group that received vaccinal seeds the titre of total and specific IgAs were higher 
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than the control group that did not receive vaccinal seeds. Although the results 
were not statistically significant, (probably due to the small number of animals), 
the antigenic proteins administered to piglets in feed have stimulated an increase 
of production of IgAs in the gastrointestinal tract. Based on these results and 
considerations Nicotiana tabacum based vaccine could be a promising way to 
protect piglets against enteric disease caused by VTEC. The most important 
factor in moving plant-produced heterologous proteins from developmental 
research to commercial products is to ensure competitive production costs, and 
the best way to achieve this is to boost expression. Thus, considerable research 
effort has been made to increase the amount of recombinant protein produced in 
plants. This research includes molecular technologies to increase replication, to 
boost transcription, to direct transcription in tissues suited for protein 
accumulation, to stabilize transcripts, to optimize translation, to target proteins 
to subcellular locations optimal for their accumulation, and to engineer proteins 
to stabilize them. In addiction engeneered plants and vegetables can be used as 
delivery system to deliver pharmaceuticals and additives for gut health of 
humans and animals. Further studies are needed to better evaluate the correct 
dose of vaccinal seed. Dose-curve response studies should be performed, but this 
implies a production of an higher amount of engineered seeds. A further aspect 
to be considered is the mucosal immune response. The underlying mechanism 
of mucosal immunity has been deepened in an independent project in 
collaboration with the University of Denver (Colorado). The main goal of the 
project was to characterize the effects of different mucosal bacterial pathogens 
(two strains of Haemophilus influenzae, Moraxella catarrhalis and 
Staphylococcus aureus) on the isotype of antibody production from human B 
cells. Further applications of this technology in the future would make it possible 
to produce modern drugs in plants. Plants are easy to grow; they produce a large 
amount of biomass, and are appropriate for a cheap production of high quality 
and bioactive recombinant proteins. Besides, the mechanism of N-glycosylation 
in plants and mammals is similar until the developing N-glycan reaches the Golgi 
apparatus. One of the main features of molecular pharming that distinguishes it 
from other industrial concepts - and has debatably worked against its profitable 
development - is that there isn’t a standardized platform or a single technological 
foundation. Instead, different platforms and technologies have been developed 
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with diverse and sometimes overlapping benefits, connected only by their 
employment of plant tissues (Stoger et al., 2014). The platforms vary from plant 
cells or simple plants growing in bioreactors containing fully defined synthetic 
media, to whole plants growing in soil or in hydroponic environments. These 
technologies encompass a stable transgene integration and transient expression 
when using bacterial, viral, or hybrid vectors (Fischer et al., 2013). An important 
discovery was achieved in 2012, when the first molecular pharming product was 
approved for humans’ use. In particular, this was the enzyme taliglucerase alfa, 
a recombinant form of the human glucocerebrosidase - developed by Protalix 
Biotherapeutics – used to treat the lysosomal storage disorder known as 
Gaucher's disease. Two clinical trial applications for plant-derived 
pharmaceuticals were also approved in the European Union (EU), one for insulin 
production in safflower (developed by SemBioSys Genetics) and another for an 
HIV-neutralizing monoclonal antibody production in tobacco, significant 
because of its public funded consortium (Pharma-Planta) development. In either 
case, new manufacturing procedures based on engineered plants were developed 
to guarantee the compliance with pharmaceutical good manufacturing practices 
(GMP). Moreover, Mapp Biopharmaceutical Inc., a company situated in San 
Diego, CA, USA produced a drug in tobacco leaves called ZMapp, which has 
been used to fight the 2014 Ebola virus outbreak in Africa (Arzten et al., 2015). 
The main influence of molecular farming is therefore likely to be the delivery of 
new strategies for medical involvement that removes some of the limitations of 
conventional manufacturing processes, instead of the indiscriminate 
replacement of current manufacturing infrastructures. 
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6-SUPPLEMENTARY STUDY: 
In order to examine in depth, the aspects related to local immunity, an 
independent project to characterize the effects of different mucosal bacterial 
pathogens (two strains of H. influenzae, M. catarrhalis and S. aureus) on the 
isotype of antibody production from human B cells has been developed. The 
potential “decoy” stimulation by surface bacterial proteins that is proposed to 
stimulate B cells non-specifically by cross-linking surface antibody by the 
constant Fc region rather than binding these bacteria by the antigen-specific Fab 
variable region. This part of the study has been conducted in collaboration with 
the Department of infectious diseases, University of Denver, Colorado. 
 
6.1-ISOTYPES DISTRIBUTION OF ANTIBODIES IN 
RESPONSES TO T CELL INDEPENDENT 
STIMULATION 
6.1.1-Mucosal microbiota  
Indigenous microorganisms colonize in children and adult human the skin and 
the mucosal gastrointestinal canal (GI) (Hentges, 1993; Tannock, 1995). The 
normal skin, the mucosal surface, the lumen of the alimentary canal and the 
gastrointestinal tract; harbor microbial cells in numbers that in aggregate can be 
estimated over 1014. The population of various bacterial species in the biota 
differ in adults from those of children and middle-aged adults. In addition, the 
interaction of bacterial species with the immunologic system in children and in 
adults may be different. These different interacting ways may complicate the 
understanding of how the mucosal microbiota interacts with the mucosal 
systems.  
In particular, in the nasopharynx and oropharynx tract the indigenous biota of 
the anterior nares of the normal adult generally reflect the bacteria biota in the 
skin. With normal procedures, predominating species in the skin biota are the 
gram-positive, aerobic genera Staphylococcus and Corynebacterium, and 
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anaerobic, gram-positive genus Propionebacterium. Gram-negative genuses 
such as Haemophilus and Moraxella are reported to be numbers of the 
indigenous nasopharyngeal and oropharyngeal biota (Table 34). 
Table 34: Nasopharyngeal and oropharyngeal biota. 
The mucosal microbiota in various areas of the body has been known for many 
years to have the capacity either to limit the growth of, or to kill, certain 
transient microbial pathogens entering their habitats. Some strains of S aureus 
in the nasopharynx can prevent pathogenic strains of the same bacterium from 
colonizing the mucosal surface (Tannock, 1995). Moreover, for several years 
researchers have been focused in different studies on the mechanism by which 
the indigenous biota on mucosal surface interacts with the body's immunologic 
system. In particular, two major aspects have been considered the immunologic 
system is tolerant of the indigenous microbiota, the microbiota communicates 
with the cytokines network. Many researchers were involved on antibody 
responses to antigens of bacteria in mucosal surfaces. In 1983, Berg discussed 
“natural antibodies and concluded that the serum and secretions of healthy adult 
human subjects contain in low titers IgAs, IgGs, IgMs, IgDs antibodies reactive 
with antigens of indigenous bacteria. In particular, he compared antibody 
responses to indigenous and nonindigenous bacteria either into or given orally 
to GF rodents. He concluded that the results supported a hypothesis that certain 
bacteria indigenous to the mucosal tracts of body do not elicit immunologic 
responses as well as do various nonindigenous bacteria. Another main aspect in 
the relationship between bacteria and mucosal immunologic system is that the 
indigenous microbiota communicates with the cytokines network. In a famous 
review Henderson et al. (1996), assessed the ability of multicellular complex 
organisms to harmoniously live with body's mucosal microbiota. It is based on 
Gram characteristic Genus Locationb 
Not applicable Mycoplasma OP 
Positive Staphylococcus 
Corynebacterium 
Propionibacteriumc 
AN 
AN 
AN 
Negative Moraxella 
Haemophilus 
Neisseria 
NP 
OR/NP 
OR/NP 
b OP, oropharynx; AN, anterior nares; NP, nasopharynx  
c Strict anaerobe.   
From Tannock et al., (1995) and Hentges et al., (1993) 
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mutual signaling involving eukaryotic cytokines and prokaryotic cytokines 
like-molecules. These bacterial products are being listed such as proteins toxin 
cell surfaces polysaccharides, endotoxin associated proteins, lipoproteins, 
peptidoglycans and many others. 
6.1.2-Lymphoid organs of the respiratory tract  
The upper and the lower respiratory tract airways are continually exposed to 
antigen challenges. This is reflected in the specialized cells and lymphoid 
organs in the nasal and buccal mucosae and in the airways until to lungs. In the 
human nasopharynx tract, a set of lymphoid tissue surrounds the nasal. In 
contrast to this highly organized and strategically positioned oro-nasal complex 
of lymphoid tissue, in lung of human only poorly developed lymphoid tissue 
can be found and oral passages in the pharynx. This specialized part upper 
respiratory tract is generally called Waldeyer's ring and includes the adenoids 
and the tonsils (Pherry and White, 1998). 
6.1.2.a-Structure of NALT (Nasal–associated lymphoid tissue)  
The organization and structure of NALT have been studied most extensively in 
small rodents such as rats and mice. It is situated in the floor of nasal cavity as 
a pared organ, slightly bulging out into the nasal cavity right at the entrance of 
the pharyngeal duct. At those placed where the respiratory epithelium covers 
the NALT it is characterized by the presence of specialized microfold M 
(Karchev and Kabakchiev, 1984). These M cells are found in all mucosal 
epithelia covering lymphoid aggregate, such a tonsil, Peyer’s patch, and BALT. 
In addition to M cells, which can be found in small clusters or alone, the 
epithelium covering the NALT contains a few mucous goblet cells. Whereas 
most of the epithelial cells lining the nasal cavity are determined to keep 
antigens and microorganism out, being protected by a mucus layer and constant 
activity of their microvilli, the M cells have evolved special mechanisms to 
transport macromolecules and particles across the epithelium. The M cells seem 
to be specialized in transcytosis (Kraehenbuhl and Neutra, 2000). Bound 
particles such as bacteria and viruses induce changes in the apical membranes 
and cytoskeleton, after which phagocytosis take s place. Reorganization of the 
cells membrane and extension of the cellular process around the particles have 
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been described, and the particles are transported through the cells in phagocytic 
vesicles (Owen et al., 1999). Smaller particles and macromolecules are taken 
up through clathrin-coated pits or by receptor mediated phagocytosis. 
Nevertheless, there seems to be an active interaction between the M cells and 
underlying lymphocytes because after depletion of lymphocytes by irradiation 
the intraepithelial pocket of the M cells in Payer’s patches is lost (Ermak et al., 
1989) (Figure 27). Data on the phenotype of the lymphocytes that reside in the 
pockets of the M cells in NALT are limited, but in Payer’s patches the majority 
of cells that are localized in the M cells pockets are CD4+T cells. B cells are 
also found in the pockets. The number of B cells in NALT roughly equaled the 
number of T cells.  
 
 
 
 
 
Figure 27: Peyer’s Patch, small intestine Sprague–Dawley rat, male, 31 days old. The follicle-
associated epithelium (FAE) contains clusters of lymphocytes, which may be associated with 
an M-cell. It is also slightly attenuated and has fewer goblet cells relative to the villous 
epithelium (VE). (Toxicologic Pathology, 34:599–608, 2006 Copyright C. Mark Cesta, 2006) 
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6.1.3-Function of the NALT  
In the past years, evidence has been accumulating that NALT is an important 
inductive site of immune responses after nasal immunization. Indeed, 
immunization via nose is an effective way to induce mucosal immune response 
s at remote effector site, and a role for NALT in the induction of these responses 
has been recognized. A scheme with and position of NALT in relationship with 
nose-draining lymph nodes and the nasal epithelium is shown in Figure 28 and 
is based on the work of Kupfer et al. (1992). Particulate antigen is 
predominantly taken up by M calls of the follicle-associated epithelium of the 
NALT. Whereas soluble smaller antigens are taken, up by the nasal epithelium 
and drain into lymph nodes directly or associated with DC (dendritic cells). In 
the lymphoid organs, B cells will preferentially switch to IgA plasma-blasts, 
after which they leave the lymphoid tissue to localize as effector plasma cells 
in and underneath the epithelium of the nasal passage 
 
 
 
 
 
 
 
 
 
 
Figure 28. Scheme showing the interaction between NALT, nose drawing lymph nodes and the 
spleen PCLN, posterior cervical lymph node. SCLN, superficial cervical lymph node. 
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6.1.4-The B Cell Development  
6.1.4.a-B cell development and immunoglobulin class switching  
The bone marrow, in both mouse and human being, is the primary site of early 
B cell maturation. At this location, B cells pass through a series of antigen 
independent maturational stages defined by the presence or absence of certain 
surface and cytoplasmic markers and by specific stages of Ig variable region 
heavy and light chain gene rearrangements and expressions. In each B cell, the 
selection and assembly of the genes encoding the variable region of the Ig 
molecule occur as a result of a random recombination process in which the 
selected variable region (V) diversity(V) and Joining (J) gene segments come 
together to form a single variable region gene complex. The heavy chain V 
region gene is formed by two rearrangements. First the joining of D and J genes 
occur, followed by the joining of a V gene to the fused DJ sequence whereas 
the light chain variable region gene is formed by a single rearrangement joining 
V and J genes. This variable region recombination ultimately results in the 
production of specific heavy and light chain proteins that can then be assembled 
to produce the unique Ig molecules that characterize each B cell and its progeny. 
The V(D)J recombination is tightly controlled by the transcriptional regulation 
of the recombinase genes that encode RAG-1 and RAG-2 proteins. The most 
immature B cells contain unarranged heavy and light chain variable region 
genes. Upon recombination of the heavy chain variable region genes, heavy 
chain encoded by the rearranged variable genes linked to the downstream Cm 
gene are present in the cytoplasm and on the cell surface in combination with 
surrogate light chain. Then following completion of the light chain gene 
rearrangement, both heavy and light chains are produced, and a complete IgM 
or IgD molecules can be assembled from the organized variable region genes 
linked to C or Cheavy chain genes The immature IgM B cells that co-
expresses high levels of surface IgM and low levels of surface IgD can then be 
formed. These immature B cells leave the bone marrow and pass via the 
circulation to various peripheral lymphoid tissues, including the spleen, Peyer’s 
patches (PPs) of the intestine, and lymph nodes. Upon specific immune 
challenge, a humoral immune response can be induced that is characterized by 
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the formation of activated B cells. Once antigen bind the specific antigen 
receptor on the surface of B cells, the clones committed to producing antigen-
specific Ig are selectively expanded After that SIgM positive B cells might 
undergo terminal differentiation to become IgM-secreting plasma cells or class-
switch recombination (CSR) into B cells producing another Ig isotype. Somatic 
hyper-mutation (SHM) might also take part at this stage of B-cell development, 
resulting in intraclonal diversity and enhanced antibody affinity or specificity. 
The encounter of a particular antigenic array serves to enhance the host’s state 
of preparation of its immune response to successive encounters with the same 
antigenic stimuli. This is practiced by providing a memory B cells response 
characterized by B cells that have antigen receptors with enhanced affinity for 
antigen and that produced classes of Ig with more specialized effector functions 
through a mechanism called Ig class switching. 
Immunoglobulin class switch: molecular events. During the early stage of 
both B cells and T cells differentiation, V(D)J recombination allows the 
assembly of variable (V), diversity (D), and joining(J) segments of the V 
exon of the immunoglobulin and T cells receptor genes, giving rise to diverse 
repertoires of B and t cells, each expressing receptors for specific antigen. 
Mature B cells that have finished functional V(D)J recombination of both 
heavy (H) and light (L) chain genes and expressing IgM on the surface 
migrate to the secondary lymphoid organs, where they allowed to encounter 
antigens. Activate B cells proliferate and differentiate into plasma cells or 
memory B-cells. During this peripheral differentiation B cells undergo a 
second wave of remodeling the immunoglobulin loci with CSR and SHM as 
mentioned before. These unique events are responsible for isotype switching 
and affinity maturation. These two recombination events are regulated by a 
single molecule, activation induced cytidine deaminase (AID) (Muramatsu 
et al., 2000) (Figure 29).  
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Figure 29: Antibodies diversification. (a) A deletional recombination event between individual 
V, D and J segments creates the variable region of the immunoglobulin gene. This process is 
catalyzed by the RAG-1–RAG-2 recombinase complex and occurs in an antigen-independent 
way. C, constant. (b) SHM, the first of two secondary antibody-diversification processes, 
results in the accumulation of point mutations in the recombined variable region. AID initiates 
this process through the deamination of cytidine to uridine, followed by removal of the uracil 
base by UNG and repair by several base-excision repair (BER) and mismatch-repair (MMR) 
enzymes. The asterisk indicates the rearranged, mutated variable region. (c) CSR completes the 
secondary antibody diversification and results in the exchange of the default constant region, C
 (IgM), for one of many downstream regions (C 3 (IgG3) is presented here. AID is thought 
to initiate this process through deamination of bases in the switch (S) region (yellow circles) 
upstream of each constant region, resulting in the formation of DSBs and recombination 
(Muramatsu et al., 2000). 
6.1.5-Outline of molecular mechanisms for CSR  
The immunoglobulin Ch locus consists, of an ordered array of CH genes, which, 
except for Cd, are flanked at their 5’ region by unique repetitive sequences 
called S regions (Honyo and Kataoka, 1978; Kataoka et al., 1980; Davis et al., 
1980; Rabbitts et al., 1980). The presence of the S region is required for CSR. 
Indeed, artificial switch substrates lacking S sequences are unable to perform 
class switch recombination. (Leung and Maizels, 1992). CSR take place 
between S regions (region specific S-S recombination). It requires double 
strand breakages, one in Sand other in one of the downstream S regions, and it 
results in looped –out deletions of the intervening DNA segments (Iwasata et 
al., 1990). It is followed by repair and ligation of the broken DNA ends and by 
activation of the ubiquitously expressed nonhomoulogous end –joining (NHEJ) 
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repair system (Rolik et al., 1996; Casellas et al., 1998; Manis et al., 1998) the 
looped out circular DNA contains an I promoter that is still responsive to 
cytokines and directs production of I-C transcripts called circle transcripts 
(CTs). These CTs serve as hallmarks for active CSR in-vitro (Fagarasan et al., 
2001). The Cgene is located at the at the VH proximal end of the CH gene 
cluster, so that CSR between S and another S region located 5’ a CH gene 
brings that particular CH gene adjacent to the VH exon. The result is a “switch” 
of the immunoglobulin isotype from IgM/IgD to IgG, IgA, or IgE having the 
same antigenic specificity but with different biological properties. The 
molecular process that underly switch differentiation is not random event but is 
induced by external environmental factors (McIntyre and Strober, 1999). 
Initiation of CSR requires B cell activation by antigens and cytokines secreted 
by a variety of cells, such as activated B cells and the cytokines milieu to which 
the B cells are exposed. Some antigens and some anatomic locations promote 
isotype-restricted responses, as shown by the preference for IgA development 
in GALT (Cebra et al., 1998). Signal transduction through surface IgM, Toll-
like receptor, CD40, other TNF family member receptor (BCMA), and 
cytokines receptor on B cell induces two essential events that are required for 
CSR selection of a target region S and induction of AID (Zalazoswki et al., 
1995) 
6.1.5.a-Role of AID in class switch recombination  
As discussed previously, the selection of S Target S region is mediated by 
transcription from the particular I promoter of mediated by transcription from 
the particular I promoter of that S region, and this event is an absolute 
requirement for CSR. Cytokines stimulation induces not only germline 
transcription associated with chromatin opening but also activation of new 
genes involved in CSR such as AID (Kinoshita et al., 1998). In-vivo, AID is 
strongly expressed in B cells located in the germinal center, the anatomic site 
where CSR and SHM take place with high efficiency. The essential role of AID 
on CSR was revealed by loss-of-function studies in both mice and humans. 
Mice AID deficient cannot produce any Ig Isotype other IgM, which is 
abundantly secreted under both immunized and non-immunized conditions. 
CSR is not detected in AID-deficiency B cells even after stimulation in vivo. 
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Neverthless these B cells proliferate normally and express normal germline 
transcripts of all downstream region in response to cytokines stimulation. 
Human AID deficiency, called hyper-IgM syndrome type II, shows an identical 
phenotype to AID deficiency in mouse, clearly indicating that AID is required 
for both CSR and SHM (Durandy and Honijo, 2001).  
6.1.6-The Human Mucosal B-cell System 
Lymphoid cells are located in three histologically distinct tissue compartments 
at the mucosal surface; the immune-inductive organized mucosa-associated 
lymphoid tissue (MALT), the lamina propria or glandular stroma, and the 
surface epithelia and Payer’s patches in the distal small intestine. Typical 
MALT structures are believed to be a main source of conventional B2 sIgA-
expressing primed mucosal B cells. Primary lymphoid follicles contain 
recirculating naïve B lymphocytes (sIgD+ IgM+), which pass into the network 
formed by antigen–capturing follicular dendritic cells (FDCs). Primary follicles 
are turned into secondary follicles by the germinal center reaction. In humans, 
this process has been extensively studied in tonsils by MacLennan, (1994) and 
Liu and Arpin, (1997), but much relevant mechanistic information relies on 
observation of lymph nodes and the spleen from immunized animals. Germinal 
centers are of vital importance for T cell-dependent generation of conventional 
(B-2) memory B cells, affinity maturation of the B cell receptor (BCR), and Ig 
class switching. It has been show that naïve B cells are first stimulated at the 
edge of the primary follicle by cognate interaction with activated CD4 T cells, 
which have previously been presented with processed antigens by MHC class 
II expressing DCs. The B cells then re- enter the follicles to become 
proliferating sIgD+ IgM+ CD38 germinal center “founder cells“ as noted in 
human tonsils. Such initial stimulated B cells produce mutated IgM and some 
IgG antibodies of low affinity that can bind circulating antigen; the resulting 
soluble immune complex subsequently becomes deposited in the FDCs, where 
the antigen is retained for prolonged periods to maintain B-cell memory. Such 
a role for IgM in the induction of secondary immune responses with antibody 
affinity maturation has been strongly supported by observation in knock-out 
mice lacking natural (non-specific) background IgM antibodies. The 
complement receptor CR1/CR2 is considered a cell surface molecules that plays 
130 
 
a crucial role in the germinal center reaction. CD21 is expressed abundantly on 
both FDCs and B cells and may function by localizing antigen to the FDC 
network and/or by lowering the threshold of B-cell activation via recruitment 
of CD19 into the BCR. The germinal center can be divided into different 
compartment in which antigen –dependent selection of B cells takes place. 
Stimulation in the dark zone produces exponential growth of B cell blasts 
positive for Ki-67 nuclear proliferation marker. (Brandtzaeg and Halstensen, 
1992) The resulting centroblasts somatically hypermutate their Ig-variable (V) 
region genes and give rise to sIgD-IgM+CD38+. 
Some centrocytes with specificity for exogenous antigens undergo apoptosis 
unless selected by high affinity binding to FDCs via their sIgM/BCR. The 
importance of cognate interaction between B and T cells is well documented by 
the fact that no germinal center is formed when CD40-CD40L (CD54) ligation 
is experimentally blocked (Lindhout et al., 1997). Moreover, this ligation 
promotes switching of the Ig heavy-chain constant region (CH) genes from 
Cto downstream isotypes, while apparently representing a negative signal for 
terminal B cells differentiation within the follicles. Interaction between CD27 
on CD38+ germinal center B cells and CD27L in T cells may be a determining 
event (Jung et al., 2000). 
Exit of B cells from germinal center.  
Migration of activated B cells from the germinal center is most likely directed 
by chemokynes, and the actual cues may be extrafollicular ligands for CCR7. 
Thus, activated germinal center B cells downregulate CXCR5 and upregulate 
CCR7. Most MALT-induced sIgD- IgM+ CD38- putative memory B cells 
migrate continuously out of the germinal center to sites such as the tonsillar 
crypt epithelium or to Payer’s patches M cell pockets. (Yamanaka et al., 2001)  
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The switching process.  
Following activation, naïve B cells usually first change their BCR composition 
from IgD+ IgM+ to become sIgD- SIgM+ memory cells and may then switch to 
another class such as IgGs or IgAs. During plasma cell differentiation the BCR 
is gradually lost, together with several other B-cells markers, particularly the 
CD20 and then the CD19. Activation induced cytidine deaminases (AID) play 
an essential role in the process where B cell differentiation downstream (5’
 3’) switching of CH genes on chromosome 14, from IgM (C) to other 
isotypes (Flanagan and Rabbits, 1982). The tonsillar germinal center reaction 
involves extensive switching and some terminal differentiation of effector B 
cell (Dahlenborg et al., 1997). Thus, immunoistochemical studies have revealed 
a substantial although variable number of intrafollicular Ig producing 
plasmablasts. Predominantly witch cytoplasmic IgG (55% to 72%) or IgA 13% 
to 18%. Both these germinal center immunocyte classes, and also those 
producing IgM and IgD, are often associated with detectable cytoplasmic J-
chain expression (IgG 36%, IgA 29%, IgM, 55%and IgG, 82%), in normal 
palatine tonsils as well as adenoids from children and adult. 
Regional isotype-switch mechanisms differ. 
The cytokines profiles and other micro environmental factors that determine 
isotypes differentiation of B cells are likewise obscure. The fact that IgA1 
subclass dominates IgA responses both in tonsils and in regionally related 
exocrine tissues supports the notion that mucosal B cell differentiation in this 
body region mainly takes place from SIgD- IgM+CD38+ centrocytes by 
sequential downstream CH gene switching. Conversely, the relatively enhanced 
IgA2 expression in Payer’s patches and the distal gut altogether including the 
mesenteric lymph nodes (Kett et al., 1986), could reflect direct switching from 
Co C2 with excision of intervening CH gene segments. The germinal center 
reaction generates relatively more intrafollicular J chain-positive IgA cells in 
human Payer’s patches and in appendix than in tonsils (Brandtzaeg et al., 
1999b). Also in juxtaposed extra follicular GALT compartments, IgA 
immunocytes are equal to exceed in numbers their IgG counterparts, whereas 
in tonsils there is a more that two-fold dominance of IgG immunocytes outside 
of the follicles (Brandtzaeg, 1987). Therefore, the drive for switching to IgA 
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and expression of J chain is much more pronounced in GALT than in tonsils. 
Perhaps GALT is distinct from other MALT structures because of its special 
accessory cells or a particular cytokines profile.  
6.1.6.a-Microbial impact on mucosal B cell 
A regionalized microbial impact on mucosal B cell differentiation may be 
exemplified by the unique S IgD+IgM- CD38+ subset identified in the dark zone 
of palatine tonsillar germinal center (Liu and Arpin, 1997). This centroblast 
showed a deletion of the C and S gene segments therefore giving  selectively 
rise to IgD immunocytes by non-classical switching. In the literature, there is 
molecular evidence of preferential occurrences of B cells with C deletion also 
in normal adenoids and secretory and secretory effector tissues of the upper 
aero digestive tract but virtually never in the small intestinal mucosa 
(Brandtzaeg, 2002). Most strains of Haemophilus influenzae and Moraxella 
catarrhalis, which are frequent colonizers of the nasopharynx, produce an IgD 
binding factor (Protein D) that can crosslink SIgD/BCR (Ruan et al., 1990). In 
this manner it is possible that sIgD+ tonsillar centrocytes are stimulated to 
proliferate and differentiate polyclonally, hereby driving IgV- gene 
hypermutation and Cm deletion (Liu et al., 1991). Such regional microbial 
influence on B-cell differentiation is supported by observation that Cdeletion 
is more frequently detected in diseased than in clinically normal tonsils and 
adenoids (Branstzaeg et al., 2002) and there is an increased number of extra-
follicular IgD immunocytes in recurrent tonsillitis and adenoids hyperplasia 
(Brandtzaeg, 1987).  
6.1.7-Bacterial interaction with mucosal epithelial cells.  
6.1.7.a-Bacterial interaction with mucosal epithelial cells in the 
respiratory tract  
The human respiratory tract (RT) can be divided in two regions: nasopharynx 
and lung, which are sterile. Epidemiological studies have demonstrated that 
while many bacteria are capable of infecting the lower RT only few species do 
so commonly (Mandell, 1995). These pathogens cause two distinct types of 
diseases. Infection limited to the airways is exemplified due to Bordetella 
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pertussis that cause whooping cough (Cooter et al., 2001). Infection of the 
alveoli produces pneumonia. In most development countries, the most common 
agents of community-acquired pneumonia are Streptococcus pneumoniae, 
Haemophilus influenza, Moraxella catarrhalis and Mycoplasma pneumoniae.  
The respiratory pathogens initially colonize the nasopharynx and subsequently 
are aspirated into lungs. All healthy children and adults are colonized 
repetitively and asymptomatically. Colonization progress to disease commonly 
in individuals who are immunocompromised underlying conditions (e.g. cystic 
fibrosis, asthma, chronic pulmonary disease), or have habits or lifestyles that 
impair the normal functioning of the innate defense of the lung (e.g. smoking 
or alcoholism) (Mandell, 1995). As those in the gastrointestinal tract, most 
bacteria in the nasopharynx are commensal, land exist in balance with the host. 
The presence of these bacteria is also most likely beneficial, if simply to occupy 
a niche and prevent colonization by more pathogenic strains. The signature 
characteristic of bacteria that causes lower RT infection is the ability to adhere 
to and invade mucosal epithelial cellsn(MECs). Either ciliate cells of the 
airways or type I and II alveolar cells in the terminal air sacs. To gain access to 
MECs, pathogens must overcome the gauntlet of innate and specific defenses 
present in mucosal secretion. These defenses routinely protect the host from the 
onslaught of commensal and pathogenic bacteria introduced into RT daily.  
Cilia and the mucin layer. Mucus is the primary innate defense protecting 
mucosal epithelial cells from microorganisms and serves as a physical barrier 
to infection (Knowel et al., 2002). Beating of cilia of epithelial cells transports 
mucus and entrapped particles to the mouth, where they can be swallowed and 
killed in the stomach. Mucin is a complex mixture of very diverse, high 
molecular weight, glycosylated macromolecules that, by virtue of carbohydrate 
diversity, is capable of binding almost any particle that lands on the airway 
surface (Klein et al., 2000). Bacteria evade mucin entrapment by reducing the 
number of receptors in the surface or by enzymatic digestion of mucin by 
glycohydrolases. Digestion of mucin reduces the viscosity of the mucus, 
enabling bacteria to penetrate to the epithelial surface. These enzymes also 
serve to cleave terminal carbohydrate structures from the surfaces of MECs, 
exposing previously cryptic antigens that then function of receptors for the 
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bacteria (Tong et al., 2000). The most direct mechanism for protecting the host 
from bacteria is to kill prior to their contact with MECs. Accordingly, the mucus 
layer, in addition to being a physical barrier, is a chemical shield exposing 
bacteria to an extensive array of antimicrobial peptides and inhibitory proteins. 
Antimicrobial factors present in mucus, include complement, cathepsin G, 
defensins, surfactant, lysozyme, and lactoferrin (Brogden, 2000).  
Defensins are secreted by epithelial cells and damage the bacteria cell 
membrane causing blebs or lytic pores (Leherer et al., 1991). Bacterial 
strategies against defensins focus at either neutralizing the peptides or evading 
those (Brogden et al., 2000). Strategies, including altering receptors for 
defensins (such as outer membrane proteins, LPS, teichoic acid), adsorbing 
charged molecules the repel the peptides, or actively transporting the defensins 
away from the bacterial surface. Another important factor in the RT secretions 
is complement. LPS ion gram-negative bacteria activate the complement. LPS 
on the gram-negative bacteria activate the alternative pathway by binding C3b 
and C5b, which then serve a nucleus for the formation of the membrane attack 
complex (MAC) (Downey et al., 1997). Alternatively, other components such 
as IgG and C-reactive protein (CRP) once bound activate the classical 
complement pathway. Bound complement opsonized bacteria for phagocytosis, 
while soluble C3a and C5a serve potent chemotactic molecules for neutrophils 
and macrophages (Eredei et al., 1997). Some gram-negative bacteria 
circumvent complement by attaching sialic acid to their surface. Sialic acid 
serum protein H, which in turn binds protein I. Protein I degrades C3b, thus 
preventing the formation of the C5 convertase (Rautemaa et al., 1999). This 
sialic acid based defense is a common strategy with many variations. Naisseria 
gonorrheae displays sialic acid as O-antigen, while Naisseria meningitis 
display sialic acid as a major capsular component. In addition, some bacteria 
produce an elaborate array of virulence factor, including a protease, lipase, 
hemolysin, and cytotoxin. A critical element making the mucous trap for 
bacteria effective is the expulsion of secretions from the lower RT by the ciliary 
escalator. Thus, it is not surprising that pathogens secrete toxins that can stop 
ciliary beating. The most specific of these toxins, tracheal cytotoxin, is derived 
from the cell wall of B pertussis and is exquisely potent and specific at killing 
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ciliated cells (Wilson et al., 1991) to bacterial products is dependent on a family 
of membrane proteins termed. 
TOLL-like receptors (Medzhitov et al., 1997). TLRs activate the signaling 
pathway that initiates the innate immune responses to infection and begin the 
process to adaptive immunity. These receptors play a major role in phagocytosis 
cells such as alveolar macrophages and neutrophils but also dictate 
responsiveness of lung epithelial cells (Wang et al., 2002). TLR responses are 
tailored for the class for the class of the infectious agent, (Kopp et al., 1999). 
For example, TLR4 recognize LPS and as such is activated by gram-and 
negative bacteria. TLR2 recognized components of gram-positive bacteria such 
as peptidoglycan and teichoic acid. TLR9 recognized nucleic acid motifs. 
Activation if TLRs triggers intracellular signals, leading to induction of the 
innate response (defensins, cytokines , the expression of PAF and ICAM) and 
recruitment of neutrophils and effector cells to clear the infection. During the 
invasion process, several mucosal pathogens trigger apoptosis. 
6.1.8-Briefly overview of microorganism of the respiratory 
tract. 
Haemophilus influenzae (Hib) 
Hib is a respiratory tract bacterium and is considered to be commensal 
particularly in preschool children. This type of bacteria is divided into 
encapsulated strains (serotypes a–f) and unencapsulated (NTHi), that is, 
nontypeable H. influenzae (NTHi). An efficient vaccine against H. influenza 
type b (Hib) was introduced in the 1990s, and ever since the incidence of Hib 
infections has decreased dramatically. NTHi is after pneumococci one of the 
leading causes of acute otitis media in children (Murphy et al., 2009). In adults, 
NTHi causes sinusitis as well as bronchitis, and is frequently found in patients 
with chronic obstructive pulmonary disease, both during stable disease and 
acute exacerbations. Although H. influenza is associated with an array of 
respiratory tract infections, NTHi is also considered as a nasopharyngeal 
commensal of mainly preschool children (Faden et al., 1995). Immune evasion 
by H. Influenza includes the production of immunoglobulin A (IgA) protease 
and circumvention of complement-mediated attacks by accumulation of 
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complement inhibitors and delayed deposition of complement proteins 
(Vitovski et al., 2002) Another interesting mechanism, which often is 
implicated as a binding to immunoglobulins. This phenomenon implicates 
binding to the conserved regions of immunoglobulins different from 
conventional antigen binding sites. Immunoglobulin D (IgD) binding has been 
demonstrated for Hib (Samuelsson et al., 2007). 
Moraxella catarrhalis (Mcat) 
Mcat is a Gram-negative human specific pathogen of the respiratory tract. 
(Figure 30). For a long time, the potential pathogenicity of M. catarrhalis was 
ignored and the species was mainly recognized as a commensal. However, M. 
catarrhalis is now acknowledged as a causative agent of respiratory tract 
infections in children and adults leading to a considerable morbidity. M. 
catarrhalis is the third most important pathogen causing otitis media in children 
and is responsible for up to 20% of cases with a majority of the children 
experiencing at least one episode of otitis media by the age of 3 years (Verduin 
et al., 2002). Other respiratory tract infections in children associated with M. 
catarrhalis include sinusitis, conjunctivitis, bronchitis and pneumonia (Ahmed 
et al., 2008). The carriage rate of M. catarrhalis is low in healthy adults and if 
infected, adults are usually predisposed to lower respiratory tract infections 
with M. catarrhalis in case of compromised situations such as chronic 
obstructive pulmonary disease (COPD) and previous episodes of pneumonia. 
Colonization of the nasopharynx by M. catarrhalis and other predominant 
respiratory tract pathogens such as non-typeable (NTHi) and Streptococcus 
pneumoniae begins at a very early age in the life and at least 50 % of children 
are colonized by the age of 2 years. Colonization not only provides the potential 
pathogens an entry point to various associated tissues including the ear, sinuses, 
larynx and lower respiratory tract but is also means of spreading in the 
community via nasal secretions.  
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Figure 30. Moraxella catarrhalis (by www. Bacteria in photos.com). 
Staphylococcus aureus 
Sthap A is a gram-positive coccus bacterium that is a member of the 
Firmicutes, and is frequently found in the nose, respiratory tract, and on the 
skin. It is often positive for catalase and nitrate reduction. Although S. aureus 
is not always pathogenic, it is a common cause of skin infections such as 
abscesses, respiratory infections such as sinusitis, and produces a toxin that 
causes food poisoning. Pathogenic strains often promote infections by 
producing potent protein toxins, and expressing cell-surface proteins that 
bind and inactivate antibodies. Many studies demonstrate that 
Staphylococcus aureus Cowan I (SAC), a protein A-positive Staphylococcal 
strain is a potent and consistent inducer of IgM production by normal human 
peripheral blood mononuclear cells (Figure 31).  
 
 
 
Figure 31: Staphylococcus aureus. Blackwell Science Ltd, Cellular Microbiology 1,101±117 
(1999).  
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6.2-Aim of the study 
Naïve B other cell activation is dependent on multiple signals initiated by 
binding of an Antigen (Ag) to the BCR. BCR cross-linking induces a signaling 
cascade leading to internalization and processing of the bound Ag, cytokines 
production, and up-regulation of costimulatory molecules. Other factor that 
strongly influence B cell activation are complement binding thorough the 
complement receptors CD21 as well as TLR interaction. In fact, a three-signal 
model for activation of human naïve cells has been suggested involving 1) BCR 
cross-linking, 2) Physical T-cells help, 3) TLR 9 stimulation and/or cytokines. 
Based on this issues, we focused attention to characterize the effects of different 
mucosal bacterial pathogens such as Moraxella catarrhalis, (Mcat), 
Heamophilus influenzae type b (Hib), Haemophilus influenzae non typeable 
(NTHi), Staphilococcus aureus Cowan I (SAC) on the isotype of antibody 
production from human B cells. The synthesis and secretion of 
immunoglobulins by Human Peripheral Blood Mononuclear cells (PBMCs) and 
Tonsils were evaluated by enzyme-linked immunosorbent assay (ELISA). 
Samples of cells actively secreting immunoglobulins and immunoglobulins 
quantification released into culture supernatant is a useful information in order 
to assess the Immunoglobulin class switch of B cells without T- cells help. In 
addition, flow cytometry analysis (BD FACSDiva 4.0) was performed to 
characterize the potential stimulation by surface bacterial protein before and 
after stimulation on mucosal B cell. The cells were stained with monoclonal 
antibodies to B cells markers in order to obtain a B-cells panel. Data were 
analyzed using FlowJo Softwere to evaluate the subpopulation of B-cells 
through the parental population of B-cells.  
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6.3-Materials and methods 
6.3.1-Bacteria and culture conditions 
Moraxella catarrhalis was clinically isolated as described in Mollenkvist et al., 
(2003). The bacterial strain was taken in sterile conditions from the Eppendorf 
tube. Two /three beds were placed into a blood agar petri dish and turned around 
and then wasted. The bacteria were grown on blood agar base solid medium at 
37 C° 5% CO2 over-night. 
24 hours later in sterile conditions, one CFU (colony forming unit) was taken 
with a plastic stick and placed in 10 mLs of brain heart infusion (BHI) liquid 
medium. 
Haemophilus influenzae type b (Hib) (ATCC 10211, Manassas, Virginia) and 
Haemophilus influenzae non-typeable (NTHi) (ATCC 49247) were rehydrated 
with 500 Ls tryptic soy broth. The whole content was aseptically taken and 
placed in 6 mL of TSB. Three drops have been placed in achocolate agar plate 
and incubated at 37° C (o/n). The suspension was spinned down (800 rpm 10’ 
at RT) re-suspended in 1 mL of TSB +20% of glyceraldehyde and frozen at -
80° C.  
Serial dilution and plate count: Moraxella grew in 10mL of BHI. Six tubes, 
each with 9 mL of BHI, were settled up and six dilutions (1:10 until to 1:106) 
were done. Some drops of each tube were placed in five petri blood agar plates 
and placed upside down inside the incubator at 37° C 5% CO2. 
Hib and NTHi were taken from the plate and diluted in 2 mL of BHI and diluted 
6 times as described below (30L of bacteria + 270L PBS) and plated in 
chocolate agar plates. The bacteria were allowed to multiply for 24/48 hours. 
6.3.2-Formaldehyde killing assay  
Original bacteria tubes were spinned down and washed 3 times in phosphate 
buffer saline (PBS), at a pH of 7.2, by centrifugation. Thereafter they were 
suspended immediately in 0.5 % formaldehyde for 3 hours at room temperature 
followed by heat treatment at 80° C for 3 minutes. Formaldehyde stock at 10% 
was diluted to 1:20 (250 L of PFA +4750 L PBS) in 5 mL of PBS. After 
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being washed three times by centrifugation in PBS the bacteria were re 
suspended in RPMI-1640 (Gibco, Paisley, UK) and stored in five aliquots at -
20’C. The CFUs of each bacteria strain were counted in order to do the stim 
assay. 
6.3.3-Reagents 
Protein A from Staphylococcus aureus Cowan I strain was purchased (P7155, 
Sigma Aldicrh, 3050 Spruce Street, St Louis, MO 63103 USA). Protein A is a 
highly stable cell surface receptor produced by several strains of 
Staphylococcus aureus. It consists of a single polypeptide chain with a 
molecular mass of 42 kDa, containing four repetitive domains rich in aspartic 
and glutamic acids, but devoid of cysteine. It contains little or no carbohydrate 
(Boyle and Reis, 1997). Protein A is capable to bind to the Fc portion of 
immunoglobulins, especially IgGs, from a large number of species. One protein 
A molecule has been shown to bind at least 2 molecules of IgG simultaneously 
(Sjöquist, 1972). The IgG binding domain of Protein A consists of three anti-
parallel α-helicies, the third of which is disrupted when the protein is complexed 
with the Fc region of the immunoglobulin. Protein A will bind to the Fc portion 
of human IgG subclasses, IgM, IgA, and IgE; and mouse IgG1 (weakly), IgG2a, 
and IgG2b. Protein A also binds IgGs from other species, including monkey, 
rabbit, pig, guinea pig, dog, and cat (Lindmark, 1983). Protein A may be 
conjugated with various reporter molecules, including fluorescent dyes (FITC), 
enzyme markers (peroxidase, β-galactosidase, and alkaline phosphatase), 
biotin, and colloidal gold without affecting the antibody-binding site on the 
molecule. These conjugates are used to detect immunoglobulins in various 
immunochemical assays including Western blotting, immunohistochemistry, 
and ELISAapplications. In addition, Protein A may be immobilized on a solid 
support such as agarose or acrylic beads for the purification of either polyclonal 
or monoclonal immunoglobulins (Current Protocols in Immunology, Coligen 
et al., 1991). 
CpG DNA ODN. (3950 Sorrento Valley Blvd, Suite 100 San Diego, California 
92121 USA). Aliquots 1 mg/mL of CpG were stored at -80°. CpG ODNs are 
synthetic oligonucleotides that contain unmethylated CpG dinucleotides in 
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particular sequence contexts (CpG motif). These CpG motifs are present at a 
20-fold greater frequency in bacterial DNA compared to mammalian DNA. 
CpG ODNs are recognized by Toll-like receptor 9 (TLR9) leading to strong 
immunostimulatory effects. Three classes of stimulatory CpG ODNs have been 
identified, classes A, B, C, which differ in their immunostimulatory activities. 
CpG strongly activate B cells but weakly stimulate IFN- secretion. 
Interleukin 21 (IL-21): This cytokine is produced primarily by T follicular 
helper cells, which support B cell differentiation, and greatly enhance 
proliferative responses and antibody production from purified human peripheral 
blood, tonsillar, and splenic B cells. Aliquots 100 g/mL of IL-21 were stored 
at -80° C. 
6.3.4-Culture cells and samples  
Human peripheral blood cell  
PBMCs from healthy donors were prepared by gradient centrifugation. Blood 
draw and cell isolation were approved by our local ethics committees. PBMCs 
were separated from 60 mL of fresh whole blood by centrifugation on Ficoll–
Hypaque (Pharmacia, Uppsala, Sweden). Lymphocytes of the buffy coat were 
washed in RPMI 1640 and the cell pellet was washed and finally resuspended 
in ‘cellwash’ medium (Becton Dickinson, Mountain View, CA) containing 
0.5% (v/v) bovine serum albumin (cell wash/BSA). 17 samples were employed 
in the experimentation. Of these, 14 were frozen and three were fresh.  
Tonsils.  
Four patients with adenotonsillar hypertrophy who underwent tonsillectomy 
were enrolled. Tonsils were placed in ice-cold DPBS (1X) (GIBCO by Life 
technologies) plus antibiotics, and processing began <30 min after surgical 
excision. Tonsils were manually dissected and gently grounded with a syringe 
plunger through a 70-μ mesh screen. Lysis buffer removed red blood cells. 
Cellular viability was determined by trypan blue exclusion. Specimens with a 
viability <70% were discarded. In addition, two frozen samples of tonsils were 
employed (Table 35). 
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Table 35: Samples enrolled during the experimentation.  
6.3.5-B-cell stimulation (stimulation assay). 
All stimulatory reagents were optimized for cell stimulation in the settings 
described (Table 36). PBMCs and Tonsils cells (1x106 cells/mL) in RPMI 
media (Invitrogen) with 10% heat-inactivated FCS (HyClone Laboratories) and 
10mg/mL gentamicin (Invitrogen) were cultured in 96 well/plate in media alone 
or stimulated with IL-21 (10 ng/mL; Peprotech, Inc., Rocky Hill, NJ), CpG 
(1ug/mL, 3ug/mL, 10ug/mL; Integrated DNA Technologies, Inc. San Diego, 
CA), Moraxella catarrhalis (Mcat), Heamophilus influenzae type b (Hib), 
(ATCC 49247) and non typeable (NTHi) (ATCC 102111), at the final 
concentration of 105,105.5, 106, 106.5 and Staphilococcus aureus Cowan I (SAC) 
(SIGMA) with a dilution factor from y20000 till y10
6), at 37° C for three or five 
days. After three or five days the 96 wells plate was centrifuged at 12000 rpm 
for 10 min. The supernatant of cells was transferred into a new sterile 96 wells 
plate and analyzed by ELISAin order to establish the titer of Immunoglobulins, 
in particular IgGs and IgMs. The pellets were placed into tubes for FACS 
analysis. 
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Table 36: Scheme of stimulation assay with two plate 1-2 in order to establish the best 
concentration of bacteria for using during experimentation. PBMCs were cultured with Mcat, 
Hib, NTHi, at the concentration of 105,105.5, 106, 106.5 and SAC) (SIGMA) with a Df y20000to 
y106. CpG (10g/mL) with or without IL-21 (10ng/mL). 
 
6.3.6-Enzyme–linked immunosorbent assay (ELISA) 
ELISA Total IgG and IgM antibodies were measured in the supernatant of cells 
following the manufacturer protocol. Briefly: 96 –well microtiter plates (NUNC 
Maxisorp; Thermo Fisher Scientific) were coated with capture antibody. IgM 
(Jackson Lab. 10902) diluted 1:12000; IgG (Jackson lab 116836) diluted 
1:4000. Capture antibodies goat anti human were added to carbonate buffer 
(50mM) at the concentration mentioned before. 100L of capture antibodies 
were placed in each well and incubated o/n. After 24 hours, the plates were 
washed (plate washer Skatron) three times with PBS and 200L of PBS-t-BSA 
were placed in each well. The plates were incubated for 2 hours at room 
temperature. After 2 hours’ immunoglobulins stocks Human IgM (Jackson 
49215) and Human IgG (Jackson 80294 were diluted with PBS-t-BSA at the 
final concentration of 500 ng/mL. The plates were washed and 100L of PBS-
t-BSA were added into wells A1-A2. 100 L of standard were added 
simultaneously and mixed up and down at least 8 times. 100 L of suspension 
was removed and through in B1-B2. The mix was repeat until H1-H2. This 
gives 1:2 dilutions. The practice was repeated adding 50 L of samples; samples 
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give 1:3 serial dilution (Table 37). The plates were incubated for two hours at 
room temperature. 
 
 
 
 
 
 
 
 
Table 37: Serial dilutions for standards and samples applied in ELISA assays. 
Unbound samples were removed and an anti-antibody molecule which is 
covalently bound to horseradish peroxidase (H2O2 oxidoreductase) labeled 
affinity- purified goat anti-human IgG and IgM (Jackson Laboratories, Bar 
Harbor, ME) were added to the wells. Conjugated antibody was added to PBS-
t-BSA at the recommended dilution (record below in Table 38) and mixed 
thoroughly. The plates were washed using plate washer. 100 uL conjugate 
placed in each well and incubated one hours at room temperature. 
 
 
Table 38: Dilutions of capture antibodies using in ELISA assays. 
The detection of antibodies was performed by using the ABTS developer. The 
developer contains both the substrate (H2O2) and the chromogenic reactant 
ABTS [2, 2’-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid)]/ H2O2. When 
H2O2 was degraded, the byproduct causes the chromogen to develop a green 
color. The amount of color formed is directly proportional to the amount of 
H2O2 degraded, which is directly proportional to the amount of anti-antibody–
HRPO in the well, which is directly proportional to the amount of unknown 
bound in the well by the capture antibody. Concentrations were extrapolated 
from purified human IgG and IgM standards (Jackson Laboratories) bound to 
capture antibody that showed comparable slopes of binding Data were acquired 
 Standard 
 Final concentration 
Samples diluition 
Dilution factor 1:3 
A 250 ng/mL Y3 
B 125 ng/mL Y9 
C 62.5 ng/mL Y27 
D 31.2 ng/mL Y81 
E 15.6 ng/mL Y243 
F 7.8 ng/mL Y729 
G 3.9 ng/mL Y2187 
H 1.95 ng/mL Y6561 
Goat anti-human Lot# Dilution  
M-HRPO Jackson 49215 1:1000 
G-HRPO Jackson 96091 1:2000 
145 
 
with the SoftMax program software and read with the VersaMaxPLUS 
ROMv1.21 at wavelength of 405 nm. 
6.3.7 Statistics 
Data were analyzed using the IBM SPSS Software (IBM Corporation 1 New 
Orchard Road Armonk, New York 10504-1722 United States). We have 
applied Non-Parametric Tests for Independent Samples, using the NPTESTS 
post hoc tests procedure for the Kruskal-Wallis omnibus test. Comparisons of 
antibody titers between groups were done using the Mann–Whitney test after 
base 10 logarithmic transformations. A p< 0.05 was considered to indicate 
statistical significance. In addition, the one-way analysis of variance (ANOVA) 
with a Dunnett’s post hoc test in SPSS. The Dunnett’s test is used when only 
the comparisons between treatments and a control group are of interest. 
Differences between groups were considered significant at a p <0.05. 
6.3.8 Flow cytometer Analysis 
All samples (PBMCs and Tonsil cells) were stained with monoclonal antibodies 
to B cells markers (Table 39) (CD19-AF700, IgM-FITC, IgD-PE (Biolegend), 
CD21-PE Cy7, CD86 Pacific blue (BD Pharmingen) in order to evaluate the 
subsets, activation and responsiveness of B cells (switch class isotypes) after 
stimulation.  
 
Table 39: Antibodies used in cells staining  
The cells were washed in 40 mL of media, 40xg for 7 minutes. The supernatant 
was decanted and the pellet re-suspended by flicking the tube or by gentle 
vortexing. Samples were re-suspended in 5mL PBS and gently vortexed to 
create a homogenous cell suspension. 10 L of the cell suspension was removed 
in order to have 106 cell/mL. Cells were stained for 30 min at room temperature. 
Subsequently they were washed twice and fixed in 1% paraformaldehyde for 
Marker Fluor. 
(Manufacturer) 
Vol (l) Marker Fluor. 
(Manufacturer) 
Vol (l) 
CD19 AF-700 2 CD86 P cific-Blu  2 
IgM FITC 5 Viability 
die 
Amcyan 0.5 
IgD PE 5    
CD27 APC-H7 2    
CD21 PE-Cy7 2    
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10 minutes at 4°C. Data were acquired within 4 hours using a BD LSRII flow 
cytometer (BD Biosciences – Immunocytometry Systems, San Jose, CA). Data 
were analyzed using FlowJo Software (Tree Star Inc., Ashland,) based on B-
cells subsets and markers (Figure 32)  
 
 
 
 
 
 
Figure 32: Summary of the developmental stages and markers of B-cells 
 
6.4-RESULTS AND DISCUSSION 
6.4.1-Bacteria cultures 
Moraxella catarrhalis was grown on brain heart infusion (BHI) agar plate and 
incubated at 37° C o/n (Figure 33). Heamophilus influenzae type b, 
Heamophilus influenzae non typeable were grown in chocolate agar petri dishes 
and incubated at 37° C o/n. 
 
 
 
 
 
 
Figure 33: Colony Forming Unit of Moraxella catarrhalis. 
Igs IgM- IgM- IgM- IgM+IgD- IgMhighIgDlow IgM+IgDlow 
Human 
positive 
markers 
CD34, CD10, 
CD38 
CD34, 
CD10, 
CD19, 
CD38, 
CD24 
IL7/3R 
CD19, CD10, 
CD20, Cd24, 
CD38, 
IL7/4/3R 
CD19 CD10, 
CD20, CD21, 
CD40, CD34, 
CD38 IL4R 
CD19, CD20, 
CD5, CD38, 
CD21, CD24, 
CD38 
CD1c, CD19, 
CD20high, 
CD21high, 
CD27high, 
Human 
negative 
markers 
Ckit low Ckit low CD34, ckit Ckit CD27, 
IL7R 
CD27, CD10  
Positive 
selection 
Negative 
selection  
Peripheral 
selection 
selection 
Development of 
conventional B 
cells 
Pre-
Pro-
B 
Pro-
B 
Pre-
B 
Tran
sition
al-B 
Imm
ature
-B 
Migration to 
2°lymphoid 
organs 
Marginal 
zone B 
147 
 
CFUs of each bacterium were counted with program Promega colony counter 
(Promega Corporation Madison, WI 53711 USA). The number of bacteria for 
each strain is showed in Table 40. 
Table 40: CFUs obtained after 24 hours of growth at 37°C 5% CO2 of Moraxella catarrhalis, 
Haemophilus influenzae (type b), Haemophilus influenzae (non typeable). 
6.4.2-Stimulation assay  
Primarily we had to set up the optimal concentration of bacteria strain for its 
application in stimulation assays. Moraxella catarrhalis, Hib, NTHi, SAC, 
CpG, and IL-21 were cultured for five days with frozen PBMCs (1x106/mL) in 
two 96 well/plate as described before. An ELISA assay was performed in order 
to measure the IgGs titer in the samples. 
PLATE#1: the amount of IgG of PBMCs after stimulation with media (control) 
and Moraxella catarrhalis (105 105.5 106 106.5 concentrations) with and without 
IL-21 is shown in Figure 34. 
 
 
 
 
 
 
 
 
Figure 34: IgG titer of PBMCs after stim assay with Moraxella catarrhalis  
We obtained optimal result with Mcat at the concentration 106.5 with and 
without IL-21. Medium is the control, Moraxella catarrhalis have increased 
IgG production about of a 1.5 fold. In the past years the ability of Moraxella to 
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induce B cells activationhas been shown. It is also clear that Moraxella by 
means of the IgD binding protein MID induces a polyclonal B cells activation 
to promote a response, which is characterized by B cell proliferation and 
unspecific Igs production. (Singh at al., 2012). However, a low quantity of IgGs 
could be explained since after stimulation with Mcat. B cells need additional 
signals, (such as IL-4, IL-10 CD40L). In addition, most of data regarding the 
interaction of Moraxella with IgD+ B cells suggest that Mcat redirects the 
immune response by promoting the production of polyclonal low specificity 
Igs and thus results in avoidance of specific antibody response against the 
bacteria. Learning from in-vitro experiments with whole Mcat, it is evident that 
stimulation of BCR and TLR leads to initial IgM production but not in class 
switching (Souwer et al., 2009; Mollenkvist et al., 2003). On the other hand, if 
additional TH2 cytokines are provided BCR cross-linking by MID induces class 
switching (Nordstrom et al., 2002). 
In Figures 35 (A-B) were shown the results of ELISA performed with Hib and 
NTHi cultured with PBMCs. 
 
 
 
 
 
 
 
 
Figure 35 A: Titer of IgG obtained in stim assay with Hib and PBMCs after 5 days of 
culture. B: Titer of IgG obtained in stim assay with NTHi and PBMCs after 5 days of 
culture. 
Antibodies against capsular polysaccharides (PSs) of bacteria, such as 
Haemophilus influenza type b (Hib), fix the complement to the bacterial surface 
and are protective in animals and humans. Capsular PSs, however, are T-
independent type 2 antigens, do not induce immunologic memory, and yield 
isotype-restricted antibodies that mature late in ontogeny, so children <24 
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months of age do not make protective anti-PS antibody titers. The total ELISA 
IgGs measured in PBMCs after stimulation with Hib shows a better result with 
Hib 105 without IL-21 and Hib 106.5 with IL-21. Hypogammaglobulinemia with 
IgG deficiency is the immune deficiency most clearly associated with NTHi 
infection (Van der Hilst et al., 2002). The administration of IgG replacement 
therapy has been shown to reduce systemic NTHi infections including a study 
which showed a reduction in nasopharyngeal colonization (with a possible 
effect from antibiotics as well) (Lindenberg et al., 2001). The data showed the 
best stimulation using NTHi 106.5 with IL-21 (392 ng/mL) 
In Figure 36, shown below, we have obtained 6160 ng/mL of IgGs after 
stimulation with SAC (y10
6) + IL-21, 1091 ng/mL after stimulation with CpG 
(10ng/mL) and 1889 ng/mL of IgG after stimulation with CpG +IL-21 
compared with a control medium 121ng/mL. 
 
 
 
 
 
 
 
 
Figure 36: ELISA results obtained with SAC with a concentration range of (y20000 
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6), and CpG (10ug/mL). 
Protein A is a 42 kDa surface protein originally found in the cell wall of the 
bacterium Staphylococcus aureus. It is encoded by the spa gene and its 
regulation is controlled by DNA topology, cellular osmolarity, and a two-
component system called ArlS-ArlR. It has found use in biochemical research 
because of its ability to bind immunoglobulins. It is composed of five 
homologous Ig-binding domains that fold into a three-helix bundle. Each 
domain is able to bind proteins from many mammalian species, most notably 
IgGs. It binds the heavy chain within the Fc region of most immunoglobulins 
and within the Fab region in the case of the human VH3 family. Through these 
0
1000
2000
3000
4000
5000
6000
7000
Ig
G
 n
g
/m
L
s 
Stimulants
IgGs 
150 
 
interactions in serum, where IgG molecules are bound in the wrong orientation 
(in relation to normal antibody function), the bacteria disrupt opsonization and 
phagocytosis. IL-21 plays an important role in murine B cell differentiation into 
memory cells and plasma cells; we investigated the role of IL-21 in human B 
cell differentiation. In this study, we report that IL-21 co-stimulation not only 
is capable of inducing plasma cell differentiation from CD27+ memory B cells, 
but also has the capacity to induce class switch recombination (CSR) and 
stimulate poorly responsive naive cord blood B cells into IgG-secreting plasma 
cells. Based on the ELISA performed with a concentration range of bacteria in 
order to achieved anboptimal stimulation of cells we used the concentrations 
reported in table 41. 
 
 
 
 
 
Table 41: Optimal concentration of stimulants obtained from ELISA assays, used in next 
stimulations assays. 
We applied the stimulants concentration reported in table 41 in order to 
measure the titer of IgM in PBMCs culture in the same conditions which are 
described previously. In Figure 37 the IgM ELISA assay result are showed. 
 
 
 
 
 
 
 
 
Figure 37: IgM titer in PBMC culture at days 5 of stimulation with bacteria, CpG and IL-21. 
Stimulant Concentration in culture cells  
Moraxella catarrhalis  106.5 
Haemophilus influenza type b  106.5 
Heamophilus influenzae non typeable  106.5 
Staphilococcus aureus Cowan I  y106 
CpG 10ng/mL 
IL-21 10ng/mL 
0
50
100
150
200
250
300
350
Ig
M
 n
g
/m
L
 
Stimulants 
IgM ng/mL
151 
 
The IgMs baseline (medium) was undetectable as IL-21, Hib and NTHib. The 
higher concentration of immunoglobulins M was achieved with SAC 
(62ng/mL) and SAC+IL-21 (74ng/mL). 
In Figure 38 (A-B-C-D), we showed the results obtained after five days of 
stimulations of frozen PBMCs in two subjects. In subject 5, the titer of IgG 
increased after culture with CpG+IL-21 (1389 ng/mL) compared to the medium 
(control) (89ng/mL). A slight increase was observed also with Mcat+ IL-21 and 
Hib+IL-21 (Figure 38-A). The titer of IgMs showed higher stimulation with 
CpG+IL-21. The production of IgM was about three time higher then IgG, these 
data suggest that the stimulants increase production of IgM into supernatants. 
These results indicate that naive B cells are activated to proliferate and to 
produce IgM by CpG ODN +IL-21 (Figure 38-B) On the hand the stimulation 
of IgG was not statistically different in subject 1, (Figure 38-C), but statistical 
different were IgMs after stimulation with SAC and CpG (3ug/mL) compared 
to control (medium).  
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Figure 38: Titer of IgG and IgM of two samples (Patient ID5, and ID1) after 5 days of 
incubation with stimulants. 
We considered also the production of IgG and IgM after five days’ stimulation 
of fresh PBMCs and frozen tonsils (data no shown). In this assay no statistical 
differences were showed between control (medium and stimulants) nor in 
PBMC (p-value IgG, IgM; 0.429), neither in frozen tonsils (p-value= 0.443). 
In all culture cells analyzed after five days of stimulation, no statistical 
differences were observed in production of IgG and IgM. The data obtained 
suggest that SAC increase the production of IgG better than IgM, on the other 
hand CpG increase the production of IgM rather than IgG (Figure 39). 
 
Figure 39: The histogram bars represent the average of IgGs and IgMs titer in cultured cells 
with medium (control) and stimulants ± standard deviation. 
The data confirm the data observed by Jang et al. (2007). In addition, we have 
performed stimulation assays and ELISA assays after three days in order to 
compare the titer of IgG and IgM in the supernatants. 
In Figure 40 ELISA results are shown after three days of stimulation in the 
same conditions mentioned before. We obtained stimulation of IgG by all 
stimulants; however, CpG and CpG+IL-21 showed a higher production of IgG 
in all cell cultures. IgM stimulation was higher than IgGs and again CpG and 
CpG +IL-21 showed the best results. 
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Figure 40: IgM and IgG titer in supernatant of culture cells obtained after three days of 
stimulation, Bars represent mean and SEM of samples analyzed  
We performed statistical analysis on the production of IgGs and IgMs by 
different cultured cells after three days of stimulation with selected bacteria, 
IL-21 and CpG (Table 42). 
Stimulant Mean IgG ±SEM Mean IgM±SEM  
Medium 33.25 (34.25) 29.75 (50.2) 
Medium+IL-21 18.75 (13.8) 13 (17) 
Mcat 25.5(22.3) 2 (27.7) 
Mcat+IL-21 22.2(24.3) 33.5 (29.5) 
SAC 59.7 (88) 124 (89.4) 
SAC+IL-21 43.5 (61) 101.7 ( 92.8) 
CpG 245 (346) 245 (313.06) 
CpG+IL-21 256 (347) 266.7 (325)  
Table 42: Mean of values of IgG, IgM into supernatants after three days of stimulation 
Figure 41 showed the graph of IgG mean quantity produced by cells after three 
days of stimulation. Higher stimulation was observed in the supernatants of 
cells stimulated with CpG and CpG+IL-21. However, the difference of titer of 
IgG among the stimulants was not statistically different.  
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Figure 41: The graph showing the type of stimulant (Medium, medium+IL-21, Mcat, Mcat+IL-
21, SAC, SAC+IL-21, CpG, CpG+IL-21) X-axis, against the mean quantity of 
immunoglobulins G (y-axis). 
The same approach was performed with the data of IgM titer (Figure 42). In 
addiction the production of IgMs into the supernatant after three days resulted 
statistically different. We applied Dunnet T test for multiple comparisons, the 
data obtained showed that the titer of IgMs after stimulation with CpG +IL-21 
was statistically different compared to the medium (p-value=0.037), IL-21 (p-
value=0.023), Mcat (p-value=0.032), andMcat +IL-21 (p-value=0.003). The 
differences among other stimulants were not statistically different. 
 
Figure 42: The graph showing the type of stimulant (Medium, medium+IL-21, Mcat, Mcat+IL-
21, SAC, SAC+IL-21, CpG CpG+IL-21) X-axis, against the mean quantity of 
immunoglobulins M (y-axis). +P-value<0.05. 
The data confirmed those obtained after five days of stimulation with CpG+IL-
21.  
6.4.3-Flow Cytometer Analysis 
All samples (PBMCs and Tonsil cells) were stained with monoclonal 
antibodies to B cells markers as previously described. In all samples cells 
(PBMCs fresh and frozen, tonsils fresh and frozen) the distribution of 
circulating B-cells subsets, as defined in table 43.  
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Table 43: Surface Markers Defining B Cell Subsets IgM memory and class switching memory 
are each divided into two subsets based on CD27 expression  
B cells are identified among PBMC based on initial selection of lymphocytes 
by forward and side scatter, selection of singlets (FSC-W vs FSC-H), and fating 
on CD19+cells (live cells). 
In addition, the subsets were identified through Boolean gating with anti-IgD, 
IgM, and CD27. Activation is determined by a lack of expression of CD21 and 
expression of CD86 on each subset. In Figure 43 a population of PBMC 
cultured in medium (control) is shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43: Gating scheme for CD19+ B cell subset of PBMC at baseline.  
At day 5 in PBMC culture control and culture with stimulants naïve B cells 
(CD27-IgD+) represented a comparable majority of the B cells in all samples 
analyzed. The membrane form of Ig is expressed on the surface of B cells in 
Surface Markers Defining 10 B cell Subssets 
B cell Subset IgD IgM CD27 CD21 CD86 
Naïve/Transitional  + + - ↓ ↑ 
IgM Memory - + ± ↓ ↑ 
BND anergic + - - ↓ ↑ 
IgD Memory + - + ↓ ↑ 
Class Switch Memory (IgG, A, E) - - ± ↓ ↑ 
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the bone marrow. Stimulants, in particular SAC, SAC+IL-21 and CpG+IL-21 
through the BCR not only steer the B cells through development but also allow 
to express a second isotype followed by class switch memory (IgD- IgM-) in 
medium but no in cultures with stimulants (Figure 44). In both cases (medium 
and stimulants) the majority of classes switch memory cells expressed CD27. 
(Memory cells CD27+ IgD-). Another subset of IgD+ B cells, circulating BND 
(IgD+ IgM- CD27-), considered to be both autoreactive and typically anergic, 
were significantly prevalent in all cultured cells with stimulants. IgM class 
switch memory (IgD- IgM+) is a subset of B cells that contains high secretion 
in response to T independent antigen. 
 
Figure 44: Distribution of B cell subset in cultures cell after 5 days stimulated with medium 
(control) and stimulated with Mcat, SAC, SAC+IL-21, CpG, CpG+IL-21.  
By using Mann-Whitney non-parametric test that compares the ranks of two 
independent samples we didn’ observe any statistical difference regarding the 
B cell subset between cultured cell with medium and cultured cells with 
stimulants. 
B cell subsets in response to stimulation in-vitro  
An essential element of the B cells function is their ability to be activated by 
exogenous and endogenous stimuli. As mentioned before, we focused our 
attention to characterize the effects of different mucosal bacterial pathogens on 
the isotype of antibody production from human B cell. This potential “decoy” 
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stimulation by surface bacterial protein that are proposed to stimulate B cells 
non-specifically by cross-linking surface antibody by the constant Fc region 
rather than binding these bacteria by the antigen-specific Fab variable region. 
In PBMC cultures, stimulation in-vitro with Mcat, Sac, CpG and IL-21, was 
associated with a lower density of CD21 and a higher density of CD86, on the 
cells surface. The magnitude of stimulation of PBMC was compared whit 
PBMC culture with medium only, (control) (see Figure 45). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45: FlowJo analyses after 5 days of stimulations (medium, Mcat, SAC, CpG, CpG+IL-
21). 
The gating scheme for CD21 and CD86 comparing representative data from a 
representative PBMC culture in medium and PBMC culture whit Mcat, SAC, 
CpG and CPG +IL 21is shown. The percentage of CD19+ B cells expressing 
CD21 and CD86 was compared among PMBC cultures with medium and 
PBMC culture cell stimulated with Mcat SAC, CpG, CpG+IL-21. Values are  
shown for the mean and standard deviation (Figure 46).  
CpG (Day 5) CpG+IL-21 (Day 5) 
Moraxella catarrhalis (Day 5) Medium SAC (Day 5) 
158 
 
 
 
 
 
 
 
 
 
Figure 46: B cells activation markers CD21 (blue bars) CD86 (red bars). 
Groups were compared through one-way ANOVA with the Dunett post-hoc 
test. As shown in Figure 20, the expression of CD21 decreases in cell cultures 
stimulated for 5 days. However, no statistical difference was observed in the 
CD21 expression between medium and stimulants. The expression of CD86 
was statistically different among the groups (p-value=0.027). In particular, 
significant differences were observed between medium and SAC (p-value 
0.0214) and medium and CpG (p-value= 0.0123) and between Mcat and SAC 
(p-value=0.0129) and Mcat and CpG (p-value =0.0123). Compared to other 
stimulants CpG and SAC elicited in-vitro activation of B cell after 5 days of 
stimulation. Expression of CD86 were less prominent in stim culture whit Mcat 
and CpG+IL-21. Indeed, despite differences between medium and stimulants 
the magnitude of change (percentage expression) of CD21 and CD86, 
activation markers in PBMC population was not statistically significant for all 
stimulants. CpG + IL-21 and Mcat probably required other molecules to 
activate B cell differentiation. 
6.5-CONCLUSIONS 
We identified B cells subsets and activation after stimulation with different 
nasopharyngeal and lung infected bacteria, CpG DNA, and Interleukin-21 (IL-
21) compared with those in control subset, after 3 or 5 days. IgG ELISA assays 
were performed to identify the optimal concentration to use in the subsequent 
stimulation experiment. CpG + IL-21 enhances the production of 
immunoglobulins (IgG, IgM). CpG dinucleotides induce B cells to proliferate 
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and secrete immunoglobulins, without T-cells help. IL-21 is a pleiotropic 
cytokine, whose action generally enhances antigenic-specificity responses in 
immune cells; nevertheless, it requires T-cells help. We have applied the 
optimal concentration of stimulant in order to assess immunoglobulins 
production in 23 samples composed by frozen PBMC, fresh PBMC frozen 
tonsils and fresh tonsils. In all samples, the data showed higher increase of IgGs 
and IgMs after stimulation by SAC, CpG +IL-21. In particular, the magnitude  
change of IgGs production was on average 2071 ng/mL of IgG production after 
stimulation by SAC and on average 1917 ng/mL of IgM production after 
stimulation by CpG+IL-21. The results were confirmed in samples stimulated 
three days in the same conditions. On the other hand, IgMs production was 
higher after stimulation with CpG and IL-21. Cultures set up with B cells of 
healthy donors produced large amounts of IgM even in the absence of T cells 
stimulated by CpG +IL-21. Compared with stimulation by only medium Mcat 
influenced the serum levels of IgG or IgM in frozen PBMC but no in tonsils 
cells. However, no statistical difference was observed in samples, Hib and 
NTHi failed to produce significant levels of IgG, and IgM. Bacterial pathogens 
are not sufficient to induce class switching. The mechanism to account for co-
colonization of bacterial pathogens influencing the host adaptive immune 
responses may involve activation and crosstalk of host multiple pattern-
recognition receptors (PRRs) in innate immune cells, and components bridging 
innate and adaptive immunity. The host innate immune system detects 
microorganisms and responds to their stimuli mainly through Toll-like 
receptors (TLRs) (Kawai and Akira, 2005). Hib and Mcat can be recognized 
by TLR-2, 4 and 9 (Vuononvirta et al., 2007; Hassan et al., 2012; Clemente et 
al., 2012) found that the innate immunity induced by NTHi can provide 
protection against the Streptococcus pneumoniae (Spn) infection in mouse 
lung, probably through multiple innate immune mechanisms including formyl 
peptide receptors, complement receptors, and TLRs. Lim et al. (2008) reported 
that Spn synergizes with NTHi to induce inflammation via up-regulating TLR2. 
Spn and Hib synergistically activate NF-κB as well as the subsequent 
inflammatory TNFα, IL-1β, and IL-8 responses via IKKβ-IκBα and p38 MAPK 
pathway (Kweon et al., 2006). Such effects of co-colonization by Spn with Hib 
on innate immune immunity may lead to influence adaptive immunity. 
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Dendritic cells (DC) play important roles in bridging innate and adaptive 
immunity (Novak et al., 2010). TLRs and cross-talk between TLRs, and 
complement receptors in antigen present cells (APC) control adaptive immune 
responses (Pasare et al., 2005). TLR signaling not only helps to initiate adaptive 
immune response, but also is required for it (Schnare et al., 2001; Medzhitov 
et al., 2002). Activation of TLR in DCs results in elevated levels of pro-
inflammatory cytokines or chemokines leading to the induction of the adaptive 
immune response, where both T and B-lymphocytes play a crucial role 
(Majewsaka et al., 2006). We observed that after three days of stimulation by 
CpG+IL-21 the magnitude of change of IgMs into the supernatant was 
statistically different compared to the medium, IL-21, Mcat, but not statistically 
different compared to the SAC.  
We found that the majority of B cell subsets were similar between medium 
(control) and stimulated culture cells. However, we did not confirm the 
increased frequency of class switch memory B cells in stimulated cultures. It 
worth to mention that a higher percentage of IgM Memory B-cells in stimulated 
culture with SAC, SAC+IL-21, CpG+Il-21 compared to the medium. 
Immunological memory is our reservoir of ready-to-use antibodies and 
memory B-cells. Because of the immunological memory, a secondary infection 
will be very light or not occur at all. Antibodies and cells, generated in the 
germinal center in response to the first encounter with antigen, are highly 
specific, remain in the organism virtually forever and are mostly of IgG isotype. 
Long-lived plasma cells homing to the bone marrow ensure the constant 
production of protective antibodies, whereas switched memory B cells 
proliferate and differentiate in response to a secondary challenge. IgM memory 
B cells represent our first-line defense against infections. They are generated 
by a T-cell independent mechanism probably triggered by Toll-like receptor-9. 
They produce natural antibodies with anti-bacterial specificity and the spleen 
is indispensable for their maintenance. IgM memory B-cells have a great 
importance in the immediate protection against pathogens. The more mature 
class switch memory cells were lower in all stimulated cells compared to the 
medium. Among the minority B cells subsets, the frequency of BND cells was 
similar in cells culture in medium as well as cell cultured with stimulants. 
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Studies in human subjects have demonstrated that a substantial frequency of 
newly generated B cells was autoreactive. Deficiency of proper B-cell tolerance 
contributes to the development of autoantibodies, leading to initiation and 
perpetuation of autoimmune processes. At least three main mechanisms 
accounting for silencing of self-reactive B cells are known: receptor editing, 
deletion, and anergy. The process of anergy is an important tolerance 
mechanism whereby cells are functionally inactivated. Anergic B cells are 
characterized by a reduced ability to proliferate and secrete antibodies on 
antigens encounter accompanied by reduced BCR-signaling responses, 
including intracellular calcium mobilization and tyrosine phosphorylation 
(Szodoray et al., 2016). However, the stimulation condition used in our study 
may not have been of sufficient potency or duration to induce these BND cells 
to differentiate in vitro. Almost all B cell subsets, other than BND, showed 
changes with stimulation. These data supports the hypothesis that, Mcat SAC, 
CpG and IL-21, using appropriate conditions could induce the class-switching 
isotype without T-cell help. Post stimulation, expression CD21 decreased and 
CD86 increased compared to the control. For the future, we will investigate 
intracellular AID protein concentration. AID is required for SHM, which drives 
antibody affinity and function. Potential limitations of this study include a small 
sample size. We will enroll higher number of patients. In addiction based on 
these issues, we could investigate Streptococcus pneumoniae (Spn), 
Haemophilus influenzae (Hi) and Moraxella catarrhalis (Mcat), the most 
common pathogenic bacteria of respiratory infections and common commensal 
microbes in the human nasopharynx (NP). The effect of interactions among 
bacteria during co-colonization of the NP on the host immune response has not 
been well evaluated. The objective of future study could be to assess the impact 
of co-colonization by Hi or Mcat on the systemic antibody response and to 
vaccine protein candidate antigens and similarly, the impact of co-colonization 
by Spn and Mcat on antibody responses to Hi vaccine protein candidate 
antigens. 
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